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Abstract	
		
		DKK3	 is	a	 tumour	suppressor	gene	encoding	a	secreted	protein,	Dkk-3,	which	 is	 found	 in	
benign	 prostate	 and	 prostate	 cancer	 stroma.	 Dkk-3	 maintains	 normal	 prostate	 epithelial	
acinar	morphogenesis	by	limiting	TGF-β/Smad/matrix	metalloproteinase	signalling.		
		The	role	of	stromal	Dkk-3	was	investigated	in	this	thesis.	The	human	prostate	stromal	cell	
line,	WPMY-1,	secreted	a	high	level	of	Dkk-3	that	was	further	increased	by	TGF-β.	DKK3	gene	
silencing	increased	TGF-β-dependent	signalling	and	migration,	but	did	not	affect	proliferation.	
WPMY-1	 cell	 co-culture	 and	 WPMY-1	 cell	 conditioned	 media	 reduced	 proliferation	 and	
rescued	acinar	morphogenesis	of	the	DKK3-silenced	RWPE-1	prostate	epithelial	cells	in	a	Dkk-
3-dependent	manner.	DKK3-silenced	WPMY-1	cell	conditioned	media	increased	PC3	prostate	
cancer	 cell	 invasion	probably	 in	 an	MMP2-dependent	manner.	 Control	 and	DKK3-silenced	
conditioned	media	were	compared	using	an	antibody	array,	identifying	two	proteins,	TGFBI	
and	ECM-1,	that	were	affected	by	DKK3	silencing.	DKK3	silencing	increased	TGFBI	and	reduced	
ECM-1	in	WPMY-1	cell	conditioned	media,	and	increased	both	TGFBI	and	ECM-1	in	RWPE-1	
cell	 conditioned	 media.	 Purified	 recombinant	 TGFBI,	 but	 not	 ECM1,	 increased	 PC3	 cell	
invasion,	and	purified	ECM1,	but	not	TGFBI,	increased	normal	acinar	morphogenesis	of	DKK3-
silenced	RWPE-1	cells.		
	 	 Immunohistochemical	 analysis	 of	 Dkk-3,	 TGFBI	 and	 ECM-1	 in	 prostate	 cancer	 showed	
significantly	lower	levels	of	Dkk-3	in	prostate	cancer	than	in	benign	epithelium	and	in	tumour	
stroma	 compared	 to	 benign	 stroma.	 TGFBI	 levels	 were	 higher	 in	 prostate	 cancer	 than	 in	
benign	prostate	epithelium	and	were	inversely	correlated	with	Dkk-3	expression.	ECM-1	was	
highly	expressed	in	cancer,	and	correlated	with	Dkk-3	and	TGFBI	levels	in	low-Gleason-score	
cancer	stroma.		
		Together,	these	in	vitro	studies	and	the	immunohistochemical	data	support	a	model	in	which	
stromal	Dkk-3	plays	a	protective	role	 in	prostate	cancer,	and	the	downregulation	of	Dkk-3	
leads	to	an	increased	expression	of	TGFBI,	which	may	promote	prostate	tumour	cell	invasion.	
	
	
	 3	
Statement	of	originality	
	
		I	hereby	certify	that	I	am	the	sole	author	of	this	thesis	and	that	all	the	experiments	presented	
here	were	conducted	by	me	unless	otherwise	stated.	
		The	 experiments	 carried	 out	 by	 others	 were	 as	 follows:	 Dr	 Yoshiaki	 Kawano	 (Imperial	
College)	 generated	 the	 control	 and	 DKK3-silenced	 RWPE-1	 cell	 lines;	 Dr	 Diana	 Romero	
(Imperial	College)	carried	out	the	proteome	array	using	RWPE-1	cell	CM;	Dr	Hoda	Kardooni	
(Imperial	College)	helped	with	the	statistical	analysis	and	carried	out	some	of	the	qPCR	assays;	
Dr	Jenny	Steel	(Imperial	College)	prepared	sections	for	immunohistochemistry	and	carried	out	
staining	for	VIM,	SMA	and	H&E;	Dr	James	Carton	(Imperial	College)	scored	the	TMAs	for	the	
Gleason	stage;	Dr	Miriam	Rabano,	from	Dr	Maria	Vivanco’s	laboratory	(CIC	bioGUNE),	carried	
out	FACS	analysis	of	GFP-transfected	cells;	Ms	Virginia	Murillo	(CIC	bioGUNE)	carried	out	some	
of	the	qPCR	assays.	
	
	
	
	 	
	 4	
	
Copyright	declaration		
	
		The	copyright	of	 this	 thesis	 rests	with	 the	author	and	 is	made	available	under	a	Creative	
Commons	Attribution	Non-Commercial	No	Derivatives	licence.	Researchers	are	free	to	copy,	
distribute	or	transmit	the	thesis	on	the	condition	that	they	attribute	it,	that	they	do	not	use	
it	 for	commercial	purposes	and	that	they	do	not	alter	 it	or	build	upon	 it.	For	any	reuse	or	
distribution,	researchers	must	make	clear	to	others	the	licence	terms	of	this	work.		 	
	 5	
Acknowledgements	
	
		I	would	first	 like	to	express	my	thanks	to	my	supervisor	Dr	Robert	Kypta	for	his	excellent	
supervision	and	endless	encouragement	during	my	PhD.	His	experience	greatly	helped	this	
project	to	be	a	success,	for	which	I	am	grateful.	
		I	would	 also	 like	 to	 thank	my	 co-supervisor	Professor	 Jonathan	Waxman	 for	 the	 fruitful	
discussions	and	advice	he	provided,	which	are	much	appreciated.	
		I	am	grateful	to	the	Ministry	of	Presidential	Affairs	in	the	UAE	under	H.H.	Mansour	bin	Zayed	
Al	Nahyan,	who	generously	 funded	my	PhD	and	without	whom	this	would	not	have	been	
possible.	I	am	also	thankful	to	the	employees	at	the	Scholarship	office	in	UAE/Abu	Dhabi,	who	
followed	my	progress	and	showed	great	patience	in	solving	PhD-related	difficulties.	I	would	
also	like	to	extend	my	thanks	to	Khaled	Al	Shewiki	from	the	UAE	embassy	in	the	UK.	
		Moreover,	I	want	to	thank	the	postdocs	in	Dr	Robert	Kypta’s	lab,	Dr	Diana	Romero	and	Dr	
Hoda	Kardooni.	I	am	grateful	to	our	collaborator	from	Spain,	Dr	Maria	Vivanco	(CIC	bioGUNE),	
for	welcoming	me	in	her	lab	and	for	her	warm	hospitality.		
		This	project	would	not	have	been	possible	without	the	kind	support	and	help	of	my	loving	
and	magnificent	parents.	Mommy,	Daddy,	 I	 love	 you	 so	much.	 I	would	 like	 to	extend	my	
extreme	gratitude	to	my	family,	particularly	to	my	smart	brother	Hamdan	Al-Shareef.	They	
have	always	been	my	inspiration.	
		I	would	like	to	offer	my	warm	thanks	to	my	colleagues	on	the	first	floor	of	the	IRDB,	who	
made	the	four	years	of	my	PhD	a	lot	of	fun	and	shared	their	knowledge	and	friendship	during	
this	time;	I	would	also	like	to	thank	my	close	friend,	Foteini	Kalofonou.	
		Finally,	 I	would	 like	 to	 thank	a	very	close	person	who	doesn’t	want	me	to	mention	 their	
name.	I	won’t	forget	the	unconditional	love	and	support	they	have	given	me.	Thank	you.	
	
	
	 6	
Contents	
Table	of	contents	
	
Abstract	..................................................................................................................................................	2	
Statement	of	originality	.........................................................................................................................	3	
Copyright	declaration	.............................................................................................................................	4	
Acknowledgements	................................................................................................................................	5	
Contents	.................................................................................................................................................	6	
List	of	tables	and	figures	........................................................................................................................	9	
Abbreviations	.......................................................................................................................................	12	
Chapter	one	.........................................................................................................................................	14	
Introduction	.........................................................................................................................................	14	
Introduction	.....................................................................................................................................	15	
The	prostate	.....................................................................................................................................	15	
Prostate	anatomy	and	histology	.................................................................................................	15	
Prostate	cancer	................................................................................................................................	19	
Prostate	cancer	and	the	micro-environment	...................................................................................	23	
Insight	into	the	micro-environment	............................................................................................	23	
Activation	of	fibroblasts	into	myofibroblasts	(CAFs)	..................................................................	27	
TGF-β	signalling	in	prostate	cancer	(PCa)	.........................................................................................	28	
TGF-β	signalling	in	epithelial-stromal	interactions	in	the	prostate	cancer	micro-environment32	
Dickkopf-3	(Dkk-3)	is	a	unique	member	of	the	Dickkopf	family	.......................................................	34	
The	Dkk-3	protein	........................................................................................................................	34	
The	potential	roles	of	Dkk-3	in	the	immune	system	..................................................................	37	
The	DKK3/REIC	(reduced	expression	in	immortalised	cells)	gene	..............................................	38	
Possible	functions	of	Dkk-3	.........................................................................................................	40	
Dkk-3	in	the	prostate	and	PCa	..........................................................................................................	42	
Regulation	of	DKK3	gene	expression	in	PCa	...............................................................................	42	
Studies	on	Dkk-3	in	prostate	epithelial	cells	...............................................................................	44	
The	role	of	Dkk-3	in	non-epithelial	cells	in	the	prostate	..................................................................	45	
Studies	using	Dkk-3	as	therapy	for	PCa	............................................................................................	46	
Dkk-3	expression	in	the	endothelium	..............................................................................................	46	
Dkk-3	in	other	tissues	and	diseases	.................................................................................................	47	
Prostate	and	PCa	cell	line	models	....................................................................................................	48	
Transforming	growth	factor	beta	induced	(TGFBI)	..........................................................................	50	
	 7	
Extracellular	matrix	protein	1	(ECM-1)	.............................................................................................	53	
Hypothesis	and	aims	............................................................................................................................	54	
Hypothesis	........................................................................................................................................	54	
Aims	..................................................................................................................................................	54	
Chapter	two	.....................................................................................................................................	55	
Cell	culture	.......................................................................................................................................	56	
Generation	of	WPMY-1	shRNA	cell	lines	..........................................................................................	56	
Western	blotting	..............................................................................................................................	57	
RNA	extraction,	cDNA	synthesis	and	q-PCR	.....................................................................................	58	
Fluorescence	activated	cell	sorting	(FACS)	.......................................................................................	60	
Acinar	morphogenesis	(AM)	assays	..................................................................................................	60	
Gene	reporter	assays	.......................................................................................................................	61	
Cell	proliferation	assays	...................................................................................................................	61	
Invasion	and	migration	assays	..........................................................................................................	62	
Proteome	profiler	array	...................................................................................................................	63	
Histochemistry	.................................................................................................................................	64	
Statistical	analysis	.............................................................................................................................	65	
Chapter	three	...................................................................................................................................	66	
Introduction	.....................................................................................................................................	67	
3.1	Generation	and	the	initial	characterisation	of	DKK3-silenced	WPMY-1	cell	lines	......................	67	
3.2	DKK3	silencing	increases	TGF-β/Smad	signalling	in	WPMY-1	cells	.............................................	68	
3.3	TGF-β	treatment	of	WPMY-1	cells	increases	the	level	of	secreted	Dkk-3	..................................	75	
3.4	DKK3	silencing	does	not	affect	WPMY-1	cell	proliferation	.........................................................	75	
3.5	DKK3	silencing	increases	WPMY-1	cell	migration	......................................................................	78	
3.6	Comparison	of	the	effects	of	DKK3	silencing	on	gene	expression	in	RWPE-1	and	WPMY-1	cells
	..........................................................................................................................................................	78	
3.7	DKK3	silencing	increases	s-SHIP	promoter	activity	in	RWPE-1	cells	...........................................	83	
Conclusions	......................................................................................................................................	85	
Chapter	four	.....................................................................................................................................	86	
Introduction	.....................................................................................................................................	87	
4.1	WPMY-1	cell	CM	promotes	normal	acinar	morphogenesis	of	RWPE-1	cells	in	a	Dkk-3-
dependent	manner.	.........................................................................................................................	87	
4.2	WPMY-1	cell	CM	has	variable	effects	on	acinar	morphogenesis	in	control	RWPE-1	cells.	........	88	
4.3	WPMY-1	cell	CM	inhibits	proliferation	of	DKK3-silenced	RWPE-1	cells	in	a	Dkk-3-dependent	
manner.	............................................................................................................................................	95	
4.4	Conditioned	medium	from	DKK3-silenced	WPMY	-1	cells	increases	PC3	cell	invasion.	.............	97	
	 8	
Conclusions	......................................................................................................................................	99	
Chapter	five	...................................................................................................................................	100	
Introduction	...................................................................................................................................	101	
5.1	Identification	of	proteins	affected	by	DKK3-silencing	in	CM	from	WPMY-1	and	RWPE-1	cells	
using	antibody	arrays	.....................................................................................................................	101	
5.2	DKK3	silencing	increases	TGFBI	levels	in	WPMY-1	and	RWPE-1	cell	CM.	.................................	105	
5.3	DKK3	silencing	reduces	ECM-1	levels	in	WPMY-1	cell	CM	and	increases	ECM-1	levels	in	RWPE-1	
cell	CM.	...........................................................................................................................................	105	
5.4	Analysis	of	the	effects	of	recombinant	TGFBI	and	ECM-1	on	acinar	morphogenesis	of	DKK3-
silenced	RWPE-1	cells	.....................................................................................................................	108	
5.5	Analysis	of	the	effects	of	recombinant	TGFBI	and	ECM-1	on	PC3	cell	invasion	.......................	110	
Conclusions	....................................................................................................................................	112	
Chapter	six	.....................................................................................................................................	113	
Introduction	...................................................................................................................................	114	
6.1	TMA	description	and	characteristics	........................................................................................	114	
6.2	Immunohistochemistry	of	smooth	muscle	actin	(SMA)	and	vimentin	(VIM)	...........................	118	
6.3	Dkk-3	expression	is	reduced	in	PCa	and	the	PCa	stroma,	compared	to	in	benign	epithelium	and	
stroma	............................................................................................................................................	118	
6.4	TGFBI	expression	is	higher	in	PCa	and	lower	in	PCa	stroma,	compared	to	in	benign	epithelium	
and	the	stroma	respectively.	..........................................................................................................	122	
6.5	Analysis	of	ECM-1	expression	in	prostate	TMAs	......................................................................	126	
6.6	Inverse	correlation	of	Dkk-3	and	TGFBI	expression	in	low-Gleason-grade	PCa	.......................	130	
6.7	Positive	correlation	of	Dkk-3	and	ECM1	expression	in	low-Gleason-grade	PCa	stroma	..........	130	
6.8	Positive	correlation	of	ECM-1	and	TGFBI	in	cancer	stroma	of	low-Gleason-grade	PCa	...........	135	
6.9	Analysis	of	correlations	between	DKK3,	TGFBI	and	ECM1	gene	expression	and	PCa	patient	
survival	...........................................................................................................................................	135	
Summary	........................................................................................................................................	139	
Chapter	seven	................................................................................................................................	140	
Supplementary	Tables	...................................................................................................................	151	
References	.........................................................................................................................................	155	
	
	 	
	 9	
List	of	tables	and	figures	
Chapter	One	
Figure	1.1	Prostate	anatomy	
Figure	1.2	Prostate	gland	histology	
Figure	1.3	Prostate	cancer	follow–up	pipeline	and	summary	of	current	treatments		
Table	1.1	Common	molecular	alterations	in	PCa	
Figure	1.4	Active	involvement	of	stromal	cells	as	a	hallmark	of	cancer	
Figure	1.5	Cartoon	of	TGF-β	signalling	
Figure	1.6	Schematic	of	Dickkopf	(DKK)	family	proteins		
Table	1.2	Summary	of	published	data	describing	tumours	with	deregulation	of	DKK3	expression	
Figure	1.7	Schematics	of	Transforming	growth	factor-beta-induced	protein	(TGFBI)	and	Extracellular	
matrix	protein	1(ECM1)	
Chapter	Two	
Table	2.1	Cell	lines	used	in	this	study	
Chapter	Three	
Figure	3.1	DKK3	mRNA	and	protein	expression	in	control	and	DKK3-silenced	WPMY-1	cells	
Figure	3.2	DKK3	silencing	does	not	affect	Smad2	or	Smad4	levels		
Figure	3.3.	Effects	of	DKK3	silencing	on	Smad3	and	PSmad3	level	
Figure	3.4	Gene	reporter	analysis	of	TGF-β-dependent	transcriptional	activity	in	WPMY-1	cells	
Figure	3.5	DKK3	silencing	does	not	significantly	affect	MMP2	cells	or	αSMA	levels		
Figure	3.6	TGF-β1	increases	Dkk-3	in	CM		
Figure	3.7	Silencing	DKK3	does	not	affect	WPMY-1	cell	proliferation		
Figure	3.8	DKK3	silencing	increases	WPMY-1	cell	migration	
Figure	3.9	Analysis	of	gene	expression	in	RWPE-1	and	WPMY-1	cells	
Figure	3.10	FACS	analysis	of	RWPE-1	cells	transfected	with	GFP	reporter	plasmids	
	
Chapter	Four	
Figure	4.1	Principle	of	CM	co-culture	assay	
Figure	 4.2	WPMY-1	 cell	 CM	 promotes	 normal	 acinar	 morphogenesis	 of	 RWPE-1	 cells	 in	 a	 Dkk-3-
dependent	manner	
Figure	4.3	WPMY-1	cell	CM	has	variable	effects	on	acinar	morphogenesis	in	control	RWPE-1	cells	
	 10	
Figure	4.4	WPMY-1	cell	CM	inhibits	proliferation	of	RWPE-1	cells	in	a	Dkk-3-dependent	manner		
Figure	4.5	DKK3-silenced	WPMY-1	cell	CM	increases	PC3	cell	invasion	and	this	effect	is	inhibited	by	
the	MMP2	inhibitor	ARP100.	
Chapter	Five	
Figure	5.1	Antibody	array	analysis	of	CM	from	control	shRNA	(PSM2)	and	DKK3	shRNA	(Wsh8)	WPMY-
1	cells	
Figure	5.2	Antibody	array	analysis	of	CM	from	control	shRNA	(NS11)	and	DKK3	shRNA	(sh6)	RWPE-1	
cells	
Figure	5.3	Effects	of	DKK3	silencing	on	TGFBI	protein	and	mRNA	levels	in	WPMY-1	and	RWPE-1	cells	
Figure	5.4	Effects	of	DKK3	silencing	on	ECM-1	protein	and	mRNA	levels	in	WPMY-1	and	RWPE-1	cells	
Figure	5.5	Effects	of	recombinant	ECM-1	and	TGFBI	on	acinar	morphogenesis.	
Figure	5.6	Effects	of	recombinant	ECM-1	and	TGFBI	on	PC3	cell	invasion	
Chapter	Six	
Figure	6.1	TMA	characterisation	
Table	6.1	TMA	demographics	and	clinico-pathological	features	
Figure	6.2	Examples	of	immunohistochemistry	for	SMA	and	vimentin.	
Figure	6.3	Scoring	system	for	Dkk-3	
Figure	6.4	Example	of	patient	with	reduced	levels	of	Dkk-3	in	cancer	and	cancer	stroma	
Table	6.2	Statistical	analysis	of	Dkk-3	expression	 in	benign	prostate	and	PCa;	Gleason	 (Gl.),	benign	
stroma	(NS),	cancer	stroma	(CS),	benign	epithelium	(epi)	
Figure	6.5	Scoring	system	for	TGFBI	
Figure	6.6	Example	of	patient	with	high	TGFBI	in	cancer	and	low	TGFBI	in	cancer	stroma	
Table	 6.3	 Statistical	 analysis	 of	 TGFBI	 expression	 in	 benign	 prostate	 and	 prostate	 cancer;	 benign	
stroma	(NS),	cancer	stroma	(CS),	benign	epithelium	(epi)	
Figure	6.7	Scoring	system	for	ECM-1	
Table	 6.4	 Statistical	 analysis	 of	 ECM-1	 expression	 in	 benign	 prostate	 and	 prostate	 cancer.	 Benign	
epithelium	(epi)	
Figure	 6.8	 Example	 of	 patient	 with	 increased	 ECM-1	 in	 cancer	 and	 decreased	 ECM-1	 in	 benign	
epithelium	
Figure	6.9	Examples	of	patients	with	inverse	correlation	of	Dkk-3	and	TGFBI	
Figure	6.10	Example	of	patient	showing	positive	correlation	of	Dkk-3	and	ECM-1	in	cancer	stroma	
	 11	
Figure	6.11	 Example	of	patient	with	positive	 correlation	of	 TGFBI	 and	ECM-1	expression	 in	 cancer	
stroma	
Table	6.5	Statistical	analysis	of	Dkk-3/TGFBI/ECM-1	expression	in	benign	prostate	and	prostate	cancer;	
Gleason	(Gl.),	benign	stroma	(NS),	cancer	stroma	(CS),	benign	epithelium	(epi),	cancer	(can)	
	
Figure	6.12	Gene	expression	and	relapse-free	survival	of	PCa	patients	
	
Chapter	Seven	
Figure	7.1	Dkk-3	epithelial-stromal	negative	feedback	model	in	prostate	reactive	stroma	and	PCa	
	
Supplementary	Tables	
Supplementary	Table	1	Solutions	for	polyacrylamide	gel	electrophoresis	(PAGE)		
Supplementary	Table	2	Buffers	
Supplementary	Table	3	Primary	antibodies	used	for	western	blotting	and	immunohistochemistry	
Supplementary	Table	4	Secondary	antibodies	used	for	western	blotting	and	immunohistochemistry	
Supplementary	Table	5	Western	blotting	stripping	methods	
Supplementary	Table	6	Drugs	and	proteins	used	for	experiments	
Supplementary	Table	7	Proteome	Profiler	reagents	
Supplementary	Table	8	Histochemistry	reagents	
	
	
	
	
	
	 	
	 12	
Abbreviations	
	 	 	
ADT		
Ad-REIC	
APS		
AR			
AM	
BME	
BPE	
BPH	
Androgen	deprivation	therapy	
Adenovirus	vector	expressing	human	DKK3	
Ammonium	persulfate	
Androgen	receptor	
Acinar	morphogenesis	
Basement	membrane	extract		
Bovine	pituitary	extract	
Benign	prostatic	hyperplasia	
CAF		
CRC	
CRPC		
CRD	
DAB	
dH₂O	
DKK		
DKKL1	
ECM-1		
ECM		
EGF			
EMT		
ER	
ERa	
Cancer	associated	fibroblast	
Colorectal	cancer	
Castration-resistant	prostate	cancer			
Cysteine-rich	domain	
Diaminobenzidine	
Distilled	water	
Dickkopf	
Dkk-3-like	protein					
Extracellular	matrix	protein	1	
Extracellular	matrix	
Epidermal	growth	factor		
Epithelial-mesenchymal	transition		
Endoplasmic	Reticulum	
Oestrogen	receptor	alpha											
FCS	
FGF	
FSP-1	
GAPDH	
H+L	
HGF	
HPV	
H₂O₂	
IgG	
Foetal	calf	serum	
Fibroblast	growth	factor	
Fibroblast	specific	protein-1	
Glyceraldehyde	3-phosphate	dehydrogenase	
Heavy	and	Light	chains	of	IgG	
Hepatocyte	growth	factor	
Human	papillomavirus	
Hydrogen	peroxide	
Immunoglobulin	G	
	 13	
IGF		
IL-1a			
KSFM		
MeOH	
ml	
min	
MiR	
MKL1			
MMP		
MSC	
NE	
NF		
NSCLC			
PAP			
PCa    	
PI3K	
PDGFR			
PGE2		
pH	
PIN		
PP2A		
PSA 	         	
Insulin-like	growth	factor	
Interleukin-1a	
Keratinocyte	serum-free	medium	
Methyl	alcohol	
Millilitre	
Minute	
MicroRNA	
Megakaryoblastic	leukaemia	1	
Matrix	metalloproteinase	
Mesenchymal	stromal	cells	
Neuroendocrine		
Normal	fibroblast			
Non-small	cell	lung	cancer							
Prostatic	acid	phosphatase	
Prostate	cancer	
Phosphoinositide	3-Kinase	
Platelet-derived	growth	factor	receptor	
Prostaglandin	E2	
Potential	of	hydrogen	(numeric	scale)	
Prostatic	intraepithelial	neoplasia	
Protein	phosphatase	2A	
Prostate	specific	antigen	
rh	
R-Smad	
RP		
SASP		
SMA		
SMC	
SNP		
TGFBI		
TGF-β		
TRAF		
VSMC	
ZO-1	
Recombinant	human	
Receptor	Smad	
Radical	prostatectomy	
Senescence-associated	secretory	protein			
Smooth	muscle	actin	
Smooth	muscle	cells			
Single-nucleotide	polymorphism	
Transforming	growth	factor-β	induced	
Transforming	growth	factor	beta	
Tumour	necrosis	factor	receptor	associated	factor	
Vascular	smooth	muscle	cells	
Zona	occludens-1	
	 14	
	
Chapter	one	
	
Introduction	
	 	
	 15	
	
Introduction	
		The	development	of	advanced	methods	of	cancer	detection	and	our	deeper	understanding	
of	the	oncogenic	process	have	increased	the	possibility	of	winning	the	war	against	cancer	[1].	
One	 strategy	 that	 might	 help	 us	 win	 this	 battle	 is	 the	 modulation	 of	 the	 host	 micro-
environment	 so	 that	 it	 becomes	 a	 more	 hostile	 environment	 for	 cancer	 cells.	 Autocrine	
factors	and	their	receptors	mediate	communication	between	epithelial	cells	and	their	stromal	
micro-environment,	 and	 may	 be	 novel	 targets	 for	 molecular	 therapies.	 In	 this	 context,	
evidence	is	accumulating	in	studies	on	a	wide	variety	of	tumour	cell	types	that	the	secreted	
protein	Dickkopf-3	(Dkk-3)	has	the	potential	to	be	both	an	effective	tumour	biomarker	and	
promising	anti-tumour	therapy	[2].	
	
The	prostate			
	
Prostate	anatomy	and	histology	
The	prostate	is	a	tubuloalveolar	exocrine	gland	found	in	males	[3].	Prostate	glands	secrete	a	
milky	colour	alkaline	fluid	that	helps	to	neutralise	the	acidity	of	vaginal	secretions,	as	well	as	
support	sperm	survival	[4].			
Prostate	anatomy	
					The	normal	prostate	gland	is	pyramidal	in	shape	and	slightly	larger	than	the	size	of	a	walnut	
[5].	The	base	of	the	prostate	is	in	contact	with	the	urinary	bladder	and	the	apex	surrounds	
the	 urethra	 inferiorly	 (Figure	 1.1)	 [6].	 The	 prostatic	 secretions	 enter	 the	 urethra	 [6].	 The	
weight	of	the	prostate	is	usually	7–16	g	in	youth	but	there	is	considerable	variation	in	size,	
which	increases	with	age,	and	increasing	body	mass	index	[5,	7].	
			The	human	prostate	gland	can	be	divided	into	four	zones	(Figure	1.1).	The	peripheral	zone	
(PZ)	is	located	at	the	posterior	aspect	surrounding	the	urethra.	The	PZ	consists	of	70%	of	the	
prostate	in	adults.	Up	to	80%	of	prostate	cancers	occur	in	the	PZ	[8].	The	central	zone	(CZ)	
surrounds	the	ejaculatory	ducts	and	forms	25%	of	the	adult	prostate.	Only	2.5%	of	cancers	
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occur	in	the	CZ.	The	transitional	zone	(TZ)	consists	of	5%	of	the	prostate	gland	and	surrounds	
the	proximal	urethra.	It	enlarges	with	age,	leading	to	benign	prostatic	hyperplasia	(BPH).	The	
incidence	of	cancer	in	the	TZ	is	10–20%.	The	anterior	fibro-muscular	zone	(FMZ)	or	stroma	
consists	of	5%	of	the	prostate,	comprising	smooth	muscle	and	collagen	fibres.	
Prostate	histology	
		The	prostate	is	made	up	of	branched	glands	and	ducts	with	two	distinct	layers	of	epithelium;	
the	 secretory	 and	 basal	 epithelia	 (Figure	 1.2).	 The	 secretory	 epithelium	 consists	 of	 tall	
columnar	 cells	 that	 are	 responsible	 for	 the	 secretion	 of	 prostate-specific	 antigen	 (PSA),	
prostatic	acid	phosphatase	(PAP)	and	kallikrein-related	peptidase	2	(KLK2),	which	are	found	
in	the	seminal	fluid	[9,	10].	The	basal	layer	consists	of	cuboidal	epithelium	and	is	believed	to	
be	 the	 repository	 of	 stem	 cells	 that	 are	 responsible	 for	 regenerating	 the	 epithelial	
compartment	of	the	prostate.		
	It	has	been	suggested	that	secretory	cells	originate	from	prostate	stem	cells	that	undergo	
asymmetric	cell	division	to	produce	a	stem	cell	and	a	progenitor	cell.	Progenitor	cells	then	
further	divide	into	two	daughter	cells	that	differentiate	 into	the	secretory	epithelium	[11].	
The	 basal	 cell	 layer	 is	 undifferentiated,	 androgen-independent	 and	 does	 not	 exhibit	 any	
secretory	activity,	in	contrast	to	the	secretory	epithelial	cell	layer	[12,	13].		
		The	basal	cell	layer	is	embedded	in	the	basement	membrane	that	separates	the	epithelial	
cells	 from	 the	 stroma.	 Neuroendocrine	 (NE)	 cells	 are	 another	 type	 of	 cell	 that	 are	 found	
scattered	 in	 the	epithelial	 layers	 [14].	 The	origin	of	NE	 cells	 is	 unclear,	with	 some	 studies	
suggesting	 that	 they	 come	 from	basal	 stem	 cells	 and	other	 studies	 suggesting	 a	 neuronal	
origin	[15,	16].	The	precise	function	of	NE	cells	 is	not	fully	understood	but	they	have	been	
recognised	as	cells	that	play	roles	in	prostate	embryology,	differentiation	and	carcinogenesis.	
NE	cells	are	androgen-independent,	terminally	differentiated	cells	[15,	16].			
		Stromal	cells	are	also	present	in	the	prostate,	and	consist	of	a	mixture	of	a	variety	of	cell	
types,	which	 include	 fibroblasts,	 smooth	muscle	 cells,	 lymphatic	 cells	 and	nerve	 cells.	 The	
interactions	of	the	three	types	of	cells	in	the	epithelium	(secretory,	basal	and	NE	cells)	with	
the	 stroma	 contribute	 to	 the	 regulation	 of	 prostate	 growth,	 differentiation	 and	 prostate	
cancer	progression	[17].	However,	the	underlying	mechanisms	are	not	fully	understood	[18].		
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Importantly,	pre-malignant	histopathological	modifications,	such	as	“dysplasia”	or	“atypia”	
[19],	are	found	in	the	prostate	epithelium.	It	is	thought	that	prostatic	intraepithelial	neoplasia	
(PIN)	 starts	 as	 mildly	 dysplastic	 epithelium	 (PIN	 grade	 1)	 within	 the	 architecture	 of	 the	
prostate	acinus,	progresses	to	moderate	alteration	(PIN	grade	2)	and	then	to	severe	alteration	
(PIN	grade	3)	until	the	eventual	development	of	cancer	[20,	21].	The	average	timeline	of	PIN	
progression	to	prostate	cancer	is	approximately	10	years,	based	on	autopsy	studies.	However,	
it	is	not	universally	accepted	that	all	prostate	tumours	originate	from	PIN.	
Prostate	cancer	
	
		Prostate	 cancer	 (PCa)	 is	 the	most	 common	non-skin	 cancer	 and	 the	 sixth	most	 common	
cause	of	cancer-related	deaths	worldwide	(the	former	in	the	UK	and	the	latter	in	the	USA)	
[22].	In	2013,	29,720	patients	out	of	238,590	men	diagnosed	with	PCa	died	from	the	disease	
in	the	USA	[23].	Furthermore,	those	above	50	years	of	age	are	part	of	a	risk	category	(99%	of	
PCa).	Currently,	there	are	intensive	studies	to	identify	high-risk	PCa,	which	is	found	in	roughly	
15%	 of	 patients	who	 experience	 disease	 recurrence	 either	 locally	 or	 systemically	 and	 are	
destined	to	die	from	the	disease	[24].	A	refined	classification	scheme	is	required	to	assist	in	
early	diagnosis	and	proper	intervention	of	the	high-risk	PCa	population.	In	addition,	a	refined	
classification	 system	should	be	associated	with	 the	prediction	of	overall	 survival	 [25].	 The	
measurement	of	PSA	levels,	the	TNM	system	(T	stands	for	tumour	size,	N	stands	for	nearby	
lymph	nodes,	and	M	stands	for	metastasis)	and	the	Gleason	score	[26]	are	indices	commonly	
used	to	classify	risk	group.	However,	more	specific	and	sensitive	indices	are	needed	[27,	28].	
		The	 available	 treatments	 for	 PCa	 (Figure	 1.3)	 are	 radical	 prostatectomy	 (RP,	 surgery),	
radiotherapy,	and	hormonal	therapy	(androgen	deprivation	therapy	(ADT)).	In	addition,	there	
are	new	therapies	in	development	based	on	studies	in	the	fields	of	immunotherapy	(cancer	
vaccination)	and	targeted	therapies	(cell	signalling)	[29].	It	is	well	known	that	the	androgen	
receptor	 is	 responsible	 for	 the	 proliferation	 and	 survival	 of	 PCa	 cells	 [30].	 The	 first	 line	
treatment	for	patients	with	metastatic	PCa	is	ADT.	The	first-line	treatment	for	patients	with	
metastatic	PCa	is	ADT.	However,	the	majority	of	patient	tumours	become	androgen	resistant	
in	a	median	time	of	18–24	months.	This	phenomenon	is	called	castration	resistant	prostate	
cancer	(CRPC)	[31].	Drug	resistance	may	develop	in	a	subpopulation	of	cancer	cells	that	are	
resistant	to	cancer	therapies,	such	as	drug	efflux	activity.	Moreover,		 	
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cancer	 cells	 and	 their	 surrounding	micro-environment	 undergo	 intensive	 crosstalk,	 which	
leads	to	the	activation	of	signals	that	allow	cancer	cells	to	survive	therapy	[33].	Another	cause	
of	cancer-drug	resistance	is	insufficient	drug	delivery	[34].	Drug	resistance	mechanisms	are	
being	targeted	in	the	hope	that	they	can	be	combined	with	ADT	[34].	
		The	 aggressive	histopathological	 phenotype	of	 PCa	 is	 acquired	 through	multiple	 steps	of	
epigenetic	 and	 genetic	 modifications	 that	 facilitate	 cancer	 cell	 survival,	 proliferation	 and	
capacity	 for	 invasion	 [35].	 These	 modifications	 are	 associated	 with	 alterations	 in	 many	
biological	 aspects	 (Table	 1.1).	 First,	 increased	 systemic	 levels	 of	 growth	 factors	 –	 such	 as	
insulin-like	growth	factor	(IGF)	-1	and	IGF-2,	mainly	secreted	by	the	liver,	which	correlate	with	
PSA	 levels	>	10	and	high	Gleason	 score	and	can	promote	proliferation	 [36].	 Second,	 gene	
mutations,	 such	as	 in	PTEN,	which	normally	 counteracts	 activation	of	phosphoinositide	3-
kinase	(PI3K)	and	its	downstream	mediators	Akt	and	mTOR,	which	promotes	protein	synthesis	
and	enhances	tumour	growth	[37].	Third,	activation	of	transcription	factors,	such	as	AR	and	
c-Myc,	 whose	 genes	 are	 frequently	 amplified	 in	 PCa	 [38].	 AR	 is	 a	 110	 kDa	 zinc	 finger	
transcription	 factor	 and	 its	 stimulation	 initiates	 upon	 the	 binding	 of	 its	 ligands,	 mainly	
dihydrotestosterone	 (DHT)	 but	 also	 testosterone,	 leading	 to	 AR	 translocation	 from	 the	
cytoplasm	to	the	nucleus,	where	it	regulates	the	transcription	of	genes	important	for	prostate	
gland	growth,	development	and	survival	[32].	Activation	of	c-Myc	is	also	associated	with	the	
loss	of	FOXP3	[39].	Point	mutations	in	the	AR	ligand-binding	domain	facilitate	activation	by	
other	hormones	and	even	by	AR	antagonists	used	 in	 therapy.	TMPRSS2-ERG	gene	fusions,	
found	 in	 40–60%	 of	 PCa	 patients,	 result	 in	 androgen-dependent	 expression	 of	 the	
transcription	factor	ERG	[44]	and	contribute	to	androgen	resistance	and	PCa	progression	[45,	
46].	Fourth,	increased	expression	of	transcriptional	co-regulators,	such	as	steroid	receptor	co-
activator	 2	 (SRC2),	 a	 potent	 AR	 activator	 [40].	 SRC2	 is	 over-expressed	 in	 PCa	 and	 alters	
expression	of	AR	target	genes	[41].	Fifth,	the	activation	of	proteases,	such	as	MMP2	[42]	and	
MMP9	[43],	which	promote	PCa	invasion	and	metastasis.	
		At	diagnosis,	10–20%	of	PCa	patients	present	with	bone	metastasis	[35].	PCa	is	commonly	
asymptomatic	(two	thirds	of	patients	had	no	symptoms	when	diagnosed).	Once	symptoms	
are	noticed,	patients	usually	present	with	advanced	stage	PCa	and	metastases	[47].		
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It	is	hoped	that	the	characterisation	of	the	epigenetic	and	genetic	modifications	that	control	
the	molecular	mechanisms	that	 lead	to	PCa	 initiation	(biomarker	detection)	and	drive	PCa	
towards	an	aggressive	phenotype	(changes	in	cell	signalling	or	the	micro-environment)	will	
be	beneficial	for	detecting	PCa	at	an	early	stage	and	reduce	the	incidence	of	metastasis,	thus	
reducing	morbidity	and	mortality	rates	[35].	On	the	other	hand,	a	limited	understanding	of	
the	molecular	mechanisms	involved	reduces	the	possibility	of	creating	new	therapies	–	for	
example,	 the	 relative	 contributions	 of	 c-Myc,	 TMPRSS2-ERG	 and	 loss	 of	 PTEN	 to	 PCa	
progression	are	still	not	fully	understood	[48].	
	
Prostate	cancer	and	the	micro-environment	
	
Insight	into	the	micro-environment	
		Prostate	 cancer	 is	 likely	 initiated	 from	 the	 epithelial	 compartment	 after	 critical	 genetic	
and/or	 epigenetic	 changes	 that	 accumulate	 throughout	 cancer	 progression.	However,	 the	
micro-environment	 also	 plays	 a	 role	 and	 can	 either	 accelerate	 or	 reduce	 cancer	
aggressiveness,	 resistance	to	therapy,	 immune	escape	and	metastasis	 [49].	 In	general,	 the	
tumour	 micro-environment	 consists	 of	 cells,	 the	 extracellular	 matrix	 (ECM)	 and	 soluble	
factors.	There	are	several	cell	types:	endothelial	cells,	pericytes,	fibroblasts	and	bone	marrow-
derived	cells,	such	as	mast	cells,	mesenchymal	stem	cells,	macrophages	and	neutrophils	[50,	
51].	These	can	promote	cancer	progression	by	secreting	chemokines	(which	act	as	chemo-
attractants	for	PCa	and	other	cells	[52]),	cytokines	(which	affect	the	behaviour	of	nearby	cells	
but	do	not	necessarily	attract	them	[53]),	and	growth	factors	and	proteases	(which	remodel	
the	 ECM).	 Many	 growth	 factors	 and	 cytokines	 influence	 the	 epithelial	 to	 mesenchymal	
transition	 (EMT).	 the	 process	 in	 which	 epithelial	 cells	 lose	 their	 polarity	 and	 adhesion	 to	
adjacent	cells	and	acquire	migratory	and	invasive	features,	becoming	more	like	mesenchymal	
cells	 [54].	 EMT	 is	 driven	 largely	 by	 transforming	 growth	 factor	 beta	 (TGF-β),	 but	 also	 by	
hepatocyte	 growth	 factor	 (HGF),	 fibroblast	 growth	 factor	 (FGF),	 epidermal	 growth	 factor	
(EGF),	 IGF	 and	 interleukin	 1	 alpha	 (IL-1α)	 [55-59].	 EMT	 endows	 epithelial	 cells	 with	
mesenchymal	features,	such	as	an	increased	expression	of	SMA,	vimentin,	N-cadherin,	type	
I/III	collagen,	fibronectin	and	fibroblast-specific	protein	1	(FSP-1)	and	reduces	expression	of	
epithelial	markers,	 such	as	cytokeratin	18,	 zona	occludens	 (ZO)-1,	mucin	1	and	E-cadherin	
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[33].	 Another	 biological	 reflection	 of	 TGF-β	 signalling	 is	 the	 regulation	 of	 the	 zinc	 finger	
transcription	factors	Snail,	Zeb-1	and	Slug,	increased	expression	of	which	promotes	EMT	and	
contributes	to	poor	clinical	prognosis	[34].	
		Importantly,	 the	 crosstalk	 between	 cancer-associated	 fibroblasts	 (CAFs)	 and	 tumour	
epithelial	cells	is	fundamental	to	facilitating	EMT	and	vascular	invasion	via	many	molecules,	
mainly	those	secreted	by	the	fibroblasts	[35].	Stroma	can	also	promote	drug	resistance	via	
paracrine	signalling	loops	of	cytokines	and	growth	factors,	such	as	stromal	cell-derived	factor-
1	(SDF-1)	and	IL-6	[60].	
		The	healthy	micro-environment,	which	consists	of	fibroblasts,	smooth	muscle	cells,	immune	
cells	and	vascular	cells	(Figure	1.4)	[61],	can	provide	a	barrier	against	PCa	progression	and	
metastasis.	Some	stromal	components	show	the	ability	to	restrain	cancer	cells	and	regulate	
immune	suppressor	protective	mechanisms,	as	has	been	demonstrated	in	pancreatic	ductal	
adenocarcinoma	 [61,	62].	However,	 the	conversion	of	benign	 stroma	 to	cancer	 stroma	by	
signals	from	cancer	cells	creates	a	supportive	environment	for	cancer	cell	invasion	[62,	63].	
For	example,	P62	 is	a	 tumour	 suppressor	protein	 that	becomes	downregulated	 in	 tumour	
stroma,	altering	the	metabolism	through	the	regulation	of	mTORC1	and	c-Myc,	resulting	in	
increased	 IL-6	 secretion,	which	promotes	PCa	progression	 [64].	Cancer-associated	 stroma,	
also	known	as	“reactive	stroma”,	are	characterised	by	the	presence	of	CAFs,	myofibroblasts	
and	the	remodelled	ECM	[64-66].	
Fibroblasts	and	CAFs	
Fibroblasts	are	the	predominant	cell	type	in	the	stroma	of	solid	tumours,	such	as	breast	and	
prostate	cancer	[36].	In	addition,	they	contribute	to	many	vital	processes	in	the	tumour	micro-
environment,	 such	 as	 the	 expression	 and	 secretion	 of	 either	 pro-tumorigenic	 or	 tumour	
suppressive	factors,	the	deposition	of	the	ECM	(desmoplastic	response),	the	modulation	of	
immune	responses,	the	regulation	of	EMT,	epigenetic	changes	and	the	promotion	of	a	cancer	
stem/progenitor	 cell	 phenotype	 [37-41].	 Fibroblasts	 can	 be	 sub-classified	 into	 fibrocytes,	
myofibroblasts,	senescent	fibroblasts	and	fibroblast	progenitors.	Fibroblast	progenitors	have	
three	different	fates:	they	stop	dividing	(senescent	cells),	differentiate	into	myofibroblasts	or	
resume	cell	division	[42-44].	Senescent	fibroblasts	accumulate	in	many	tissues	as	the	tissues		
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grow	 older	 [45,	 46]	 and	 secrete	 inflammatory	 cytokines	 called	 senescence-associated	
secretory	proteins	(SASPs)	–	for	example,	EGF	and	CXCLs,	which	 increase	PCa	proliferation	
and	survival	[47].	In	addition,	SASPs	contribute	to	the	increased	proliferation	of	transformed	
and	non-transformed	prostate	epithelial	cells	[43].	
		Myofibroblasts	are	a	transient	population	of	contractile	cells	found	during	wound	healing	
and	 inflammation	 that	 express	 smooth	 muscle	 actin	 (SMA)	 and	 collagen	 [48].	 They	 can	
become	 permanently	 differentiated	 and	 a	 predominant	 cell	 type	 in	 reactive	 stroma.	
Differentiated	 myofibroblasts	 are	 also	 called	 CAFs	 [49,	 50].	 In	 addition,	 the	 micro-
environment	and	tumour-derived	factors	direct	the	CAF	phenotype.	Thus,	the	CAF	phenotype	
and	the	state	of	differentiation	and	activation	vary	from	one	tissue	to	another.	This	is	called	
“topographic	 differentiation”,	 where	 differentiation	 is	 based	 on	 anatomical	 position	 [51].	
CAFs	express	mesenchyme-specific	proteins,	such	as	fibroblast	activation	protein	(FAP),	FSP-
1,	vimentin	and	SMA.	In	addition,	they	secrete	chemokines	and	cytokines,	such	as	IL-6	and	
CXCLs,	and	growth	factors	including	TGF-β,	vascular	endothelial	growth	factor	(VEGF),	HGF,	
EGF	and	FGF	[52,	53].	There	are	no	precise	markers	for	CAFs,	as	they	come	from	different	
origins.	Their	likely	origins	are	resident	fibroblasts	and	bone	marrow-derived	mesenchymal	
precursor	cells.	There	is	also	a	controversial	hypothesis	that	they	are	generated	from	tumour	
cells	that	have	undergone	EMT	[54-56].	Many	recent	studies	show	the	pivotal	impact	of	CAFs	
on	tumour	progression	[57].	CAFs	play	fundamental	roles	in	multistep	cancer	progression:	in	
tumorigenesis	 [58,	59],	pro-metastatic	signalling	 [60,	61]	and	distant	metastasis	 [62].	CAF-
derived	pro-inflammatory	factors	increase	the	activation	of	immune	suppressor	cells,	creating	
a	pro-inflammatory	environment	characterised	by	an	attenuated	 immune	response	rich	 in	
cancer-supporting	growth	factors	[63-65].	For	example,	CXCL12	promotes	tumour	cell	growth	
and	 stimulates	 endothelial	 precursor	 cell	 invasion	 into	 tumour	 tissue	 [66],	 and	 CXCL14	
activates	 fibroblasts	 in	 the	PCa	micro-environment	 in	an	autocrine	manner	 [67].	 In	breast	
cancer,	breast	cancer	cells	secrete	Wnt-7a	to	increase	CAF	recruitment	and	activation	[68].	
The	proposed	mechanism	is	the	indirect	activation	of	TGF-β	signalling	in	stromal	fibroblasts.	
			In	 contrast,	 other	 studies	 show	 that	 CAFs	 and	 normal	 fibroblasts	 (NFs)	 restrict	 tumour	
progression,	depending	on	tissue	type	and	tissue	context.	Thus,	both	stroma	and	cancer	type	
should	 be	 taken	 into	 consideration	 to	 determine	 the	 end	 response	 of	 CAF/NF-cancer	 cell	
crosstalk.	One	study	demonstrated	the	impact	of	Slit-2	ligands	expressed	by	NFs	and	CAFs,	
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which	 bind	 to	 Robo-1	 on	 breast	 cancer	 cells	 to	 reduce	 tumorigenesis	 by	 interfering	with	
PI3K/β-catenin	signals	[69].	Cancer	cells	that	do	not	express	Robo-1	show	increased	tumour	
aggressiveness.	Slit-2	 is	also	correlated	with	overall	survival	and	metastasis.	Another	study	
demonstrated	 a	 dual	 function	 of	 fibroblast-derived	Wnt-3a,	 in	 which	Wnt-3a	 inhibits	 the	
growth	of	 triple	negative	breast	 cancer	 cells	but	 increases	 the	growth	of	 cancer	 cells	 that	
overexpress	the	human	EGF	receptor-2	(HER2)	[70].	
			Some	studies	have	revealed	the	consequences	of	alteration	 in	 the	expression	of	stromal	
factors	 in	 terms	 of	 predicting	 patient	 relapse	 and	 tumour	 aggressiveness,	 based	 on	
race/ethnicity	[71,	72].	For	example,	PCa	is	more	aggressive	in	African	American	men,	and	a	
comparison	of	gene	expression	 in	 tumours	 in	African	American	and	Caucasian	men	 found	
more	alterations	in	stromal	gene	expression	in	the	former	that	contributed	to	poor	prognosis	
[72].	Therefore,	the	evaluation	and	validation	of	stromal	proteins	that	promote	changes	in	
the	epithelium	could	have	an	 impact	on	the	development	of	novel	therapies	targeting	the	
stroma	in	PCa.	This	may	be	achieved	by	targeting	stromal	secreted	glycoproteins	and	their	
related	epithelial	receptors	in	the	cancer	micro-environment	[73-75].		
	MicroRNAs	(miRs)	also	play	roles	in	the	communication	between	stromal	and	epithelial	cells.		
These	 22	 nucleotides	 non-coding	 RNAs	 regulate	 gene	 expression	 by	 inhibiting	 the	
transcription	and/or	the	translation	of	mRNAs.	For	example,	miR-409,	miR-379	and	miR-154,	
which	 are	 located	 together	 on	 human	 chromosome	 14,	 are	 transmitted	 via	 extracellular	
vesicles	 (EVs)	 from	 CAFs	 to	 the	 prostate	 epithelium	 in	 a	 paracrine	 manner	 and	 enhance	
tumour	 growth	 in	 a	 PCa	mouse	model	 [76,	 77].	 In	 addition,	 this	 group	of	miRs	 promotes	
stem/progenitor	cell	phenotype	in	PCa	and	enhances	EMT	in	the	prostate	epithelium	[78].		
Activation	of	fibroblasts	into	myofibroblasts	(CAFs)	
		Myofibroblasts	were	 first	 recognised	by	Gabbiani	et	al	 in	 inflammatory	 tissues	 that	show	
alterations	in	granulation.	The	contractile	properties	of	myofibroblasts,	which	are	considered	
to	be	mid-differentiated	between	fibroblasts	and	smooth	muscle	cells	(SMCs),	are	essential	
in	wound	closure	and	in	accelerating	the	healing	process	[79].	After	a	few	weeks,	the	tissue	is	
restored	to	normal	physiology	by	reversible	differentiation	of	myofibroblasts	to	fibroblasts.	
However,	irreversible	differentiation	of	the	myofibroblast	phenotype	is	chronically	sustained	
in	 pathological	 states,	 such	 as	 cancer,	 keloids,	 scleroderma,	 rheumatoid	 arthritis	 and	
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hypertrophic	 scars	 [80].	 TGF-β	 signalling	 is	 a	 key	 driver	 of	 fibroblast	 to	 myofibroblast	
differentiation	and	the	continuous	activation	of	TGF-β	signalling	is	observed	in	pathological	
states	 [81-83].	 In	 addition,	 gene	 expression	 profiling	 has	 shown	 that	 the	 major	 genes	
regulated	by	TGF-β	and	MAPK	are	more	highly	expressed	in	CAFs	compared	to	NFs	[84,	85].	
		Myofibroblasts	 have	 several	 characteristic	 features,	 including	 the	 expression	 of	 SMA,	
proliferative	activity,	high	motility,	secretion	of	cytokines	and	the	ability	to	remodel	the	ECM	
[86].	 Recent	 studies	 have	 added	 other	 sources	 of	myofibroblasts,	 including	 pericytes	 and	
SMCs	during	vascular	wound	healing	[87],	epithelial	cells	during	EMT	and	endothelial	cells	
during	endothelial	to	mesenchymal	transition	(EndMT).	During	EndMT,	endothelial	cells	lose	
the	expression	of	TIE1,	TIE2,	CD31	and	VE-cadherin	and	express	myofibroblast	markers	[88,	
89].	Furthermore,	stem	cells	can	undergo	myofibroblast	differentiation	in	response	to	specific	
stimuli	[90].	Another	promoter	of	myofibroblast	differentiation	is	connective	tissue	growth	
factor	 (CTGF),	 which	 potentiates	 TGF-β	 signalling	 [91].	 In	 addition,	 PDGF	 promotes	 the	
synthesis	of	TGF-β	in	fibroblast	cultures	[92]	and	ZEB	transcription	factors	act	as	TGF-β/EMT	
activators	to	suppress	the	expression	of	E-cadherin	[92].	Other	signalling	pathways	may	also	
be	involved	in	myofibroblast	differentiation.	Wnt-3a,	for	example,	differentiates	fibroblasts	
to	myofibroblasts	in	a	β-catenin-dependent	manner	[93],	and	Notch	signalling	crosstalk	with	
TGF-β/Smad3	activates	myofibroblast	differentiation	[94].	Until	recently,	the	concept	of	the	
irreversibly	 differentiated	 myofibroblast	 was	 predominantly	 accepted;	 however,	 in	 fact,	
myofibroblasts	 can	 be	 dedifferentiated	 and	 pass	 through	 further	 proliferation	 and	
differentiation	depending	on	tissue	context.	Factors	that	promote	dedifferentiation	include	
FGF,	prostaglandin	E2	(PGE2),	MyoD	and	nuclear	factor	erythroid	2-related	factor	2	(Nrf2)	[95-
98].	Generally,	TGF-β	is	the	key	inducer	of	myofibroblast	differentiation	and	EMT,	and	other	
mediators	either	directly	or	indirectly	act	on	TGF-β	signalling	[99,	100].	
TGF-β	signalling	in	prostate	cancer	(PCa)	
		Tumour	cells	maintain	their	growth	and	survival	in	the	tissue	by	converting	the	surrounding	
environment	through	alterations	in	cancer/stromal	cell	interactions	at	the	primary	site	and	at	
secondary	 (metastatic)	 sites	 [101,	 102].	 The	 fundamental	 elements	 involved	 in	 the	 two	
compartment	 interactions	 are	 growth	 factors,	 cytokines,	 pro-angiogenic	 factors	 and	
components	 of	 the	 ECM	 [103,	 104].	 The	 TGF-β	 signalling	 pathway	 is	 potent	 and	
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multifunctional,	 contributing	 to	 embryogenesis,	 organogenesis,	 wound	 healing,	
immunomodulation	and	cancer	progression	[105,	106].	The	TGF-β	isoforms	in	mammals,	TGF-
β1,	TGF-β2	and	TGF-β3,	generally	have	similar	functions.	In	addition,	there	other	ligands	that	
activate	TGF-β	signalling,	such	as		Bone	Morphogenetic	Proteins	(BMPs),	Activin,	Nodal,	and	
Growth	and	Differentiation	Factors	(GDFs)	[107,	108].	
		The	TGF-β	signalling	pathway	begins	with	the	formation	of	TGF-β	75	kDa	homodimers,	which	
are	processed	in	the	Golgi	and	cleaved	into	mature	25	kDa	homodimers.	The	cleaved	TGF-β	
homodimer	then	binds	to	latency-associated	protein	(LAP)	to	form	the	small	latent	complex	
[109].	This,	in	turn,	binds	another	TGF-β	homodimer	via	disulphide	bonds	to	form	the	large	
latent	complex	(LLC)	 in	the	endoplasmic	reticulum	(ER),	which	 is	exported	to	the	ECM	and	
interacts	with	fibronectin	fibrils	and	heparin	sulphate	proteoglycans	(HSPGs).	Furthermore,	
fibrillin-rich	microfibrils	 serve	as	a	 repository	 for	 the	LLC	 in	 the	ECM.	 Importantly,	 the	LLC	
requires	proteases,	thrombospondin	1,	integrin	and	reactive	oxygen	species	to	be	activated	
to	initiate	signalling	[109].	
		Signalling	is	initiated	when	TGF-β	binds	to	the	serine/threonine	(S/T)	kinase	TGF-β receptor	
II	(TβRII).	This	binding	leads	to	phosphorylation	and	trans-activation	of	TβRI	(Activin	receptor-
like	 kinase	 (ALK5))	 [110].	 Activated	 receptors	 propagate	 signalling	 to	 the	 nucleus	 via	
phosphorylation	of	the	receptor	Smads	(R-Smads)	–	Smad2	and	Smad3,	as	well	as	Smads	1,	5,	
8	–	which	bind	to	Smad4	to	regulate	gene	expression	(Figure	1.5).	This	process	can	be	blocked	
by	 inhibitory	Smads	 (I-Smads),	 Smad6	and	Smad7	 [110].	TGF-β	 signalling	can	be	canonical	
(Smad-dependent),	 activating	 gene	 expression	 via	 Smads,	 and	 non-canonical	 (Smad-
independent),	acting	through	MAPK	kinase,	Rho-like	GTPases	and	PI3K/AKT	[111]	(Figure	1.5).	
		TGF-β	signalling	activity	switches	from	tumour	suppressive	to	tumour	promoting	depending	
on	 the	 tumour	 stage	 [112,	 113].	 TGF-β	 is	 anti-proliferative	 and	 pro-apoptotic	 in	 benign	
prostate	 epithelial	 cells,	 with	 activity	 through	 c-Myc	 and	 cyclin-dependent	 kinase	 (CDK)	
inhibitors	 [114,	115].	 In	advanced	PCa,	TGF-β	signals	are	aberrantly	activated	 (Figure	1.5),	
leading	to	the	dysregulation	of	several	factors,	such	as	MMP9	(which	promotes	invasion)	and	
VEGF	(which	regulates	the	growth	of	new	blood	vessels,	thus	contributing	to	PCa	progression)	
[116].	However,	the	mechanism	of	TGF-β	switching	to	a	tumour	promoting	pathway	is	not	
well	understood.		
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Low	 concentrations	 of	 TGF-β1	 (0.1	 ng/ml)	 promote	 auto-induction	 of	 TGF-β	 signalling	 in	
benign	prostate	and	PCa,	while	higher	concentrations	(10	ng/ml)	induce	the	recruitment	of	
protein	 phosphatase	 2A	 (PP2A),	 leading	 to	 the	 termination	of	 both	MAPK/ERK	 and	 TGF-β	
signalling	 [117].	 In	 PCa	 cells,	 TGF-β	 auto-induction	 is	 associated	 with	 a	 defect	 in	 the	
recruitment	of	PP2A	 [118].	PP2A	plays	a	 role	 in	CRPC	by	protecting	 the	SP-1	 transcription	
factor	from	degradation,	thereby	suppressing	the	expression	of	AR	and	other	genes	important	
in	PCa	[119,	120].	
		Changes	in	the	TGF-β	signalling	pathway	in	cancer	often	result	from	the	altered	expression	
of	the	major	TGF-β	receptors,	TβRI	and	TβRII	[114,	116,	121,	122].	Inactivation	or	mutation	of	
TGFβRs	has	been	observed	to	promote	PCa.	For	example,	in	the	TRAMP	mouse	model	of	PCa,	
dominant-negative	 TβRII	 increases	 prostate	 epithelial	 cell	 proliferation	 and	 induces	 EMT,	
metastasis	 and	 angiogenesis	 [123].	 In	 addition,	 an	 SNP	 variant	 of	 TβRII	 correlates	 with	 a	
higher-Gleason-score	PCa	and	is	a	risk	factor	of	relapse	after	ADT	in	CRPC	patients	[124,	125].	
		TGF-β	is	secreted	by	the	bone	matrix	at	sites	of	bone	metastasis,	altering	the	homeostatic	
balance	 of	 bone	 formation	 towards	 increased	 bone	 destruction	 [126].	 In	 addition,	 TGF-β	
enhances	the	expression	of	genes	that	promote	metastasis	[127]	and	inhibition	of	the	TGF-β	
signalling	reduces	breast	cancer	bone	metastasis	in	a	mouse	model	[126].	An	important	TGF-
β	 target	 gene	 in	 PCa	 is	PMEPA1	 (prostate	 transmembrane	 protein,	 androgen	 induced	 1),	
which	is	induced	by	and	inhibits	AR	and	TGF-β	signalling;	its	downregulation	leads	to	increased	
TGF-β/Smad3	signalling	and	the	promotion	of	metastasis	[128].	
		TGF-β	signals	also	increase	the	expression	of	DNA	methyltransferases	(DNMTs),	resulting	in	
hypermethylation	 in	many	 gene	 promoters,	 including	 those	 of	 the	 TGF-β 	 receptors,	 and	
thereby	reducing	their	expression	[129].	Another	proposed	mechanism	of	inhibiting	TβRI	in	
prostate	 cancer	 is	 by	ubiquitination	 and	 cleavage	 via	 the	ubiquitin	 ligase	 tumour	necrosis	
factor	receptor-associated	factor	(TRAF6)	and	ADAM	metallopeptidase	domain	17	(ADAM17).	
This	results	in	the	release	of	the	TβRI	intracellular	domain	(ICD),	which	has	been	proposed	to	
promote	gene	expression	in	the	nucleus	[130].	In	addition,	TGF-β	plays	a	role	in	mediating	the	
effects	of	the	actin-binding	protein	cofilin,	a	promoter	of	cell	invasion	and	metastasis	in	PCa	
[131].	
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		There	 is	 remarkable	 crosstalk	 between	AR	 and	 TGF-β	 signalling.	 Androgen	 signalling	 can	
regulate	 TGF-β	 signalling	 in	 PCa	 cells	 at	 the	 early	 stages	 and	 in	 advanced	 PCa	 [132].	 For	
example,	DHT	promotes	the	effects	of	TGF-β/TGFβRII	on	increasing	apoptosis	and	cell	cycle	
arrest	 in	 LNCaP	PCa	 cells,	while	 in	PC3	 cells,	 forced	expression	of	AR	attenuates	 the	TGF-
β/Smad	pathway	[133].	However,	in	CAFs,	AR	knockdown	reduces	TGF-β2	ligand	expression,	
indicating	AR’s	role	in	CAFs	as	a	barrier	against	PCa	invasion	through	the	inhibition	of	TGF-β	
signalling	[134].	In	another	context,	AR/TGF-β	signalling	crosstalk	promotes	EMT	by	regulating	
MMPs	in	the	tumour	micro-environment.	TGF-β	is	a	key	regulator	of	MMP	gene	expression	
in	 many	 types	 of	 cancer	 [135,	 136],	 as	 well	 as	 in	 stromal	 fibroblasts	 [137,	 138].	 The	 AR	
inhibitors	 bicalutamide	 and	 enzalutamide	 have	 been	 found	 to	 increase	 invasiveness	 by	
stimulating	TGF-β	activation	of	MMP9	[139],	suggesting	that	simultaneous	inhibition	of	both	
AR	and	TGF-β	signalling	may	not	always	be	beneficial		
		MiRs	 also	 contribute	 to	 PCa	 progression	 [140],	 partly	 by	 regulating	 TGF-β	 signalling.	 For	
example,	miR-21	 is	upregulated	 in	PCa	and	 interactions	between	Ras	and	TGF-β	signalling	
increase	the	expression	of	miR-21	[141]	[142]	[143,	144].	PCa	with	high	risk	of	bone	metastasis	
correlates	with	 the	downregulation	of	miR-15	and	miR-16	and	the	upregulation	of	miR-21	
[145].	The	downregulation	of	miR-15	and	miR-16	increases	Nodal	and	Activin	receptor	RIIA	(a	
TGF-β	family	receptor	for	Nodal	and	Activin	A)	[146]	to	TGF-β/Smad	signalling	[140],	and	the	
upregulation	of	miR-21	enhances	TGF-β	expression	[140].	MiR-21	also	downregulates	TβRII	
(working	 with	 AR),	 with	 miR-21	 and	 AR	 regulating	 each	 other’s	 expression	 in	 a	 positive	
feedback	loop	to	inhibit	the	tumour-suppressive	activity	of	TGF-β	signalling	[147].	
TGF-β	signalling	in	epithelial-stromal	interactions	in	the	prostate	cancer	micro-environment	
		Signalling	crosstalk	between	the	epithelial	and	stromal	cells	starts	during	embryogenesis	as	
the	two	cell	types	develop	a	suitable	micro-environment	to	initiate	prostate	gland	formation	
from	the	urogenital	sinus	[148].	Secretion	of	TGF-β	during	the	development	of	the	prostate	
ductal	 system	 preserves	 the	 composition	 and	 cellular	 haemostasis	 of	 the	 proximal,	
intermediate	 and	 distal	 regions	 [149].	 The	 stroma	 around	 the	 subdivided	 regions	 of	 the	
developing	prostate	consist	mainly	of	smooth	muscle	cells	around	the	proximal	region,	which	
secrete	a	high	level	of	TGF-β,	while	the	distal	region	is	mainly	surrounded	by	fibroblasts,	which	
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secrete	low	levels	of	or	no	TGF-β.	These	patterns	of	TGF-β	expression	maintain	the	normal	
size	 and	 composition	 of	 the	 prostate	 gland	 by	 regulating	 the	 growth	 and	 proliferation	 of	
prostate	epithelial	cells.	Disturbance	in	these	patterns	of	expression	can	lead	to	pathological	
conditions,	such	as	BPH	and	PCa	[50,	150,	151].		
		In	 the	 normal	 prostate,	 TGF-β	 is	 a	 gatekeeper	 that	 maintains	 cellular	 homeostasis	 and	
structural	integrity.	The	cross	talk	between	two	cellular	components	of	the	epithelium	and	
the	stroma	relies	on	the	 interaction	between	TGF-β	and	IGF	signalling.	 Indeed,	continuous	
activation	and	the	synergistic	role	between	both	pathways	in	the	tumour	micro-environment	
can	lead	to	the	progression	of	prostate	cancer	[152].	
		The	 adult	 prostate	 is	 arranged	 as	 individual	 ductal	 systems	 consisting	 of	 the	 proximal,	
intermediate,	 and	 distal	 regions	 [152].	 The	 stability	 of	 these	 regions	 is	 maintained	 in	 a	
homeostatic	state	through	strictly	regulated	TGF-β	signalling	cross	talk	between	the	stromal	
and	epithelial	compartments	[152].	The	epithelium	of	the	distal	duct	consists	of	proliferative	
cells,	 whereas	 the	 epithelium	 cells	 in	 the	 proximal	 region	 consist	 of	 cells	 undergoing	
apoptosis.	Majority	of	the	epithelial	cells	in	the	intermediate	region	of	the	ductal	system	are	
in	a	differentiated,	quiescent	state	[152].	Smooth	muscle	cells	are	mainly	in	the	proximal	part	
and	produce	high	levels	of	TGF-β,	whereas	fibroblasts	are	in	the	distal	part	and	secrete	either	
low	 or	 no	 TGF-β.	 This	 pattern	 of	 differential	 TGF-β	 secretion	 plays	 a	 fundamental	 role	 in	
maintaining	epithelial-stromal	homeostasis,	as	TGF-β	is	a	potent	inhibitor	of	proliferation	in	
the	ductal	epithelium.	An	imbalance	in	TGF-β	production	can	contribute	to	BPH	and	PCa	[152].	
These	pathological	effects	can	be	amplified	by	IGF,	which	stimulates	PI3K/Akt	signalling	and	
supports	the	formation	of	reactive	stroma	through	the	increased	production	of	CAFs,	which	
produce	more	TGF-β	than	fibroblasts	[152].	
		TGF-β	 signalling	 is	 a	 potent	 regulator	 of	 PCa	 aggressiveness	 and	 progression,	 due	 to	 its	
effects	on	myofibroblast	differentiation	and	the	expression	of	VEGF	 [153,	154].	Silibinin,	a	
compound	extracted	from	milk	thistle	seeds	that	is	under	investigation	for	cancer	treatment,	
significantly	 reduces	 fibroblast	 differentiation	 into	 myofibroblasts	 by	 inhibiting	 TGF-β2	
expression	 by	 PCa	 cells	 [153].	 Further	 evidence	 regarding	 the	 role	 of	 TGF-β	 in	 regulating	
fibroblast	differentiation	is	demonstrated	in	breast	cancer,	where	Wnt-7a	secreted	by	cancer	
cells	potentiates	TGF-β	signalling	in	fibroblasts	[68].	In	addition,	TGF-β	signalling	regulates	the	
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production	of	VEGF,	a	regulator	of	angiogenesis	 in	the	prostate.	Apigenin	(a	plant	flavone)	
reduces	 the	 production	 of	 VEGF	 in	 PCa	 cells	 by	 inhibiting	 TGF-β/Smad	 signalling	 [154].	 In	
addition,	 TGF-β	 can	 affect	 the	 stromal	micro-environment	 through	 its	 effects	 on	 immune	
system	cells.	Infiltrated	inflammatory	cells	in	the	tumour	micro-environment	activate	the	CAF	
production	 of	 exosomes	 that	 further	 convert	 the	 stroma	 to	 a	 more	 favourable	 micro-
environment	for	cancer	cells	[155].	
		Mouse	models	have	been	used	to	evaluate	the	effects	of	TGF-β	on	PCa	stroma.	In	a	xenograft	
model,	prostate	stromal	cells	null	for	TβRII	or	expressing	dominant-negative	Smad3	failed	to	
support	 the	growth	and	angiogenesis	of	LNCaP	xenograft	 tumours	because	 this	presented	
stromal	expression	of	FGF2,	which	is	required	for	tumour	growth	[156].	Similarly,	the	TβRII	
knockout	in	mouse	prostate	fibroblasts	demonstrated	the	role	of	paracrine	HGF	signalling	in	
the	formation	of	PIN	lesions	[157].	Thus,	TGF-β	signalling	in	prostate	fibroblasts	is	important	
for	modulating	the	growth	and	oncogenic	potential	of	adjacent	epithelia.	
		MMPs,	in	particular	MMP2	and	MMP9,	are	important	for	prostate	development	and	ECM	
remodelling	 [158]	and	both	are	upregulated	by	TGF-β	signalling	 in	PCa	 [159].	At	 the	same	
time,	Dkk-3	is	a	potent	regulator	of	TGF-β/Smad	signalling	in	prostate	epithelial	cells,	where	
it	maintains	normal	prostate	morphogenesis	and	epithelial	proliferation	by	attenuating	TGF-
β	 signalling	 [160].	 Silencing	 of	 Dkk-3	 increases	 the	 levels	 of	 MMP2	 in	 RWPE-1	 prostate	
epithelial	cells	and	of	MMP9	 in	primary	prostate	epithelial	cells	 [161].	Dkk-3	may	regulate	
MMP	activity	 via	 its	effects	on	TGF-β	 signalling	 [162],	 and	as	a	 result	has	 the	potential	 to	
restrict	prostate	cancer	metastasis.	 Interestingly,	control	of	MMP	activity	 is	also	important	
for	 acinar	 morphogenesis:	 the	 broad-spectrum	 MMP	 inhibitor	 marimastat	 increases	 the	
proportion	of	normal	acini	formed	by	prostate	epithelial	cells	[161].	
Dickkopf-3	(Dkk-3)	is	a	unique	member	of	the	Dickkopf	family	
The	Dkk-3	protein	
Dkk-3	is	a	secreted	glycoprotein	that	is	a	member	of	the	Dickkopf	family,	consisting	of	Dkk-1	
to	4	and	Dkk-3-like	1	(DKKL1/Soggy)	[163].	Dkk-3	is	also	found	in	many	invertebrates,	but	not	
in	 Drosophila	 [163].	 Dkk	 family	 members	 consist	 of	 255–350	 amino	 acids	 and	 have	 two	
conserved	cysteine-rich	domains	(CRDs)	called	Cys1	and	Cys2	(Figure	1.6).	Soggy	only	shares	
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homology	with	Dkk-3	and	does	not	have	CRDs	[2,	164].	Dkk-3	is	the	largest	family	member	
and	shares	only	about	37%	sequence	identity	with	Dkk-1,	Dkk-2	and	Dkk-4.	It	has	a	larger	N-
terminal	domain	and	a	much	shorter	region	between	Cys1	and	Cys2	than	Dkk-1,	Dkk-2	and	
Dkk-4	 [165].	 The	Cys2	domain	has	a	 colipase	 fold,	which	 is	 found	 in	 colipases,	where	 it	 is	
involved	 in	 lipid	hydrolysis	and	also	 in	unrelated	proteins,	 such	as	protease	 inhibitors	and	
invertebrate	toxins	[166,	167].			
		Mice	with	a	homozygous	deletion	in	Dkk1	lack	head	structures	anterior	of	the	midbrain	and	
show	duplications	and	fusions	of	limb	digits,	while	deletion	of	Dkk2	results	in	transformation	
of	the	corneal	epithelium	into	a	stratified	epithelium	that	expresses	epidermal	markers	and	
develops	hair	follicles	[163].	In	contrast,	the	phenotype	of	Dkk3	knockout	mice	is	relatively	
mild:	the	mice	are	hyperactive	and	have	changes	in	lung	ventilation,	changes	in	the	numbers	
of	NK	cells	[168]	and	defects	in	B	cell	development	[169].	It	has	been	suggested	that	this	mild	
phenotype	might	be	a	result	of	compensation	by	Soggy,	consistent	with	Soggy	mutant	mice	
also	 having	 no	 overt	 phenotype	 [170].	 However,	 Soggy	 is	 expressed	 primarily	 in	
spermatocytes	and	 the	 trophectoderm	[163,	171].	 In	 the	mouse	prostate,	Dkk-3	has	been	
detected	near	the	cell	surface	of	the	inner	lumen	of	the	prostate	gland	[172].	The	prostates	
of	 Dkk-3	 mutant	 mice	 show	 changes	 in	 the	 prostate	 tissue	 organisation	 and	 increased	
prostate	epithelial	cell	proliferation	[160].	
		Dkk-3	is	a	unique	member	of	the	Dkk	family	and	its	influences	on	cell	signalling	differ	from	
the	prototype,	Dkk-1	[163,	166,	173].	Dkk-1	is	the	founding	member	of	DKK	family	and	it	was	
first	identified	as	a	stimulator	of	head	formation	in	Xenopus	embryos,	where	it	inhibits	Wnt/β-
catenin	signalling	[174].	Wingless-type	mouse	mammary	tumour	virus	integration	site	(Wnt)	
signals	exert	roles	in	embryogenesis	and	alterations	in	Wnt	signalling	pathway	components	
are	common	in	tumorigenesis	[175,	176].	Secreted	inhibitors	of	Wnt	signalling	are	frequently	
downregulated	 in	 cancer.	 They	 include	Wnt	 inhibitory	 factor	 1	 (WIF-1),	 secreted	 frizzled-
related	 family	 proteins	 (sFRPs)	 and	 Dkk	 family	 proteins	 [2].	 The	 effects	 of	 Dkk-3	 on	Wnt	
signalling	vary:	Dkk-3	has	been	reported	to	inhibit	Wnt	signalling	in	osteosarcoma	cell	lines,	
malignant	glioma	cells,	breast	cancer	cells	and	non-small	cell	lung	cancer	(NSCLC)	cells	[2].	In	
contrast,	Dkk-3	has	no	effect	on	Wnt	 signalling	 in	Xenopus	embryos	 [2].	Although	ectopic	
expression	of	Dkk-3	does	not	directly	affect	Wnt	signalling	in	PCa	cells	[177],	DKK3	silencing		
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in	RWPE-1	prostate	epithelial	cells	can	potentiate	Wnt/β-catenin	signalling	activity	induced	
by	 the	 transfection	 of	 limiting	 amounts	 of	 β-catenin,	 and	 this	 could	 be	 inhibited	 by	 co-
transfected	Dkk-3	(61),	suggesting	that	endogenous	Dkk-3	indirectly	represses	β-catenin/Tcf	
signalling.	In	addition,	a	recent	study	in	mice	found	an	alternative	start	site	in	the	mouse	Dkk3	
promoter	 that	 produces	 a	 new	 intracellular	 gene	 product,	 Dkk-3b,	 which	 inhibits	 cell	
proliferation	by	binding	to	β-catenin	in	a	complex	with	β-TrCP	[178].	However,	it	is	not	known	
if	this	intracellular	form	of	Dkk-3	also	exists	in	human	cells.	
The	potential	roles	of	Dkk-3	in	the	immune	system	
		Dkk3	knockout	mice	have	been	used	to	study	the	role	of	Dkk-3	in	the	immune	system	[169].	
Dkk3	mutant	mice	have	an	impairment	in	B	cell	development,	resulting	in	decreased	numbers	
of	follicular	B	cells	in	adult	mice,	altered	antibody	responses	and	an	increased	secretion	of	IL-
10.	Additionally,	Dkk3	has	been	found	to	 limit	autoimmunity	 in	a	model	of	systemic	 lupus	
erythematosus.		
		MSCs	play	a	pivotal	 role	 in	modulating	 the	 immune	micro-environment.	Generally,	MSCs	
limit	many	aggressive	types	of	systemic	immune	responses,	such	as	is	seen	in	autoimmune	
disease,	host-versus-graft	disease,	and	auto-encephalitis	[179].	While	wild-type	MSCs	inhibit	
immune	 responses	 against	 transplanted	 tumours,	 Dkk3-deficient	 MSCs	 do	 not	 affect	 the	
rejection	process.	Increased	CD8+	T	cells	and	reduced	macrophage	infiltration	were	observed	
in	 tumours	 inoculated	 together	 with	 Dkk3-deficient	 MSCs.	 Thus,	 Dkk-3	 could	 alter	 the	
composition	of	 the	 tumour	 stroma,	 thereby	 supporting	 the	MSC-mediated	 suppression	of	
immune	responses	against	these	tumour	transplants	[180].	
	Dkk-3	also	modulates	peripheral	CD8	T	cell	tolerance.	T	cells	are	normally	tolerant	to	self-
antigens,	 thereby	 preventing	 autoimmune	 reactions.	 Dkk-3	was	 found	 to	 be	 expressed	 in	
tolerant	CD8	T	cells	and	to	be	essential	for	the	observed	CD8	T	cell	tolerance.	Dkk3	knockout	
reversed	tolerance,	leading	to	an	eradication	of	tumours	expressing	the	target	antigen	and	a	
rejection	of	autologous	skin	grafts	[181].		
		Dkk-3	secreted	by	tumours	has	been	proposed	to	help	cancer	cells	to	escape	the	immune	
system	[182].	The	injection	of	the	Dkk-3	protein	into	immune-deficient	mice	transfected	with	
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various	cancer	cell	lines	leads	to	increased	tumour	growth	by	reducing	regulatory	T	cell	(Treg)	
proliferation	in	vitro	and	reducing	Treg	activation	in	vivo	[182].	Another	study	suggested	that	
Dkk-3-Treg	 communication	 involves	 Dkk-3	 attenuation	 of	 ERK	 [183].	 Dkk-3	 also	 regulates	
cytokine	expression	and	the	differentiation	of	monocytes	to	dendritic	cells	(DC)	in	a	process	
that	involves	IL-4	and	the	granulocyte	macrophage-colony	stimulating	factor	(GM-CSF)	[184].	
Peripheral	blood	CD14+	monocytes	have	been	differentiated	successfully	to	DC	by	incubation	
with	recombinant	Dkk-3	[185].	Furthermore,	a	DKK3-expressing	virus	inhibits	tumour	growth	
in	mouse	allograft	models	of	lung	cancer	and	malignant	mesothelioma	by	inducing	cytotoxic	
T	lymphocyte	infiltration,	dendritic	and	natural	killer	(NK)	cell	activation	and	the	expression	
of	major	histocompatibility	complex	(MHC)	class	I	molecules	[186,	187].	
The	DKK3/REIC	(reduced	expression	in	immortalised	cells)	gene	
		Tsuji	 et	 al.	 first	 identified	 DKK3	 as	 a	 gene	 located	 at	 chromosome	 11p15	 with	 reduced	
expression	 in	 immortalised	 cells	 (REIC)	 in	 cancer	 cell	 lines,	 and	 also,	 for	 the	 first	 time	 in	
primary	samples	of	 lung	cancer,	where	63%	of	specimens	showed	 low	expression	of	DKK3	
mRNA	 [188].	 Downregulation	 of	 DKK3	 was	 later	 observed	 in	 a	 wide	 variety	 of	 primary	
haematological	and	solid	cancers,	with	remarkably	 low	expression	 in	a	high	proportion.	 In	
PCa,	DKK3	promoter	methylation	was	observed	in	68%	of	tumours,	correlating	with	significant	
downregulation	 of	 DKK3	 mRNA	 expression	 [189].	 Moreover,	 in	 testicular	 cancer,	 the	
estimated	downregulation	of	DKK3	is	100%	[190]	(Table	1.2).	However,	in	some	cancers	DKK3	
methylation	 is	 low	and	mRNA	and	protein	expression	are	high.	Examples	of	 this	would	be	
ganglioneuroma,	a	type	of	brain	tumour	[191],	and	in	oral	squamous	cell	carcinoma	(OSCC),	
where	DKK3	siRNA	reduces	OSCC	cell	migration	and	invasion	[192].		
		The	main	mechanism	for	DKK3	downregulation	in	cancer	is	the	reduced	transcription	of	the	
DKK3	gene	[193].	This	is	through	the	methylation	of	CpG	islands	in	the	DKK3	promoter,	which	
interferes	 with	 the	 access	 of	 transcriptional	 factors	 and	 RNA	 polymerase	 II.	 In	 addition,	
methylation	 and	 deacetylation	 of	 histones	 can	 contribute	 to	 the	 suppression	 of	 DKK3	
transcription	[193].	Hypermethylation	of	the	DKK3	promoter	has	been	detected	as	a	tumour-	
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related	event	in	many	types	of	cancer	(Table	1.2)	and	can	be	reversed	by	drugs	that	promote	
demethylation,	such	as	decitabine	and	zebularine	[194-196].	
Possible	functions	of	Dkk-3	
		In	contrast	to	Dkk-1,	Dkk-2	and	Dkk-4,	Dkk-3	does	not	bind	to	LRP5/6	receptors	and	its	effect	
on	Wnt	signalling	is	complex.	In	addition,	it	is	involved	in	the	regulation	of	TGF-β	signalling	
[160,	 197].	 Specific	 mammalian	 Dkk-3	 receptors	 have	 still	 not	 been	 identified,	 further	
contributing	to	the	mystery	of	the	Dkk-3	function.	However,	zebrafish	Dkk3	has	been	found	
to	bind	to	an	integrin	family	member	(60).		Recently,	a	novel	receptor	for	the	Cys-1	domain	in	
Dkk-1	was	 identified	as	cytoskeleton-associated	protein	4	 (CKAP4)	 [198].	The	possibility	of	
CKAP4	binding	to	Dkk-3	has	still	not	been	investigated.	Like	Dkk-1,	the	Cys2	domain	of	Dkk-2	
and	Dkk-4	also	inhibits	Wnt	signalling	by	binding	to	LRP5/6	receptors	[174].	Dkk-1,	Dkk-2	and	
Dkk-4	interactions	with	LRP5/6	also	involve	Kremen	(Krm	1/2)	co-receptors	[199].	Dkk-3	has	
been	reported	to	bind	to	Krm	1/2	in	the	retina,	but	this	interaction	was	intracellular	[200].	
The	 Cys2	 domain	 appears	 to	 be	 important	 for	 Dkk-3	 activity	 in	 PCa,	 as	 it	 inhibits	 TGF-β-
induced	MMP9	 and	MMP13	 expression	 in	 PCa	 cells	 [161],	 and	 also	 inhibits	 PCa	 invasion.	
However,	the	Cys2	domain	does	not	rescue	acinar	morphogenesis	in	DKK3-silenced	prostate	
epithelial	cells,	suggesting	that	other	domains	in	Dkk-3	are	also	required	for	full	activity	[161].	
		Most	studies	support	the	notion	that	Dkk-3	is	a	tumour	suppressor.	The	results	of		in	vivo	
and	 in	 vitro	 studies	 of	 Dkk-3	 using	 gain-of-function	 approaches	 suggest	 that	 the	 anti-
proliferative	role	of	Dkk-3	in	cancer	cells	is	mediated	via	the	induction	of	apoptosis	[2].	Ectopic	
expression	of	DKK3	in	breast	cancer	cell	lines	suppressed	cell	growth	in	basal-like	but	not	in	
luminal-like	breast	cancer	cells,	and	ectopic	expression	of	DKK3	in	mesenchymal	basal	breast	
cancer	cells	partially	restored	epithelial	cell	morphology	and	the	expression	of	E-cadherin	and	
downregulated	mesenchymal	markers,	 such	as	Snail1	 [201].	 In	addition,	 the	expression	of	
Dkk-3	has	been	shown	to	prevent	metastasis	in	osteosarcoma	(OS).	OS	is	associated	with	a	
high	rate	of	distant	metastasis,	particularly	to	the	lung,	and	poor	overall	survival	[202].	Ectopic	
expression	 of	 DKK3	 significantly	 reduced	 metastasis	 to	 the	 lung	 by	 reducing	 EMT,	 as	
demonstrated	by	the	 increased	expression	of	epithelial	markers	(E-cadherin,	keratin	8	and	
keratin	 18)	 and	 the	 reduced	 expression	 of	 the	 mesenchymal	 markers	 (N-cadherin	 and	
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fibronectin),	and	by	the	regulation	of	MMPs	(MMP2,	MMP9),	cell	motility	and	proliferation	
[138].	In	addition,	ectopic	expression	of	DKK3	in	NSCLC	cell	lines	restored	their	sensitivity	to	
cisplatin	in	vitro	[203]	and	in	vivo	[204].	However,	the	role	of	Dkk-3	in	cancer	depends	on	the	
tissue.	 For	 example,	 high	 Dkk-3	 expression	 in	 head	 and	 neck	 squamous	 cell	 carcinoma	
correlates	with	 reduced	metastasis-free	 survival	 [205].	Moreover,	DKK3	overexpression	 in	
these	cells	 increased	proliferation,	migration	and	 invasion	by	activating	PI3K/Akt	signalling	
[206].	
		In	 PCa,	Dkk-3	 is	 tumour	 inhibitory.	 Ectopic	 expression	 of	DKK3	 in	 the	 PCa	 cell	 lines	 PC3,	
DU145	and	LNCaP	induces	apoptosis	via	phosphorylation	of	JNK,	reduction	of	Bcl-2	and	Bcl-xl	
levels,	 displacement	of	BAX	 to	 the	mitochondrial	membrane	and	 release	of	 cytochrome	c	
[207].	 In	 contrast,	 recombinant	 Dkk-3	 does	 not	 affect	 the	 proliferation	 or	 viability	 of	 the	
prostate	or	PCa		cell	lines	(PrEC,	PrSC,	BPH-1	LNCaP,	and	PC3)	[208].	Moreover,	other	groups	
have	 stably	overexpressed	DKK3	 in	BPH-1,	 LNCaP	and	PC-3	cells	 [208],	and	not	 found	any	
differences	 in	 apoptosis	 [208].	 The	 different	 results	might	 reflect	 the	 lower	 physiological	
levels	of	expression	obtained	by	transient	overexpression	[208].		
		ER	stress	response	is	thought	to	contribute	to	Dkk-3-associated	apoptosis.	This	response	can	
occur	through	unbalanced	protein	induction	methods	–	for	example	producing	unfolded	or	
misfolded	protein	[209].	Expression	of	amino	acids	1–78	of	Dkk-3,	which	contains	a	coiled-coil	
domain,	strongly	induces	ER	stress-related	apoptosis	in	PC3	cells,	much	more	than	is	observed	
when	using	full-length	Dkk-3	[210].	Another	potential	function	of	Dkk-3	in	apoptosis	has	been	
described	 in	 studies	 on	 diabetes	 and	 liver	 steatosis	 (the	 accumulation	 of	 fat	 in	 the	 liver),	
where	Dkk-3	 is	 implicated	as	an	 inhibitor	of	 insulin	resistance	and	glucose	 intolerance	and	
shows	anti-inflammatory	effects.	In	this	case,	Dkk-3	was	reported	to	interact	with	Apoptosis	
signal-regulating	kinase	1	(ASK1)	and	to	attenuate	p38/JNK	signalling	[211].		
		How	 Dkk-3,	 a	 secreted	 protein,	 can	 interact	 with	 ASK1,	 a	 cytoplasmic	 protein,	 remains	
unclear.	 However,	 there	 are	 several	 other	 reports	 of	 Dkk-3	 associating	 with	 cytoplasmic	
proteins,	such	as	β-TrCP,	a	negative	regulator	of	Wnt/β-catenin	[212].	In	prostate	cancer,	a	
yeast	 two-hybrid	 screen	 for	 Dkk-3-binding	 proteins	 identified	 small	 glutamine-rich	
tetratricopeptide	repeat-containing	protein	α	(SGTA),	which	is	a	negative	regulator	of	AR.	The	
interaction	 involved	 the	N-terminal	domains	of	Dkk-3	and	SGTA,	and	Dkk-3	was	 shown	 to	
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interfere	with	SGTA	dimerisation,	preventing	the	inhibition	of	AR.	As	it	was	previously	found	
that	Dkk-3	 interacts	with	 the	dynein	 light	chain	TCTEX-1,	 it	has	been	proposed	 that	Dkk-3	
promotes	the	dynein-dependent	transport	of	AR	and	 increases	AR	signalling	by	 interfering	
with	SGTA	dimerisation	[213].	The	physiological	relevance	of	these	interactions	remains	to	be	
determined.	 However,	 as	 mentioned	 above,	 an	 intracellular	 form	 of	 Dkk-3	 was	 recently	
described	[178].	
		In	support	of	the	secreted	form	of	Dkk-3	having	a	physiological	role,	one	study	found	the	
binding	 of	 Dkk-3	 to	 the	 surface	 and	 subsequent	 endocytosis	 in	 pluripotent	 stem	 cells	 of	
embryoid	 bodies	 [214].	 Moreover,	 zebrafish	 Dkk3	 has	 been	 found	 to	 associate	 with	 an	
integrin	 [215].	 However,	 cell	 surface	 receptors	 for	 Dkk-3	 in	mammals	 have	 still	 not	 been	
identified.		
Dkk-3	in	the	prostate	and	PCa	
Regulation	of	DKK3	gene	expression	in	PCa	
		Expression	of	Dkk-3	has	been	assessed	at	the	mRNA	and	protein	 levels	 in	the	prostate	 in	
benign	and	cancer	cell	lines	[207].	DKK3	mRNA	expression	is	very	low	in	LNCaP	and	PC3	cells	
and	low	in	DU145	cells,	compared	to	benign	epithelial	and	stromal	cells	[207,	208].	There	are	
differences	in	protein	size,	most	likely	reflecting	different	levels	of	glycosylation	[207,	208].	In	
addition,	Dkk-3	has	been	evaluated	in	normal,	BPH	and	PCa	patients	[207,	208]:	Dkk-3	protein	
expression	is	heterogeneous	in	the	normal	prostate	epithelium	and	concentrated	in	the	basal	
cell	 layer.	 In	 BPH,	 Dkk-3	 expression	 in	 the	 basal	 layer	 has	 also	 been	 confirmed	 by	
immunofluorescence,	where	it	was	found	co-expressed	with	the	basal	cell	marker	p63	[208].	
In	low-Gleason-score	PCa,	Dkk-3	expression	in	epithelial	cells	is	mostly	maintained,	but	it	is	
significantly	 downregulated	 in	 high-Gleason-score	 PCa.	 Blood	 vessels	 also	 show	 the	
expression	of	Dkk-3	in	BPH	and	in	low-Gleason-score	PCa	[208].	Another	analysis	[207]	used	
quantitative	methods	 to	 assess	 the	 immunostaining	 intensity	 of	 Dkk-3	 in	 freshly	 isolated	
tissue	samples	from	patients	with	PCa	and	BPH.	This	revealed	a	significant	loss	of	Dkk-3	in	
patients	with	Gleason	scores	of	8–10,	compared	to	Gleason	scores	below	7.	The	expression	
of	Dkk-3	in	low-Gleason-score	tumours	was	still	lower	than	in	BPH	and	normal	tissues	(such	
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as	 liver,	heart,	brain,	 lymph	node,	kidney,	spleen	and	mammary	gland)	[207].	 In	PCa,	as	 in	
most	human	cancers,	the	DKK3	gene	is	downregulated	by	promoter	methylation	[2].		
		Two	promoters	 for	 the	DKK3	gene	have	been	described,	 (a)	and	 (b)	 [216],	with	 (a)	being	
more	active	 than	 (b)	 in	most	 tissues	 [217].	 In	PCa,	promoter	 (a)	 is	more	methylated	 than	
promoter	 (b)	 [216].	Another	study	estimated	DKK3	promoter	hypermethylation	 in	primary	
PCa	to	be	78%	(n=41)	[190].	
		DKK3	gene	expression	can	be	restored	in	PCa	cell	lines	by	treatment	with	decitabine	(also	
known	 as	 5-aza-2ʹdeoxycytidine),	 a	 chemical	 analogue	 of	 the	 nucleoside	 cytosine	 (which	
inhibits	DNMT	 at	 low	 doses,	 causing	 DNA	 hypomethylation)	 and	 the	 histone	 deacetylase	
inhibitor	 trichostatin	 A	 [190].	 DKK3	 is	 one	 of	 a	 group	 of	 Differentiation-Associated	
Hypermethylated	(DAH)	genes	in	PCa,	which	includes	GSTP1	[218].	It	has	been	proposed	that	
the	downregulation	of	DAH	genes	is	the	result	of	cell	differentiation	and	is	not	cancer	specific,	
as	these	genes	are	expressed	and	methylation-free	 in	undifferentiated	PCa	cells,	and	their	
hyper-methylation	 is	 not	 essential	 for	 tumour	 development.	 On	 the	 other	 hand,	 an	
intermediate	level	of	methylation	(48%)	is	sufficient	to	silence	the	DKK3	gene	and	contribute	
to	adrenal	dedifferentiation	and/or	progression	to	malignancy	[219],	so	smaller	changes	in	
the	DKK3	gene	promoter	methylation	may	be	relevant	in	terms	of	PCa	progression.	
There	are	other	mechanisms	for	the	regulation	of	DKK3	gene	expression.	For	example,	miR-
183	is	upregulated	in	PCa	and	inversely	correlates	with	DKK3	gene	expression,	and	when	miR-
183	is	silenced,	this	increases	DKK3	expression	[220].	In	addition,	in	neuroblastoma,	MYCN-
regulated	miRs	in	the	miR-17–miR-92	cluster	(miR-19b	and	miR-92a)	bind	the	3ʹUTR	of	DKK3	
and	downregulate	Dkk-3	protein	levels	[221,	222].	Single-nucleotide	polymorphisms	(SNPs)	
can	also	influence	DKK3	expression.	Kim	et	al.	 [223]	evaluated	the	association	between	53	
SNPs	in	the	DKK3	gene	and	PCa	risk	in	Korean	men	(272	with	PCa	and	173	with	BPH).	Some	of	
the	DKK3-	variant	SNPs	correlated	with	the	risk	of	PCa	progression	and	others	with	PSA	levels,	
clinical	stage	and	Gleason	score.	A	limitation	of	this	study	is	the	recruitment	of	a	small	number	
of	men	with	the	same	genetic	make-up,	so	this	study	requires	confirmation	among	a	wider	
population.	
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Studies	on	Dkk-3	in	prostate	epithelial	cells	
		Our	lab	has	been	investigating	the	function	of	Dkk-3	in	the	prostate	epithelial	cells	for	many	
years.	An	interesting	observation	was	made	by	Kawano	et	al.	[177]	using	3D	Matrigel	cultures	
of	 the	 immortalised	prostate	epithelial	 cell	 line	RWPE-1	 to	compare	cells	 transfected	with	
DKK3	 siRNA	 and	 control	 siRNA.	 The	 DKK3-silenced	 cells	 showed	 a	 higher	 proportion	 of	
deformed	acini	compared	to	the	control	cells.	A	subsequent	study	confirmed	this	result	using	
cell	lines	expressing	DKK3	shRNA	(sh6,	sh30)	and	control	shRNA	(NS11,	NS14)	[160,	224].	In	
this	study,	the	exogenous	Dkk-3	protein	only	partially	restored	normal	acinar	morphogenesis	
in	DKK3-silenced	cells	and	reduced	the	numbers	of	normal	acini	in	control	cells,	suggesting	
that	the	level	and	localisation	of	Dkk-3	is	important	in	this	process.	Further	investigation	(i.e.	
examining	 Dkk3	 null	 mice)	 revealed	 morphological	 changes	 in	 the	 prostate	 gland	 and	
increased	 prostate	 epithelial	 cell	 proliferation	 [160,	 224].	 The	 impact	 of	 Dkk-3	 restoring	
normal	acinar	morphogenesis	may	be	related	to	its	ability	to	limit	the	proliferation	of	prostate	
epithelial	cells,	since	prostate	epithelial	cell	proliferation	was	also	increased	in	3D	Matrigel	
cultures	of	DKK3-silenced	RWPE-1	cells	[160].	
		Another	finding	made	in	the	laboratory	is	that	the	ability	of	Dkk-3	to	restore	normal	acinar	
morphogenesis	 involves	the	attenuation	of	TGF-β/Smad	signalling.	The	disruptive	effect	of	
DKK3	 silencing	 on	 acinar	 morphogenesis	 can	 be	 rescued	 by	 the	 inhibitors	 of	 the	 TGF-β	
receptor	and	of	Smad3.	 In	addition,	 the	expression	of	the	TGF-β	target	gene	PMEPA1	was	
found	to	be	elevated	in	DKK3-silenced	cells.	PMEPA1	may	be	involved	in	switching	TGF-β	from	
a	tumour	suppressor	to	a	tumour	promoter	[225].	Thus,	it	has	been	suggested	that	Dkk-3	may	
be	involved	in	this	switch.	Even	though	the	Dkk	family	proteins	are	well	known	as	inhibitors	
of	Wnt	signalling,	this	relationship	is	not	direct	in	the	case	of	Dkk-3	[2].	Wnt	signalling	activity	
and	Wnt	target	gene	expression	are	very	low	in	RWPE-1	cells	during	acinar	morphogenesis	
[160].	It	 is	important	also	to	note	that	the	role	of	Dkk-3	in	the	integrity	of	prostate	acini	is	
consistent	with	PCa	histopathology	data,	since	the	loss	of	Dkk-3	expression	mostly	manifests	
in	high-Gleason-score	tumours,	where	the	architecture	of	the	prostate	is	highly	disorganised,	
with	 the	most	significant	 loss	of	expression	seen	 in	 tumours	with	a	Gleason	sum	score	≥9	
[177].	
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The	role	of	Dkk-3	in	non-epithelial	cells	in	the	prostate	
	
		Dkk-3	 is	 not	 only	 expressed	 in	 the	 prostate	 epithelium	 but	 has	 also	 been	 found	 in	 the	
prostate	 stroma	 and	 prostate	 endothelium	 [208].	 Alterations	 in	 Dkk-3	 expression	 in	 the	
prostate	 were	 first	 described	 by	 Zenzmaier	 et	 al.	 [208].	 In	 the	 diseased	 prostate,	 and	
particularly	in	age-related	proliferative	disorders	(BPH,	PCa),	Dkk-3	levels	are	reduced	in	the	
epithelial	compartment	and	expressed	at	a	higher	level	in	the	stromal	compartment	[208].	
The	same	group	investigated	the	effects	of	Dkk-3	on	the	remodelling	of	the	prostate	micro-
environment	 using	 lentiviral-delivered	 DKK3	 overexpression	 and	 shRNA-mediated	 DKK3	
knockdown	in	primary	prostate	stromal	cells	[226].	Dkk-3	has	been	found	to	participate	 in	
several	 aspects	 of	 micro-environment	 modification:	 stromal	 remodelling,	 stromal	 cell	
proliferation,	fibroblast	to	myofibroblast	differentiation,	and	the	regulation	of	the	expression	
of	angiogenic	factors.	Dkk-3	knockdown	significantly	reduced	primary	prostate	stromal	cell	
proliferation	in	BrdU	incorporation	assays,	while	apoptosis	was	not	affected,	as	phospho-p53	
and	BAX	levels	did	not	change	[226].	Furthermore,	the	knockdown	of	DKK3	reduced	fibroblast	
to	 myofibroblast	 differentiation,	 as	 demonstrated	 by	 decreases	 in	 SMA	 and	 IGF	 binding	
protein	 3	 (IGFBP3)	 expression.	However,	 overexpression	 of	DKK3	 did	 not	 affect	 fibroblast	
differentiation.	 Stromal	 remodelling	 by	 Dkk-3	 affected	 PI3K/AKT	 signalling	 due	 to	 the	
inhibition	of	AKT	phosphorylation	[226].	
		In	 addition,	Dkk-3	has	been	 shown	 to	be	upregulated	 in	 the	 tumour	 endothelium	 in	 the	
prostate	 and	 other	 cancers,	 including	 pancreatic,	 melanoma,	 colorectal,	 glioma	 and	 non-
Hodgkin	lymphoma,	suggesting	a	role	for	Dkk-3	in	angiogenesis	[227-229].	Moreover,	there	is	
an	 association	 between	 Dkk-3	 and	 the	 expression	 of	 angiopoietin-1	 in	 primary	 prostate	
stromal	 cells,	which	may	maintain	 blood	 vessel	 stability	 in	 the	 cancer	micro-environment	
[226].	
		The	expression	 level	of	Dkk-3	 in	the	stromal	compartment	can	predict	disease	prognosis.	
MSCs	reside	in	the	surrounding	micro-environment	of	the	Myelodysplastic	syndrome	(MDS)	
tissue	from	paediatric	patients,	and	adult	patients	show	variations	in	DKK3	mRNA	expression	
that	reflect	the	outcome	of	MDS	[230].	
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Studies	using	Dkk-3	as	therapy	for	PCa	
	
		The	overexpression	of	Dkk-3	using	an	adenovirus	vector	(Ad-REIC)	has	been	found	to	have	
therapeutic	effects	on	various	human	cancer	 types,	 including	PCa.	For	example,	 	 in	a	case	
study,	 a	 64-year-old	 patient	 with	 CRPC	 and	 multiple	 pelvic	 and	 para-aortic	 lymph	 node	
metastases	was	 treated	 for	 two	years	with	Ad-REIC	 therapy	 injections	 into	 the	metastatic	
sites,	leading	to	shrinking	of	lesion	growth	in	the	lymph	nodes	and	reduced	PSA	levels	[231].	
In	addition,	this	study	highlighted	more	than	one	anti-cancer	mechanism	of	Dkk-3:	firstly,	Dkk-
3	 showed	 a	 selective	 toxicity	 to	 cancer	 cells	 and,	 secondly,	 it	 modulated	 the	 immune	
response,	 promoting	 monocyte	 differentiation	 into	 dendritic-like	 cells	 to	 promote	 the	
infiltration	of	CD11c-	and	CD8-positive	cells	(dendritic	and	killer	T	cell	markers	respectively)	
[185].	Infection	of	normal	human	fibroblasts	with	Dkk-3	adenovirus	was	previously	shown	to	
induce	the	production	of	interleukin	(IL)-7,	which	may	suppress	the	growth	of	the	cancer	cells	
indirectly	[185,	232].	Another	clinical	trial	recruited	18	patients	in	a	phase	I/IIa	study.	Patients	
were	divided	into	two	groups:	CRPC	patients	with	or	without	metastasis	and	patients	with	
high-risk	 localised	PCa	scheduled	for	RP	[233].	Dkk-3	adenovirus	was	given	as	neoadjuvant	
therapy	 in	 four	 escalating	 doses,	 either	 injected	 directly	 into	 prostate	 tumours	 or	 into	
metastatic	 lesions.	 Both	 patient	 groups	 showed	 significant	 reductions	 in	 PSA	 levels.	
Furthermore,	 the	highest	dose	significantly	 increased	recurrence-free	survival.	 In	addition,	
these	clinical	studies	found	that	the	Dkk-3	adenovirus	is	safe	as	a	neoadjuvant	therapy	and	as	
a	cancer	vaccine.	
Dkk-3	expression	in	the	endothelium	
	
		In	 general,	 during	 angiogenesis	 in	 cancer	 pathology,	 endothelial	 cells	 pass	 through	
alterations	in	phenotype,	thus	protein	expression	patterns	in	cancer	endothelium	can	be	used	
as	a	prognostic	marker.	Dkk-3	may	play	an	important	role	in	regulating	vessel	formation	in	
PCa.	Enhanced	angiogenesis	is	a	feature	of	the	remodelled	stroma.	DKK3	silencing	in	prostate	
stromal	 cells	 increase	 the	 expression	 of	 angiopoietins	 [226],	 which	 are	 involved	 in	 blood	
vessel	homeostasis.	Untergasser	et	al.	 first	 reported	the	potential	 role	of	Dkk-3	 in	 tumour	
angiogenesis	 [228].	 They	 found	 that	 the	 number	 of	 blood	 vessels	 expressing	 Dkk-3	 was	
increased	in	glioma,	high-grade	non-Hodgkin	lymphoma,	melanoma	and	colorectal	carcinoma	
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compared	 to	 in	 normal	 tissues.	 They	 further	 showed	 that	 endothelial	 tube	 formation	
decreased	after	the	downregulation	of	Dkk-3	and	increased	after	Dkk-3	the	overexpression,	
and	that	overexpression	of	Dkk-3	 in	melanoma	cells	 increased	microvessel	density	 in	vivo.	
Based	on	their	results,	they	proposed	that	Dkk-3	in	endothelial	cells	acts	as	a	differentiation	
factor	 involved	 in	 remodelling	 the	 tumour	 vasculature.	 The	 same	 group	 showed	 that	
increased	Dkk-3	expression	in	tumour	endothelial	cells	is	an	independent	predictor	of	disease-
free	 survival	 in	 gastric	 cancer	 [234]	 and	 of	 a	 better	 clinical	 outcome	 in	 pancreatic	
adenocarcinoma	[229].	In	the	latter	study,	pancreatic	adenocarcinomas	(n=154)	were	stained	
for	Dkk-3	and	CD31	(an	endothelial	cell	marker).	Patients	with	high	endothelial	expression	of	
Dkk-3	showed	a	significant	improvement	in	terms	of	survival	(15	months)	compared	to	those	
with	 low	 vessel	 Dkk-3	 (7	 months).	 It	 was	 proposed	 that	 Dkk-3	 increased	 sensitivity	 to	
chemotherapy	drugs,	 such	 as	 5-fluorouracil	 or	 gemcitabine.	DKK3	was	 also	 identified	 in	 a	
screen	for	genes	specifically	upregulated	in	colorectal	cancer	tumour	endothelium	[227].		
		The	 exact	 function	 of	 Dkk-3	 in	 the	 endothelium	 remains	 unclear.	 However,	 it	 enhances	
angiogenesis	 which	 is	 one	 of	 the	 key	 feature	 of	 the	 remodelled	 stroma.	 During	 tumour	
progression,	there	is	a	shift	from	the	expression	of	vessel	stabilising	angiopoietin-1	(ANGPT1)	
to	vessel	destabilising	angiopoietin-2	(ANGPT2).	The	angiogenic	switch	renders	the	tumour	
vasculature	amenable	to	vessel	sprouting.	DKK3	overexpression	reduces	ANGPT1	expression	
in	the	melanoma	[228]	and	Dkk-3	and	ANGPT2	are	 inversely	regulated	 in	human	umbilical	
vein	 endothelial	 (HUVEC)	 cells	 after	 the	 knockdown	 of	 AXL	 [235].	 Dkk-3	 has	 also	 been	
associated	with	VEGF	signalling.	Recently,	Busceti	et	al.	[236]	reported	that	Dkk-3	promoted	
tube	formation	by	HUVEC	cells	by	 increasing	VEGF	 levels	and	activating	VEGF	signalling	by	
activating	ALK1	and	 increasing	Smad1/5/8	phosphorylation,	 recruiting	Smad4	 to	 the	VEGF	
gene	promoter.	
Dkk-3	in	other	tissues	and	diseases	
	
		Dkk-3	is	expressed	in	a	variety	of	tissues	during	embryogenesis,	such	as	the	developing	heart,	
bone,	neural	epithelium	and	limb	buds,	where	it	is	expressed	in	mesenchyme	condensations	
[237].	In	adult	tissues,	Dkk-3	is	highly	expressed	in	the	liver,	kidney,	heart	and	brain.	However,	
no	expression	of	Dkk-3	is	seen	in	peripheral	blood	or	the	spleen	[172,	188].	In	the	heart,	DKK3	
mRNA	is	expressed	during	embryonic	development	and	in	adults	[163,	185].	
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		Zhang	 et	 al.	 [238]	 performed	 gain-of-function	 and	 loss-of-function	 studies	 in	 mice	 and	
showed	 that	 Dkk-3	 has	 a	 protective	 effect	 against	 familial	 dilated	 cardiomyopathy.	 The	
beneficial	effects	were	associated	with	the	inhibition	of	apoptosis	signal-regulating	kinase	1-
c-Jun	N-terminal	 kinase	 (ASK1-JNK)	 /p38	 signalling.	They	also	 showed	 that	Dkk-3	based	 to	
ASK1	 and	 that	 dominant-negative	 ASK1	 rescued	 pressure	 overload-induced	 cardiac	
abnormalities	 in	Dkk3	knockout	mice.	Lu	et	al.	 [239]	followed	up	these	studies	 in	a	mouse	
model	for	familial	dilated	cardiomyopathy	development,	showing	that	Dkk-3	upregulated	the	
proteins	of	the	canonical	Wnt	pathway	and	downregulated	the	proteins	of	the	non-canonical	
Wnt	pathway.	Dkk-3	is	also	expressed	in	cartilage	[237]	and	is	upregulated	in	osteoarthritic	
(OA)	cartilage	and	in	the	synovial	fluid	of	OA	patients	[240].	OA	is	an	inflammatory	disease	of	
articular	cartilage	[241]	and	both	Wnt	and	TGF-β	signalling	are	implicated	in	OA	pathology	
[242,	243].	Increased	expression	of	Dkk-3	in	OA	cartilage	and	in	synovial	fluid	was	found	to	
have	a	protective	effect,	and	it	was	proposed	that	this	is	mediated	by	Dkk-3,	which	inhibited	
Wnt	signalling,	enhanced	the	response	to	TGF-β	and	inhibited	the	response	to	activin	[240].	
		More	recently,	studies	have	addressed	the	role	of	Dkk-3	in	atherosclerosis.	The	first	report	
[244]	 found	 that	 Dkk3	 ablation	 in	 mice	 attenuates	 the	 development	 of	 atherosclerosis	
because	Dkk-3	expressed	by	macrophages	modulates	inflammation	and	inactivates	Wnt/β-
catenin	 signalling.	 In	 contrast,	 Yu	 et	 al.	 [245]	 reported	 a	 protective	 role	 for	 Dkk-3	 in	
atherosclerosis,	finding	that	the	level	of	the	plasma	Dkk-3	protein	is	inversely	related	to	this	
disease	 in	 patients	 and	 in	 a	 mouse	 model,	 where	 the	DKK3	 gene	 deficiency	 accelerated	
atherosclerosis	and	delayed	re-endothelialisation.	The	different	conclusions	could	relate	to	
the	use	of	different	mouse	models	and	the	examination	of	Dkk-3	expressed	by	different	cell	
types.		
Prostate	and	PCa	cell	line	models	
	
		Three	well-characterised	PCa	cell	lines	–	PC3,	DU145	and	LNCaP	–	have	been	used	for	studies	
of	 Dkk-3.	 Interestingly,	 they	 all	 derive	 from	 sites	 of	metastasis	 and	 not	 from	 the	 original	
tumour	[246].	PC3	cells	derive	from	a	bone	metastasis	and	are	an	androgen-independent	cell	
line	(they	do	not	express	PSA	or	AR)	that	developed	from	grade	IV	adenocarcinoma	[247].	PC3	
cells	can	grow	as	subcutaneous	tumours	in	nude	mice	[247].	PC3	tumours	present	histological	
features	of	an	epithelial	neoplasm	with	abnormal	nuclei,	nucleoli	and	numerous	microvilli	
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[248].	DU145	cells	were	derived	from	a	prostate	cancer	brain	metastasis	 [249].	Cells	were	
extracted	from	a	scalp	lesion	and	cultured	in	a	petri	dish	plated	with	collagen	[250].	DU145	
cells	are	also	hormone-independent	AR-negative	cells	[250].	LNCaP	is	a	commonly	used	PCa	
cell	line	derived	from	an	aspirated	biopsy	of	the	supraclavicular	lymph	node	[249].	LNCaP	cells	
express	AR,	are	androgen-sensitive	and	form	tumours	when	injected	into	nude	mice	[251].	
While	PC3	cells	exhibit	a	high	capacity	for	metastasis,	this	is	moderate	for	DU145	cells	and	
low	for	LNCaP	cells	[252].	
		In	this	thesis,	I	used	RWPE-1	and	WPMY-1	cells	as	models	to	investigate	the	role	of	Dkk-3	in	
prostate	epithelial	stromal	cell	communication.	Both	are	non-tumour	prostate	cell	lines	that	
were	derived	from	the	benign	prostate	of	the	same	donor,	a	54-year-old	white	man,	and	so	
provide	a	unique	 in	vitro	model	with	minimal	differences	in	the	genomic	sequences	of	the	
two	 cell	 types.	 The	 RWPE-1	 prostate	 epithelial	 cell	 line	 was	 immortalised	 using	 human	
papilloma	virus	18	and	expresses	the	 luminal	epithelial	cell	cytokeratins	CK8	and	CK18,	AR	
and	PSA;	and	its	growth	can	be	stimulated	by	EGF,	b-FGF	and	reduced	(to	a	small	extent)	by	
TGF-β.	The	WPMY-1	prostate	stromal	cell	line	was	immortalised	using	SV40	large	T	antigen	
[253].	WPMY-1	cells	express	features	of	myofibroblasts,	namely	SMA	and	vimentin.	They	also	
express	MMP2	and	AR	their	growth	can	be	stimulated	by	bFGF,	PDGF,	EGF	and	the	synthetic	
androgen	mibolerone	and	reduced	by	TGF-β	[253].	
		WPMY-1	cell	conditioned	media	(CM)	can	reduce	the	proliferation	of	prostate	epithelial	cells	
[253].	WPMY-1	cells	have	been	used	as	an	 in	vitro	model	 to	 investigate	 stromal-epithelial	
interactions	and	signalling	in	the	micro-environment	[254,	255].	For	example,	WPMY-1	cells	
and	WPMY-1	CM	have	been	cultured	with	RWPE-1	cells	and	with	PCa	cell	lines	to	study	the	
mechanism	of	action	of	the	scaffold	protein	caveolin-1,	which	binds	to	multiple	membrane	
signalling	components,	including	integrins	and	tyrosine	kinases	[254].	CM	from	CAV1-silenced	
WPMY-1	 cells	was	 shown	 to	 increase	 the	migration	 of	DU145	 and	 PC3	 cells	 and	 increase	
proliferation	of	LNCaP	cells	[254].	In	addition,	Niu	et	al.	used	WPMY-1	cells	in	in	vivo	studies	
to	test	the	role	of	stromal	AR.	They	inoculated	mouse	prostates	with	different	combinations	
of	cancer	(PC3	control	and	PC3	cell	expressing	AR)	and	stromal	(control	WPMY1	and	WPMY1	
silenced	 for	 AR)	 cells	 and	 showed	 that	 the	 restoration	 of	 epithelial	 AR	 or	 knockdown	 of	
stromal	AR	inhibited	the	growth	of	tumour	metastases	[256].	Moreover,	Yu	et	al.	used	co-
culture	assays	of	WPMY-1	cells	and	PCa	cells	to	study	the	role	of	stromal	MMP2	in	cancer	cell	
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invasion.	Estradiol	increased	MMP2	secretion	in	WPMY-1	cells,	which	then	promoted	PCa	cell	
invasion	in	a	paracrine	manner.	The	effects	could	be	blocked	by	an	anti-MMP2	antibody,	the	
ER	inhibitor	ICI182780,	anti-TGFβ1	and	siRNA	to	ERα.	The	authors	propose	a	model	in	which	
estradiol	induces	expression	of	TGF-β1,	which	stimulates	MMP2	expression	in	WPMY-1	cells	
and	this	promotes	PCa	cell	invasion.	Importantly,	this	study	obtained	similar	results	in	PC3,	
DU145	and	LNCaP	cells,	suggesting	that	this	is	a	general	mechanism	[257].	
		Another	 in	 vitro	 co-culture	 model	 combined	WPMY-1	 cells	 with	 DU145	 cells	 [258].	 The	
authors	showed	that	DU145	cells	metabolise	stromal-derived	factors	to	generate	ligands	for	
ERβ,	 which	 can	 upregulate	 E-cadherin	 and	 limit	 DU145	 cell	 motility.	 However,	 unlike	
fibroblasts,	WPMY-1	cells	did	not	affect	DU145	cell	motility	because	the	DU145	cells	induced	
the	WPMY-1	cells	to	produce	H2O2,	which	acted	as	a	second	paracrine	factor	to	inhibit	ERβ	in	
DU145	 cells.	 This	 second	 signal	 was	 dependent	 on	 the	 presence	 of	 TGF-β1.	 The	 authors	
proposed	 that	 reactive	 stromal	 cells	 limit	 cancer	 cell	 motility	 through	 a	 local	 endocrine	
network,	but,	in	order	to	do	this,	they	must	be	protected	from	pro-oxidant	signals	triggered	
by	cancer	cell-derived	TGF-β1.	
Transforming	growth	factor	beta	induced	(TGFBI)	
	
		TGFBI	is	an	ECM	protein,	originally	called	βIG-H3,	which	was	identified	as	a	gene	activated	
by	TGF-β	in	a	lung	adenocarcinoma	cell	line	[259].	It	has	683	amino	acid	residues	and	in	its	
secreted	form	has	a	molecular	mass	of	68-78	kDa,	depending	on	the	isoform.	TGFBI	contains	
an	amino-terminal	signal	peptide,	a	CRD,	four	fasciclin-1	repeats	and	a	carboxyl-terminal	Arg-
Gly-Asp	(RGD)	integrin-binding	motif	[260]	(Figure	1.7).	TGFBI	plays	a	role	in	maintaining	the	
network	of	connections	between	various	ECM	molecules	and	in	cell	adhesion	to	collagen	and	
fibronectin	 [260].	 It	 functions	 in	 many	 physiological	 processes,	 including	 inflammation,	
wound	healing	and	bone	 formation.	The	 regulation	of	TGFBI	by	TGF-β	 signalling	has	been	
demonstrated	 in	a	variety	of	cell	 types,	 including	 fibroblasts,	smooth	muscle	cells,	corneal	
epithelial	 cells,	 chondrocytes	 and	 cancer	 cells.	 In	 addition,	 TGFBI	 can	 be	 induced	 by	 IL-1,	
retinoids,	TNF-α	and	lysophosphatidic	acid	[260].	
		Alterations	 in	 TGFBI	 are	 associated	 with	 many	 diseases,	 including	 diabetes,	 corneal	
dystrophy	 and	 tumorigenesis	 [260].	 In	 addition,	 the	 expression	 of	 TGFBI	 in	 arterial	 tissue	
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aggravates	atherosclerosis,	consistent	with	the	role	of	TGF-β	signalling	in	promoting	cardiac	
disease,	and	it	increases	glucose	levels	in	VSMCs	and	so	may	play	a	role	in	diabetic	angiopathy	
[260].	 In	 cancer,	 TGFBI	has	dual	 functions	 as	 a	 tumour	 suppressor	 and	 tumour	promoter,	
dependent	on	cell	context	and	the	micro-environment.	For	example,	 in	ovarian	cancer	cell	
lines	 re-expression	 of	 TGFBI	 induces	 cancer	 cell	 death,	whereas	 high	 TGFBI	 expression	 in	
peritoneal	 cells	 promotes	 metastasis	 [260].	 TGFBI	 has	 also	 been	 found	 to	 regulate	 the	
response	 to	paclitaxel	 in	ovarian	cancer	 [261].	The	 tumour	suppressor	effect	of	TGFBI	has	
been	demonstrated	in	breast	cancer,	HeLa	cells,	bronchial	epithelial	cells,	a	mesothelioma	cell	
line	and	liver	cancer	[260].	The	domain	containing	the	TGFBI	carboxyl-terminal	RGD	can	be	
cleaved	to	alter	 its	adhesive	activity	and	the	RGD-containing	peptides	released	can	 induce	
apoptosis	 [262].	 TGFBI	 overexpression	 in	 CHO	 cells	 reduces	 proliferation	 and	 attenuates	
tumour	growth	 in	nude	mice.	Of	note,	ectopically	expressed	TGFBI	 is	processed	 in	vivo	 to	
remove	its	RGD	motif	[263].	On	the	other	hand,	TGFBI	has	a	tumour-promoting	effect	in	lung,	
kidney,	 pancreatic,	 colon,	 ovarian,	 brain	 and	 oesophageal	 cancers	 [260].	 In	 colorectal	
tumours,	the	level	of	TGFBI	correlated	with	lymph	node	metastases,	distant	metastases	and	
low	 overall	 survival,	 and	 it	was	 concluded	 that	 TGFBI	 is	 an	 independent	marker	 for	 poor	
prognosis	[264].	TGFBI	upregulation	is	also	an	indicator	for	poor	prognosis	 in	renal	cancer,	
where	changes	in	cell	adhesion	regulated	by	TGF-β	play	an	important	role	[265].	
		There	are	few	studies	 investigating	TGFBI	 in	PCa.	 In	one	report,	the	long	non-coding	RNA	
H19	and	its	derivative	miR-675,	which	are	both	downregulated	in	the	metastatic	PCa	cell	line	
M12,	were	found	to	repress	PCa	migration.	Moreover,	miR-675	directly	binds	to	the	3ʹUTR	of	
TGFBI	mRNA	to	repress	 its	translation	[266],	suggesting	that	the	 inhibition	of	migration	by	
miR-675	is	mediated	by	the	downregulation	of	TGFBI.	A	study	of	PCa	patients	found	dense	
methylation	at	the	TGFBI	gene	promoter	in	39%	of	locally	invasive	tumours,	compared	with	
19%	of	tumours	without	local	invasion	[267],	suggesting	that	the	downregulation	of	TGFBI	by	
promoter	 methylation	 allows	 invasion	 in	 some	 tumours.	 However,	 this	 study	 did	 not	
determine	the	amount	of	tumour	material	in	the	analysed	DNA.	Analysis	of	TGFBI	promoter	
methylation	in	PCa	cell	lines	found	that	it	correlated	with	reduced	TGFBI	expression	in	DU145	
cells	but	not	in	PC3	cells,	where	TGFBI	could	be	induced	by	TGF-β	[267].	This	suggests	that	
there	are	multiple	mechanisms	to	regulate	expression	of	the	TGFBI	in	PCa.	
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Extracellular	matrix	protein	1	(ECM-1)	
	
		ECM-1	 is	 a	 540-amino	 acid	 protein	 that	 was	 first	 identified	 as	 an	 85	 kDa	 glycoprotein	
secreted	by	a	mouse	osteogenic	stromal	cell	line;	the	ECM1	gene	was	cloned	three	years	later	
[268].	ECM-1	is	expressed	in	a	wide	variety	of	cells	and	tissues,	including	sweat	glands	and	
hair	follicles,	the	liver,	the	kidney,	ovary,	testis,	the	lung,	the	pancreas	and	blood	vessels	[268].	
In	addition,	 the	 level	of	 ECM-1	 in	 testicular	 seminal	 fluid	has	been	considered	a	potential	
biomarker	for	azoospermia	[269].		There	are	four	alternatively	spliced	forms	of	ECM-1	(Figure	
1.7),	 with	 ECM-1a	 being	 the	most	 highly	 expressed	 in	 most	 of	 the	 tissues,	 including	 the	
prostate	 gland	 [268].	 	 ECM-1	 is	 implicated	 in	 many	 biological	 processes	 and	 disease	
conditions,	including	angiogenesis,	proliferation,	differentiation,	chondrogenesis	and	cancer	
[268].	A	variety	of	ECM-1	mutations	cause	lipoid	proteinosis,	in	which	patients	have	thickened	
and	irregular	extracellular	matrix	within	connective	tissue	[270].	ECM-1	has	been	reported	to	
associate	with	several	other	extracellular	proteins,	including	perlecan,	ﬁbulins	1C/D	and	3	and	
MMP9,	whose	activity	 is	 inhibited	by	ECM-1	[271].	ECM-1	and	perlecan	form	a	network	of	
basement	 membrane	 proteins	 that	 also	 contains	 collagen	 IV	 and	 laminin.	 Fibulins	 are	
extracellular	 matrix	 glycoproteins	 that	 bind	 to	 many	 other	 matrix	 proteins,	 including	
fibronectin	and	laminin	[271,	272].	
		ECM-1	plays	an	important	roles	in	stimulating	endothelial	cell	proliferation	and	blood	vessel	
formation,	so	it	may	play	a	role	in	regulating	angiogenesis	in	cancer	[273].	ECM-1	has	been	
found	to	be	overexpressed	in	many	types	of	cancer	[268].	In	some	cancers,	such	as	breast	and	
gastric	cancer,	ECM-1	has	a	tumour	promoting	effect,	correlating	with	increased	metastasis	
and	 poor	 prognosis.	 In	 others,	 however,	 such	 as	 hepatocellular	 carcinoma	 (HCC),	 gene-
silencing	 experiments	 revealed	 that	 downregulation	 of	 ECM-1	 increases	 cancer	 cell	
proliferation	in	colony	formation	assays	and	is	associated	with	increased	MMP9	expression	
[274].	Importantly,	the	micro-environment	and	surrounding	stroma	are	expected	to	modulate	
the	 impact	 of	 ECM-1	 on	 tumour	 cell	 invasion	 and	 metastasis,	 particularly	 as	 MMPs	 are	
predominantly	 secreted	 by	 stromal	 cells	 [271].	 There	 appear	 to	 be	 no	 published	 studies	
investigating	the	function	of	ECM-1	in	the	prostate	and	prostate	cancer.	
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Hypothesis	and	aims	
	
Hypothesis	
			
		The	hypothesis	of	this	thesis	is	that	the	loss	of	Dkk-3	expression	in	prostate	epithelial	cells	
leads	to	increased	expression	of	stromal	Dkk-3,	which	provides	a	barrier	to	prostate	cancer	
progression	 by	 limiting	 the	 effects	 of	 the	 loss	 of	 epithelial	 Dkk-3	 on	 the	 integrity	 of	 the	
prostate	epithelium	by	controlling	prostate	epithelial	 cell	proliferation,	differentiation	and	
invasion.	
		
Aims	
	
1. Determine	 the	 effects	 of	 DKK3	 silencing	 on	 prostate	 stromal	 cell	 proliferation,	
migration	and	TGF-b	signalling.	
2. Establish	in	vitro	culture	models	to	study	prostate	stromal-epithelial	cell	interactions	
and	use	them	to	investigate	the	role	of	stromal	Dkk-3	in	prostate	epithelial	cell	acinar	
morphogenesis	and	prostate	cancer	cell	invasion.	
3. Identify	 secreted	 proteins	 whose	 levels	 change	 upon	 DKK3	 silencing	 in	 prostate	
stromal	and	epithelial	cells.	
4. Examine	 the	 expression	 of	 Dkk-3	 in	 epithelial	 and	 stromal	 cells	 in	 prostate	 cancer	
patient	 samples	 and	 correlate	 these	 with	 expression	 of	 the	 identified	 secreted	
proteins.	
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Chapter	two	
	
Materials	and	Methods		 	
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Cell	culture	
	
		All	cells	were	cultured	at	37	⁰C	and	5%	CO2.	The	cell	lines	used	are	listed	in	(Table	2.1).	In	
general	 cells	were	 tested	 for	mycoplasma	 (Mycoplasma	Detection	 Kit,	 Lonza)	 every	 three	
months.	 	 The	 immortalised	 prostate	 stromal	 cell	 line	WPMY-1	 [253]	 was	 provided	 by	 Dr	
Richard	Morgan	(University	of	Surrey).	They	were	cultured	in	DMEM	(Life	Technologies)	with	
10%	FCS	(First	Link	Ltd.)	and	antibiotics	(100	units/ml	penicillin	and	100	ug/ml	streptomycin,	
Sigma).	 Equal	 numbers	 of	 cells	 were	 plated	 (2.5	 x	 105	 –	 4.5	 x	 105	 per	 25	 cm²	 flask)	 and	
passaged	when	close	 to	confluent	 (every	2-3	days).	Early	passage	cells	were	 thawed	 from	
liquid	nitrogen	every	4	months.	The	immortalised	normal	prostate	epithelial	cell	line	RWPE-1	
[224]	 was	 directly	 purchased	 from	 ATCC	 (LGC	 Standards,	 Teddington,	 UK	 and	 Barcelona,	
Spain).	Cell	 lines	derived	 from	RWPE-1	 (NS11,	NS14,	 sh6,	 sh30)	were	generated	 in	 the	 lab	
[160].	 RWPE-1	 cell	 lines	 were	 cultured	 in	 keratinocyte	 serum-free	 medium	 (KSFM)	
supplemented	with	bovine	pituitary	extract	 (BPE)	and	epidermal	growth	 factor	 (EGF)	 (Life	
Technologies),	antibiotics	and	0.75	ug/ml	puromycin	(Sigma).	Cells	were	passaged	every	2-3	
days.	Early	passage	cells	were	thawed	from	liquid	nitrogen	every	2	months.	Expression	of	Dkk-
3	was	monitored	regularly	by	western	blotting	cell	extracts	and	conditioned	media	(CM).	The	
prostate	cancer	cell	line	PC3	was	from	ATCC,	provided	by	Professor	Charlotte	Bevan	(Imperial	
College	London).	Cells	were	cultured	in	RPMI-1640	with	Glutamax	(Life	Technologies),	10%	
FCS	and	antibiotics.	Invasion	assays	were	performed	in	medium	without	FCS.	Western	blotting	
was	used	to	confirm	that	PC3	cells	do	not	express	Dkk-3.	
Generation	of	WPMY-1	shRNA	cell	lines	
		To	determine	the	minimum	dose	of	puromycin	required	to	kill	untransfected	cells,	2	x	105	
WPMY-1	cells	were	plated	in	growth	media	containing	different	doses	of	puromycin	(up	to	4	
ug/ml)	 and	media	were	 changed	 every	 2	 days.	 A	 dose	 of	 1.5	 ug/ml	was	 identified	 as	 the	
minimum	dose	required	to	kill	100%	of	cells	in	1	week.	WPMY-1	cells	were	transfected	with	
the	 DNA	 plasmids	 pSM2	 shRNAmir	 DKK3	 (RHS1764-9689535)	 and	 pSM2	 shRNAmir	 non-
silencing	 control	 (RHS1703)	 plasmids	 (Open	 Biosystems,	 now	 Thermo	 Fisher	 Scientific,	
Loughborough,	UK)	 [160]).	 2	 x	 10	 ⁵	 cells	 per	well	 in	 6-well	 plates	were	 plated	 in	medium	
without	antibiotics	the	day	before	transfection.	For	each	well,	10	ul	Lipofectamine	2000	was	
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pre-incubated	for	5	min	in	100	ul	OptiMEM	(Life	Technologies)	and	then	added	to	2	ug	of	DNA	
diluted	in	100	ul	OptiMEM	and	incubated	for	20	min.	Growth	medium	was	then	replaced	with	
0.8	ml	OptiMEM	and	 the	DNA/Lipofectamine	 2000	mixture	 added	 to	 the	 cells.	 After	 5	 h,	
without	removing	the	transfection	media,	1	ml	of	serum-rich	medium	(DMEM,	20%	FCS	and	
2	x	antibiotics)	was	added.	After	24	h,	transfected	cells	were	transferred	by	trypsinisation	to	
100	mm	plates	and	cultured	 in	medium	containing	1.5	ug/ml	puromycin.	After	2-3	weeks,	
single	DKK3	shRNA	clones	were	transferred	to	12-well	plates,	and	control	shRNA	clones	were	
re-plated	as	pools	of	20-50	clones.	DKK3	shRNA	clones	(11)	and	control	shRNA	pooled	clones	
(4)	were	expanded	and	frozen	in	liquid	nitrogen.		
Table	2.1	Cell	lines	used	in	this	study	
Cell	line	 Source	
WPMY-1	
SV40	large	T	antigen-immortalized	stromal	cells	derived	from	a	non-
neoplastic	prostate	gland	of	a	54-year-old	white	male	[253]	
PSM2,	PSM3,	PSM4,	NPSM2	 Pooled	clones	of	WPMY-1	cells	stably	transfected	with	control	shRNA	
Wsh7,	Wsh8	 Clones	of	WPMY-1	cells	stably	transfected	with	DKK3	shRNA	
RWPE-1	
HPV18-immortalised	 epithelial	 cells	 derived	 from	 a	 non-neoplastic	
prostate	gland	of	a	54-year-old	white	male	[224]	
NS11,	NS14	 Clones	of	RWPE-1	cells	stably	transfected	with	control	shRNA	
sh6,	sh30	 Clones	of	RWPE-1	cells	stably	transfected	with	DKK3	shRNA	
PC3	
Prostate	cancer	cell	line	derived	from	a	bone	metastasis	of	a	62-year-
old	Caucasian	male	[247]		
	
Western	blotting	
		WPMY-1-	and	RWPE-1-derived	cells	(2-4	x	105)	were	plated	in	duplicate	wells	of	6-well	plates	
in	 their	 respective	 growth	 media	 for	 48	 h	 prior	 to	 preparation	 of	 cell	 extracts.	 In	 some	
experiments,	media	were	changed	to	serum-free	media	with	or	without	10	ng/ml	TGF-β	for	
24	h.	For	collection	of	conditioned	medium	(CM),	media	were	centrifuged	at	500	g	for	5	min	
and	 the	 supernatants	 added	 to	 an	 equal	 volume	 of	 2	 x	 Laemmli	 buffer	 (Sigma).	 For	 cell	
extracts,	plates	were	placed	on	ice,	rinsed	with	cold	PBS	and	then	lysed	in	500	ul	of	cold	RIPA	
lysis	buffer	(0.5%	Na	deoxycholate,	1%	Triton	X-100,	20	mM	Tris	pH	8.0,	0.1%	SDS,	100	mM	
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NaCl,	50	mM	NaF,	1	mM	EDTA),	1x	cOmplete™	EDTA-free	Protease	Inhibitor	Cocktail	(Sigma)	
and,	for	detection	of	phosphorylated	proteins,	1	x	PhosSTOP	Phosphatase	Inhibitor	Cocktail	
(Sigma).	Lysates	were	incubated	for	15	min	on	ice,	centrifuged	at	15,000	g	for	15	min	at	4o C	
and	added	to	an	equal	volume	of	2x	Laemmli	buffer.	To	determine	the	levels	of	TGFBI	and	
ECM-1	in	CM	of	RWPE-1	and	WPMY-1	cell	lines,	106	cells	per	well	were	plated	in	6-well	plates	
overnight	 and	 then	 the	media	was	 changed	 to	1	ml	of	 the	 appropriate	 serum-free	media	
(KSFM	 or	 DMEM,	 respectively).	 After	 58	 h,	 CM	 were	 harvested	 and	 probed	 by	 western	
blotting,	as	described	above.	Cell	extracts	were	prepared	as	above.	Aliquots	of	CM	and	lysates	
were	stored	in	-80	for	up	to	1	month.	
		Prior	to	loading	on	gels,	samples	were	heated	on	a	shaker	for	3	min	at	95o	C.	Samples	were	
separated	on	7.5%	or	10%	SDS	polyacrylamide	gels	(Supplementary	Table	1)	at	25	mA/gel	for	
50	min.	Transfer	of	proteins	to	polyvinylidene	difluoride	(PVDF)	membranes	was	carried	out	
using	a	semi-dry	transfer	apparatus	(Bio-Rad)	for	45	min	at	25	mA.	Membranes	were	then	
rinsed	in	TBST	(1	x	Tris-buffered	saline	with	0.1%	Tween	20)	and	then	incubated	in	blocking	
buffer	(5%	BSA	in	TBST)	(Supplementary	Table	2),	on	a	shaker	at	room	temperature	(RT)	for	
1	 h.	 Primary	 antibodies	 (listed	 in	Supplementary	 Table	 3)	 diluted	 in	 blocking	buffer	were	
added	and	membranes	incubated	on	a	rocker	in	the	cold	room	overnight.	The	membranes	
were	 then	 washed	 at	 least	 3	 times	 for	 5	 min	 in	 TBST	 on	 a	 shaker,	 incubated	 with	 HRP-
conjugated	secondary	antibodies	(listed	in	Supplementary	Table	4)	diluted	in	blocking	buffer	
for	 1	h,	washed	3	 times	 for	 15	min	 and	 then	 incubated	with	ClarityTM	Western	Enhanced	
Chemiluminescence	 (ECL)	 substrate	 solution	 using	 a	mixture	 of	 7.5	ml	 Luminol/Enhancer	
solution	and	7.5	ml	of	peroxide	solution,	incubating	at	RT	on	a	shaker	for	5	min,	exposing	to	
X-ray	film	and	developing	using	an	OPTIMAX	film	processor.	Some	membranes	were	stripped	
and	re-probed	(Supplementary	Table	5).		
RNA	extraction,	cDNA	synthesis	and	q-PCR	
RNA	extraction	
		Total	RNA	was	extracted	using	PureLink	RNA	Mini	Kit	(Life	technologies	Ltd.UK).	Cells	were	
re-suspended	 in	 1	 ml	 of	 Trizol	 reagent	 (Invitrogen).	 Following	 the	 addition	 of	 200	 μl	
chloroform,	samples	were	incubated	at	RT	for	5	min	and	were	then	shaken	for	15-30	seconds	
and	 incubated	 on	 ice	 for	 5	min.	 Afterwards,	 centrifugation	 at	 15,000	 g	 for	 15	min	 at	 4˚C	
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separated	the	homogenate	into	3	different	phases;	a	lower	blue	phenol-chloroform	phase,	
an	opaque,	white	 interphase	and	an	upper	colourless	aqueous	phase.	The	aqueous	phase	
(containing	total	RNA)	was	transferred	into	a	clean	RNase	free	1.5	ml	microcentrifuge	tube.	
To	precipitate	the	RNA,	1	volume	70%	ethanol	was	added	to	each	volume	of	RNA	suspension	
and	vortexed.	700	μl	of	sample	was	transferred	to	the	spin	cartridge	and	centrifuged	at	15,000	
g	for	15	seconds.	Flow-through	was	removed	and	this	step	repeated.	Afterward,	700	μl	of	
wash	buffer	was	added	to	the	spin	cartridge	and	centrifuged	for	15,000	g	for	15	seconds	and	
repeated.	The	spin	cartridge	was	centrifuged	at	15,000	g	for	1-2	minutes	to	dry	the	membrane	
with	bound	RNA.	The	supernatant	was	removed,	and	samples	were	allowed	to	momentarily	
air-dry	before	resuspension	in	50	μl	RNase	free	water.	The	spin	cartridge	was	centrifuged	for	
2	min	at	15,000	g	to	elute	the	RNA.		
Complementary	DNA	(cDNA)	synthesis		
		cDNA	was	synthesised	from	total	RNA	using	Quantitect	Reverse	Transcription	Kit	(Qiagen,	
UK)	according	to	manufacturer’s	instructions.	1	μg	of	total	RNA	was	mixed	with	2	μl	7	x	gDNA	
Wipeout	Buffer	and	nuclease-free	water	to	make	a	final	volume	of	14	μl	and	incubated	for	5	
min	at	42oC	to	remove	genomic	DNA.	The	samples	were	then	transferred	to	tubes	containing	
6	 μl	 of	 reverse-transcription	master	mix	 (1	 μl	 Quantiscript	 Reverse	 Transcriptase,	 4	 μl	 5x	
Quantiscript	 RT	 Buffer	 and	 1	 μl	 RT	 Primer	Mix),	mixed	 and	 incubated	 for	 25	min	 at	 42oC	
followed	by	3	min	at	95oC	to	inactivate	the	reverse	transcriptase.	The	reactions	were	placed	
on	ice	for	immediate	use	or	at	-20oC	for	long	term	storage.		
Quantitative	PCR	(q-PCR)		
	Gene	expression	was	determined	by	q-PCR	using	SYBR	Green	PCR	Master	Mix	(Bio-Rad)	and	
the	 7900HT	 Fast	 Real-Time	 PCR	 thermal	 cycler	 (Applied	 Biosystems).	 1	 μg	 total	 RNA	was	
reverse	transcribed	as	described	above,	2	μl	of	cDNA	was	added	to	a	reaction	mix	consisting	
of	 5	 μl	 2	 x	 Fast	 SYBR	 Green	master	mix,	 5	 uM	 of	 each	 forward	 and	 reverse	 primer	 and	
nuclease-free	water	to	make	a	final	volume	of	10	μl.	PCR	cycling	conditions	consisted	of	initial	
enzyme	activation	at	95oC	for	20	seconds,	denaturation	at	95	oC	for	1	second	and	annealing	
at	60	oC	for	20	seconds	for	40	cycles.	The	expression	levels	of	target	gene	were	normalised	to	
an	 endogenous	 reference	 gene	 (36B4)	 and	 the	 fold	 change,	 as	 a	 measure	 of	 relative	
expression,	was	calculated	using	the	comparative	CT	(2–ΔΔCT)	method	[275].	
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Fluorescence	activated	cell	sorting	(FACS)	
		Prior	to	transfection,	cells	at	80%-90%	confluence	were	plated	overnight	in	6-well	plates	(105	
cells	per	well).	Cells	were	transfected	with	plasmids	encoding	GFP	driven	by	a	constitutive	
promoter	 (CMV),	 the	 s-SHIP	 gene	 promoter	 (s-SHIP-GFP)	 [276])	 or	 an	 ATF2-responsive	
promoter	(ATF2-GFP)	[277].	For	each	transfection,	2	ug	DNA	was	mixed	in	one	tube	with	200	
ul	OptiMEM	and	2	ul	Plus	Reagent	(Invitrogen)	and	7	ul	Lipofectamine	LTX	(Invitrogen)	was	
diluted	in	200	ul	OptiMEM	in	a	second	tube.	The	contents	of	the	two	tubes	were	mixed	and	
incubated	 for	 20	 min.	 Cell	 media	 were	 replaced	 with	 500	 ul	 of	 OptiMEM	 and	 200	 ul	 of	
DNA/lipid	mixture	added	 to	each	well	 and	 incubated	 for	3	h,	after	which	 the	media	were	
replaced	with	normal	growth	medium	for	24	h.	Cells	were	then	washed	with	1	ml	PBS,	1	ml	
trypsin	added	for	10	min	and	then	1	ml	of	growth	media	prior	to	collection.	Collected	cells	
were	centrifuged	in	FACS	tubes	at	500	g	for	5	min	at	RT,	the	cell	pellets	were	resuspended	in	
500	ul	1%	BSA	in	PBS	and	3	ul	of	7-Amino-Actinomycin	D	(7-AAD)	(Invitrogen)	to	identify	non-
viable	cells.	FACS	analysis	was	carried	out	using	a	FACSAria	flow	cytometer	(Becton	Dickinson)	
and	FACSDiva™	Software.	
Acinar	morphogenesis	(AM)	assays	
		AM	assays	were	carried	out	using	the	protocol	previously	published	by	Debnath	et	al.	[278]	
with	modifications	 by	 Kawano	 et	 al.	 [177].	 2	 x	 103	 early	 passage	 RWPE-1	 cells	 (80	 -	 85%	
confluent)	were	suspended	in	assay	media	(AM:	KSFM	with	5	ng/ml	EGF,	2%	bovine	calf	serum	
and	2%	Cultrex	basement	membrane	extract	(BME),	Trevigen,	AMS	Biotechnology,	Abingdon,	
UK)	and	plated	in	8-well	µslides	(Nunc)	that	had	been	coated	with	40	ul	Phenol	red-free	BD	
Matrigel™	(BD	Biosciences)	per	well.	CM	from	control	and	DKK3-silenced	WPMY-1	cells	that	
had	been	plated	in	AM	in	6-well	plates	for	48	h	was	collected,	centrifuged	and	used	for	AM	
assays.	The	remainder	was	kept	at	4˚C	for	subsequent	media	changes	every	2	days.	Acinar	
morphogenesis	 was	 evaluated	 as	 described	 in	 other	 studies	 [160,	 177].	 5	 photos	 (100	 x	
magnification)	per	well were	taken	at	days	4,	6,	7	and	8	using	an	Axiovert	S	100	microscope	
(Zeiss)	 and	 processed	with	MetaMorph	 (Molecular	 Devices)	 or	 using	 an	 Eclipse	 TE2000-U	
microscope	(Nikon)	and	Image-Pro	(Media	Cybernetics	Inc.).	The	numbers	of	regular,	notched	
and	deformed	acini	were	counted	using	ImageJ	software.	Each	experiment	was	repeated	in	
triplicate	 wells	 3	 or	 4	 times.	 To	 investigate	 the	 effects	 of	 TGFBI	 and	 ECM-1	 on	 acinar	
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morphogenesis,	rhTGFBI	(1	ug/ml)	and	rhECM-1	(100	ng/ml)	(Supplementary	Table	6)	were	
added	every	2	days	for	a	total	of	8	days.	Of	note,	early	passage	RWPE-1	sublines	(NS11,	sh6)	
were	used	and	were	cultured	in	puromycin-containing	media	before	use	in	the	AM	assay.	
Gene	reporter	assays	
		These	experiments	were	carried	out	in	control	and	DKK3-silenced	WPMY-1	cells.	The	aim	of	
this	assay	is	to	report	the	activity	of	the	TGF-β/SMAD	signalling	pathway.	The	plasmid	pGL3-
CAGA12-luc,	 which	 encodes	 the	 luciferase	 gene	 fused	 to	 12	 repeats	 of	 a	 Smad-binding	
element)	[279]	and	the	control	plasmid	pRL-TK	(Promega),	which	encodes	Renilla	luciferase	
driven	by	the	thymidine	kinase	promoter,	were	used	for	these	experiments.	Cells	(2	x	105	per	
well	of	a	12-well	plate)	were	plated	overnight	in	media	without	antibiotics.	Transfections	were	
carried	out	using	100	ng	pRL-TK	and	400	ng	CAGA-luc	per	well	mixed	with	Lipofectamine	LTX	
and	Plus	reagent,	as	described	above.	After	incubation	of	cells	with	the	DNA/lipid	mixture	for	
4-5	hours,	0.5	ml	growth	medium	was	added	to	each	well	and	in	addition,	0.5	ml	of	medium	
containing	either	the	TGF-β	receptor	inhibitor	SB431542	(Sigma)	(Supplementary	Table	6),	
final	concentration	1	uM	or	vehicle	(DMSO)	as	a	control.	After	24	h,	cells	were	harvested	by	
removing	 the	 media	 and	 adding	 200	 ul/well	 passive	 lysis	 buffer	 (Promega).	 Plates	 were	
incubated	at	-80oC	for	at	least	3	h	and	then	thawed	at	RT	for	30	min	before	collecting	extracts	
by	pipetting	into	1.5	ml	Eppendorf	tubes	and	centrifuging	at	15,000	g	for	1	min.	Supernatants	
were	then	subjected	to	luciferase	assays	using	the	Dual-Glo®	Luciferase	assay	kit	(Promega):	
20	or	30	ul	of	sample	was	added	to	each	well	of	a	96-well	plate,	an	equal	volume	of	Luciferase	
Substrate	then	added	and	incubated	for	10	min	before	measuring	light	emission	on	a	Vector	
Light	1420	luminometer.	Another	equal	volume	of	Stop	&	Glo®	Substrate	was	then	added,	
incubated	for	a	further	10	min	before	re-reading	light	emission.	2	control	wells	(equal	volume	
of	1	x	passive	lysis	buffer	with	the	substrates)	were	also	measured.		
Cell	proliferation	assays	
		Cells	plated	 in	flasks	with	10%	FCS	DMEM	and	antibiotics	were	grown	to	80%	confluence	
prior	to	plating	for	proliferation	assays.	8,000	cells	per	well	were	plated	in	triplicate	in	24-well	
plates	and	 incubated	at	37	oC.	Cells	were fixed	with	 ice-cold	MeOH	and	stained	with	0.2%	
Crystal	violet	in	20%	MeOH	at	days	1,	3,	5	and	7.	Stained	cells	were	solubilised	in	10%	acetic	
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acid	and	100	ul	per	well	was	transferred	in	duplicate	to	a	96-well	plate	for	measurement	of	
absorbance	at	595	nm	using	an	OptiMax	plate	reader.	For	co-culture	proliferation	assays,	5	x	
10⁴	 sh30	or	 sh6	 cells	 in	 KSFM	with	 5	 ng/ml	 EGF,	 2%	bovine	 calf	 serum	and	 600	ul	 of	 1%	
Matrigel	(100	µg	BME)	were	plated	on	0.4	µm	pore	inserts	in	6-well	plates.	The	wells	below	
the	inserts	were	plated	with	10⁵	control	(PSM2,	NPSM2)	or	Dkk-3-silenced	WPMY-1	(Wsh7,	
Wsh8)	cells	in	10%	FCS	DMEM.	Cells	were	incubated	for	48	hours	at	37˚C	and	fixed	using	cold	
MeOH,	stained	with	0.2%	Crystal	violet	and	visualized	and	counted	as	described	above.	
Invasion	and	migration	assays	
		PC3	 cells	 starved	 for	 24	h	 in	 serum-free	RPMI	were	placed	on	8	μm	pore	Polycarbonate	
Membrane	Transwell	inserts	in	24-well	plates.	For	invasion	assays,	inserts	were	pre-coated	
with	1%	Matrigel	(100	µg	BME	in	RPMI	serum	free)	and	allowed	to	dry	overnight.	The	assay	
medium	contained	CM	that	had	been	collected	after	48	h	of	serum-free	culture	of	control	and	
DKK3-silenced	WPMY-1	cell	lines.	PC3	cells	were	added	to	the	inserts	in	duplicate	in	200	ul	
serum-free	CM,	and	800	ul	of	10%	FCS	RPMI	was	added	to	the	wells	below.	Evaluation	of	
invasion	was	performed	after	48	h	incubation	at	37˚C.	Cells	were	fixed	in	cold	MeOH,	stained	
with	 0.2%	 Crystal	 violet	 in	 20%	 MeOH	 and	 at	 least	 5	 pictures	 taken	 per	 insert	 at	 100x	
magnification	 using	 an	 Eclipse	 TE2000-U	 microscope	 (Nikon)	 and	 Image-Pro	 (QImaging,	
Surrey,	BC,	Canada).	Image	J	software	was	used	to	count	the	numbers	of	invaded	cells.												
		Invasion	 and	 migration	 were	 also	 assessed	 after	 treatment	 with	 the	 MMP2	 selective	
inhibitor	ARP100	(100	nM)	at	which	it	inhibits	MMP-2,	-3	and	-9.	In	parallel,	PC3	cells	were	
seeded	directly	in	24-wells	plates,	treated	in	the	same	way	as	the	cells	used	for	invasion	and	
migration	assays	and	subjected	to	Crystal	violet	assay.	The	numbers	were	used	to	normalise	
the	migration	and	invasion	data	for	cell	number.	Matrigel	invasion	assays	were	performed	to	
evaluate	the	impact	of	TGFBI	and	ECM-1	on	PC3	cell	 invasion.	104	PC3	cells	were	plated	in	
triplicate	for	24	h	and	then	treated	as	follows:	serum-free	RPMI	only	(control),	RPMI	+	rhTGFBI	
(1	ug/ml),	RPMI	+	rhECM-1	(100	ng/ml)	or	RPMI	+	rhTGFBI	and	rhECM-1.	
		Migration	 assays	 with	 WPMY-1	 cells	 were	 performed	 using	 24-well	 8	 µm	 pore	 inserts	
without	adding	Matrigel.	2	x	104	were	plated	in	duplicate	inserts	in	serum-free	DMEM	and	
growth	media	with	10%	FCS	was	added	to	the	wells	below.	After	24	h,	cells	were	stained	with	
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Crystal	violet,	photos	were	taken,	and	the	migrated	cells	were	counted,	as	for	invasion	assays.	
Of	note,	in	parallel,	cells	were	seeded	directly	in	24-well	plates	and	treated	in	the	same	way	
to	control	for	any	differences	in	proliferation.	
Proteome	profiler	array	
		This	was	carried	out	using	the	Human	Soluble	Receptor	Array	Kit	(ARY012,	R&D	Systems),	
which	comprises	4	nitrocellulose	membrane	arrays,	2	Non-Hematopoietic	(N),	which	detect	
62	proteins,	and	2	Common	Analytes	(C),	which	detect	57	proteins.	Each	array	has	duplicate	
spots	for	each	antigen	detected	and	also	control	spots	for	quantitation.		Prior	to	harvesting	
of	CM	for	the	arrays,	106	control	(PSM2)	and	Dkk-3-silenced	(Wsh8)	cells	were	plated	in	60	
mm	dishes	in	10%	FCS	DMEM	for	24	h.	Five	photos	per	plate	were	taken	using	a	TE2000-U	
microscope	(Nikon)	and	cells	were	counted	using	Image	J.	Cells	were	then	washed	gently	in	
serum-free	DMEM	and	incubated	in	serum-free	DMEM	(approximately	3	ml)	with	the	exact	
volume	 was	 adjusted	 to	 the	 number	 of	 cells	 counted.	 After	 24	 h,	 CM	 were	 collected,	
centrifuged	and	stored	at	-80oC.	The	levels	of	Dkk-3	in	the	CM	were	determined	by	western	
blotting	prior	to	use	in	the	array	and	to	confirm	absence	of	intracellular	proteins	(by	blotting	
for	Smad3).	
		The	arrays	were	treated	as	follows:	each	membrane	was	dipped	in	2	ml	of	1X	washing	buffer	
(buffers	 are	 listed	 in	 Supplementary	 Table	 7)	 in	 each	 well	 of	 4-well	 multi-dishes.	 After	
disappearance	of	the	blue	dye	from	the	spots,	2	ml	of	1X	array	buffer	per	membrane	was	
added	as	blocking	buffer	and	incubated	for	1	h	on	a	rocking	platform	at	RT.	1	ml	of	CM	was	
mixed	with	300	ul	of	array	buffer,	adjusted	to	a	final	volume	of	3	ml,	of	which	1.5	ml	was	
added	to	each	array	(N	and	C)	and	incubated	on	a	rocking	platform	in	the	cold	room	overnight.	
Membranes	were	then	washed	3	times	in	20	ml	of	1X	washing	buffer	for	10	min	on	a	rocking	
platform,	transferred	to	4-well	multi-dishes	and	diluted	detection	antibody	cocktail	added	(30	
ul	of	reconstituted	detection	cocktail	diluted	in	1.5	ml	1X	array	buffer	8/1)	for	incubation	at	
RT	 for	2	h	on	a	 rocking	platform.	The	membranes	were	washed	again	and	 incubated	with	
streptavidin-HRP	(1	ul	Streptavidin-HRP	diluted	in	2	ml	1X	array	buffer)	for	30	min	at	RT	on	
rocking	platform	shaker.	After	washing	a	further	3	times,	membranes	were	incubated	with	1	
ml	of	Chemi	Reagent	Mixture	for	1	minute,	covered	and	wrapped	with	plastic	sheet	protector	
and	 exposed	 to	 X-ray	 film.	 2	 independent	 experiments	 were	 carried	 with	 independently	
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generated	samples	of	CM.	The	results	were	analysed	by	densitometry	of	multiple	exposures	
of	the	arrays	to	X-ray	film.	
Histochemistry	
		Tissue	arrays	(TMAs)	with	samples	from	a	total	of	99	PCa	patients	on	6	arrays	were	provided	
by	the	Imperial	Cancer	Biomarker	Resource	Centre	(ICBRC)	after	approval	from	Imperial	CRUK	
Steering	Committee	(Tissue	Bank	application	number	Project	R15043).	A	total	of	four	sections	
were	provided	per	patient,	 two	sections	with	benign	 tissue	and	 two	sections	with	cancer.	
TMAs	were	stained	for	SMA	and	vimentin	and	with	Haematoxylin	and	Eosin	(H&E)	by	Dr	Jenny	
Steel	(Imperial	College	London).	Adjacent	sections	were	subjected	to	staining	using	antibodies	
to	Dkk-3,	MMP2,	pan-cytokeratin	(CK),	TGFBI	and	ECM-1	(listed	in	Supplementary	Table	3).	
For	deparaffinisation	and	hydration,	slides	were	incubated	in	a	dry	oven	at	60oC	for	1	h,	and	
then	dewaxed	using	Histoclear	3	times	for	10	min	and	then	hydrated	by	incubation	in	100%	
EtOH	 twice	 	 for	1	min,	70%	EtOH	 	 for	30	 seconds	and	 then	 immersing	 in	dH20	 for	5	min.	
Antigen	retrieval	was	by	immersion	in	10	mM	Na	citrate	pH	6.0	(Supplementary	Table	8)		in	
a	small	glass	cup	and	heating	in	a	microwave	oven	at	560	W	for	8	min	(	for	TGFBI	and	ECM-1	
this	was	15	min	and	10	min,	respectively)	and	then	cooling	at	RT	for	30	min.	Slides	were	then	
washed	 in	 PBS	 3	 times	 for	 5	 min	 on	 rocking	 platform	 rack.	 Quenching	 of	 endogenous	
peroxidase	was	done	by	immersion	in	3%	hydrogen	peroxide	(H₂O₂)	(Supplementary	Table	8)	
for	5	min	(3	min	for	ECM-1)	and	washing	3	times	 in	PBS	for	5	min.	After	 that,	slides	were	
incubated	in	blocking	buffer	(10%	horse	serum	(HS)	in	PBS	for	Dkk-3,	3%	BSA	in	PBS	for	pan-
cytokeratin,	and	5%	goat	serum	in	PBS	for	TGFBI	and	ECM-1)	for	20	min,	excess	buffer	was	
removed,	and	slides	incubated	with	primary	antibodies	(listed	in	Supplementary	Table	3)	in	
blocking	buffer	overnight	at	4ᴼC.	Slides	were	washed	3	times	for	5	min	in	PBS,	incubated	for	
biotin-conjugated	secondary	antibodies	(Supplementary	Table	4)	in	the	appropriate	blocking	
buffer	(1.5%	HS	 in	PBS	for	Dkk-3)	for	30	min	at	RT.	Bound	antibodies	were	detected	using	
Vectastain	 Elite	 ABC	 Standard	 kit	 (Vector),	 according	 to	 manufacturer's	 instructions	
(Supplementary	Table	2.8),	with	the	chromogenic	reaction	performed	using	1	ml	ImmPACT	
DAB	(Vector)	per	slide	(2	min	for	Dkk-3,	pan-cytokeratin	and	TGFBI	and	5	min	for	ECM-1).	
Slides	 were	 counterstained	 in	 Meyer’s	 haematoxylin	 for	 15	 seconds	 and	 then	 immersed	
immediately	in	dH₂O	for	5	seconds.	Dehydration	and	clearing	was	in	70%	EtOH	20	seconds,	
100%	EtOH	30	seconds,	100%	EtOH	1	minute	and	Histoclear	twice	for	5	min.	Mounting	was	
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with	 Permount	 in	 a	 fume	 hood	 for	 30	 min.	 Pictures	 were	 taken	 using	 a	 Leica	 DM750	
microscope	at	different	magnifications	(10x	to	40x).		
Statistical	analysis	
		Paired	 Student’s	 t-test	was	 carried	 out	 using	Microsoft	 Excel.	 Statistical	 significance	was	
considered	for	p	<	0.05.	Two-Way	ANOVA	and	Tukey’s	multiple	comparison	was	done	using	
Graphpad	 Prism	 version	 6	 for	 multiple	 comparisons	 in	 acinar	 morphogenesis	 assays.	
Correlation	 analysis	 was	 done	 by	 Pearson´s	 Chi-squared	 and	 Fisher's	 exact	 tests	 using	
VassarStats	(http://vassarstats.net/tab2x2.html)	or	MATLAB-MathWorks	software.	
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Chapter	three	
	
Results	
	
Generation	and	Characterisation	of	DKK3-silenced	prostate	
stromal	cell	lines	
	
	
	
	
	
	
	
	 	
	 67	
	
Introduction	
	
		The	 mechanism	 of	 the	 action	 of	 Dkk-3	 has	 been	 investigated	 in	 vitro	 using	 different	
approaches,	 including	overexpression	of	DKK3	using	plasmid	and	adenoviral	 vectors,	 gene	
silencing	of	DKK3	using	 siRNAs	and	 shRNA	expression	vectors,	 and	by	addition	of	purified	
recombinant	 DKK3	 protein	 (rhDkk3)	 [172,	 226].	 Studies	 in	 our	 laboratory	 used	 plasmids	
expressing	control	and	DKK3-specific	shRNAs	to	generate	silenced	clones	of	RWPE-1	prostate	
epithelial	 cells	 [172].	 Here,	 I	 have	 used	 the	 same	 approach	 to	 silence	 DKK3	 in	 WPMY-1	
prostate	stromal	cells,	with	the	aim	of	determining	the	function	of	Dkk-3	in	prostate	stromal	
cells	and	on	the	role	of	stromal	Dkk-3	on	prostate	epithelial	and	cancer	cell	function,	which	
might	help	explain	how	Dkk-3	acts	as	a	 tumour	suppressor.	 In	 this	chapter,	 I	describe	 the	
generation	 of	 the	 WPMY-1	 cell	 lines	 expressing	 control	 and	 DKK3	 shRNAs	 and	 their	
characterisation	 with	 respect	 to	 WPMY-1	 cell	 proliferation,	 migration	 and	 TGF-β/Smad-	
signalling.	
3.1	Generation	and	the	initial	characterisation	of	DKK3-silenced	WPMY-1	cell	lines	
	
		To	investigate	the	function	of	DKK3	in	stromal	cells,	I	transfected	the	WPMY-1	cell	line	with	
plasmids	 expressing	 control	 and	 DKK3	 shRNAs	 and	 selected	 stable	 cell	 lines	 for	 further	
analysis.	For	the	control	shRNA,	4	pooled	clones	of	cells	were	selected,	and	for	DKK3	shRNA,	
11	single	cell	clones	were	selected.	An	optimal	dose	of	puromycin	for	selection	in	WPMY-1	
cells	was	 found	 to	be	1.5	ug/ml.	After	 approximately	2-3	weeks	of	 selection,	 clones	were	
tested	by	western	blotting	of	cell	extracts	and	CM	to	identify	those	clones	with	the	lowest	
levels	of	Dkk-3.	Samples	from	a	range	of	passages	were	tested	to	ensure	that	DKK3	silencing	
was	maintained	and	that	control	pooled	clones	contained	to	expressed	similar	levels	of	Dkk-
3	 as	 the	 parental	 cells.	 Two	 DKK3-silenced	 clones,	 Wsh7	 and	 Wsh8	 and	 two	 shRNA-
transfected	control	lines,	PSM2	and	NPSM2,	were	selected	for	further	studies.	An	additional	
two	control	clones.	PSM3	and	PSM4,	were	selected	later.	
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		The	expression	of	DKK3	mRNA	was	evaluated	via	quantitative	real-time	PCR	(Figure	3.1A).	
Compared	 to	 control	 cells,	 there	was	 an	 approximately	 10-fold	 reduction	 in	DKK3	 mRNA	
expression	in	Wsh7	and	Wsh8	cells.	
		Next,	western	blotting	was	used	to	confirm	that	Dkk-3	protein	levels	were	reduced	in	DKK3	
shRNA	cells.	Dkk-3	in	control	shRNA	cell	extracts	was	detected	as	a	protein	that	migrated	at	
approximately	 56	 kDa	 (Figure	 3.1B),	 like	 what	 was	 previously	 observed	 in	 RWPE-1	 cells.	
Considering	the	GAPDH	 loading	control,	Dkk-3	 levels	were	similar	 in	extracts	of	PSM2	and	
NPSM2	cells	as	in	extracts	of	parental	WPMY-1	cells,	while	they	were	much	lower	in	extracts	
of	Wsh7	and	Wsh8	cells	 (Figure	3.1B).	Densitometry	analysis	 indicated	 that	Dkk-3	protein	
levels	were	about	11-fold	lower	in	Wsh8	cells	and	9-fold	lower	in	Wsh7	cells,	compared	to	
WPMY-1	cells	(Figure	3.1C).	
		Finally,	 I	 examined	 Dkk-3	 protein	 levels	 in	 conditioned	 media	 (CM)	 from	 the	 cell	 lines,	
collected	after	culture	for	24	h	in	serum-free	medium.	Dkk-3	in	WPMY-1	CM	migrated	as	a	
protein	of	about	65	kDa	(Figure	3.1D),	as	previously	reported	for	the	secreted	form	of	Dkk-3	
in	other	cell	types	[207,	208].	There	was	a	clear	reduction	in	Dkk-3	levels	in	CM	from	DKK3-
silenced	cells,	compared	to	control	cell	CM,	and	again,	the	level	of	Dkk-3	in	Wsh8	cell	CM	was	
lower	than	in	Wsh7	cell	CM	(Figure	3.1E).	Densitometry	analysis	indicated	that	the	reduction	
in	Dkk-3,	as	compared	to	control	cell	CM,	was	approximately	10-fold	in	Wsh8	cell	CM	and	3.5-
fold	in	Wsh7	cell	CM.	Dkk-3	expression	in	the	cell	extracts	and	secretion	in	CM	in	the	control	
line	 PSM3,	 compared	 to	Wsh8,	was	 also	 confirmed	by	western	 blotting	 (Figure	 3.1F)	 and	
densitometry	(Figure	3.1G),	was	approximately	30-fold	lower	in	Wsh8	CM	and	extract	than	in	
PSM3	cells.	Together,	 these	 results	 indicate	 that	DKK3	silencing	has	been	achieved	 in	 two	
clones	of	WPMY-1	cells,	with	a	stronger	reduction	of	DKK3	mRNA	and	protein	expression	in	
Wsh8	cells	than	in	Wsh7	cells.		
3.2	DKK3	silencing	increases	TGF-β/Smad	signalling	in	WPMY-1	cells	
		Since	 silencing	of	Dkk-3	has	been	observed	 to	 increase	TGF-β/Smad	signalling	 in	RWPE-1	
cells,	with	increased	levels	and	phosphorylation	of	Smad2	[160],	and	WPMY-1	cells	have	been	
reported	 to	 respond	 to	 TGF-β	 [253],	 it	was	 important	 to	determine	 if	DKK3	 silencing	 also	
affects	the	TGF-β	response	in	WPMY-1	cells.	To	test	this,	I	compared	the	levels	and		
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phosphorylation	of	several	proteins	involved	in	TGF-β/Smad	signalling	in	the	cell	lines,	using	
extracts	collected	from	equal	numbers	of	cells	treated	without	or	with	10	ng/ml	TGF-β1	for	
24	h.	
			Western	blot	analysis	of	extracts	from	the	cells	did	not	reveal	any	significant	effects	of	either	
TGF-β1	treatment	or	of	DKK3-silencing	on	the	protein	levels	of	Smad2	(Figure	3.2A	and	B)	or	
Smad4	(3.2C	and	D).	 In	addition,	treatment	of	cells	with	TGF-β1	did	not	significantly	affect	
Smad3	 levels	 in	control	or	DKK3-silenced	cells	 (Figure	3.3A	and	B).	However,	basal	Smad3	
levels	showed	a	trend	for	higher	expression	in	DKK3-silenced	cells	than	in	control	cells	(Figure	
3.3A	and	B).	Treatment	of	cells	with	TGF-β1	significantly	increased	P-Smad3	levels	in	control	
and	in	DKK3-silenced	cells	(Figure	3.3C).	Densitometry	analysis	indicated	that	both	basal	and	
TGF-b-induced	P-Smad3	levels	were	higher	in	DKK3-silenced	cells	than	in	control	cells	(Figure	
3.3D).	
		The	results	above	suggest	that	DKK3	silencing	in	WPMY-1	cells	affects	Smad3	but	not	Smad2	
or	Smad4.	In	RWPE-1	cells,	where	DKK3	silencing	affects	Smad2	but	not	Smad3,	there	is	an	
increase	in	TGF-β-dependent	transcriptional	activity.	To	determine	if	the	increase	in	Smad3	
in	DKK3-silenced	WPMY-1	cells	also	has	an	effect	on	TGF-β-dependent	transcriptional	activity,	
gene	reporter	assays	were	carried	out	using	CAGA12-luciferase,	a	gene	reporter	plasmid	that	
contains	Smad2/3	binding	sites.	In	preliminary	experiments,	basal	CAGA12-luciferase	activity	
was	found	to	be	very	high	in	WPMY-1	cells	and	treatment	with	TGF-β1	had	little	effect.	To	
determine	if	the	high	CAGA12-luciferase	gene	reporter	activity	in	WPMY-1	cells	was	a	result	
of	activation	of	endogenous	TGF-β	receptors,	I	tested	the	effect	of	the	TGF-β	receptor	1	(TβRI)	
inhibitor	SB431542	on	this	activity.	Treatment	of	WPMY-1	cells	with	1	uM	SB431542	reduced	
CAGA-luciferase	activity	by	over	98%	(Figure	3.4A),	indicating	that	endogenous	TGF-β/Smad	
signalling	is	highly	active	in	WPMY-1	cells.	Despite	the	high	activity	in	parental	WPMY-1	cells,	
comparison	of	endogenous	CAGA12-luciferase	activity	in	control	and	DKK3-silenced	cell	lines	
revealed	 that	DKK3	 silencing	 further	 increased	endogenous	 TGF-β/Smad	 signalling	 (Figure	
3.4B).	
		We	 wished	 to	 determine	 if	 the	 increases	 in	 Smad3	 and	 TGF-β/Smad-dependent	 gene	
reporter	activity	could	lead	to	changes	in	proteins	that	have	been	reported	to	be	regulated	
by	TGF-β	in	stromal	cells.	Western	blotting	was	therefore	carried	out	to	examine	the	levels	of		
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MMP2	 and	 α-SMA.	 MMP2	 was	 chosen	 because	 it	 is	 elevated	 in	 DKK3-silenced	 prostate	
epithelial	 cells	 [161],	 and	 α-SMA	 was	 chosen	 because	 it	 is	 affected	 by	 DKK3	 in	 primary	
prostate	stromal	cells	[226].	MMP2	levels	in	WPMY-1	cell	extracts	were	low,	with	more	MMP2	
detected	in	WPMY-1	cell	CM	than	in	cell	extracts	(Figure	3.5A).	MMP2	levels	in	cell	extracts	
were	not	 significantly	 affected	by	DKK3	 silencing.	 There	was	 a	 trend	 for	 increased	MMP2	
levels	in	CM	from	TGF-β1-treated	Ctrl	shRNA	cells	and	also	a	trend	for	higher	basal	MMP2	
levels	in	CM	from	DKK3-silenced	cells	(Wsh8),	compared	to	control	cells	(Figure	3.5B).	α-SMA	
was	 detected	 by	 western	 blotting	 in	 WPMY-1	 cell	 extracts	 (Figure	 3.5C).	 However,	
densitometry	analysis	indicated	that	there	was	no	significant	effect	of	DKK3	silencing	or	TGF-
β1	treatment	on	α-SMA	levels	(Figure	3.5D).	
		In	 summary,	 TGF-β	 signalling	 appears	 to	 be	 active	 in	 WPMY-1	 cells	 and	 DKK3	 silencing	
increases	the	levels	of	Smad3	and	the	activity	of	the	CAGA12-luciferase	reporter.	However,	
although	 some	 trends	 were	 observed,	 DKK3	 silencing	 did	 not	 significantly	 affect	 Smad2,	
Smad4,	MMP2	or	α-SMA	levels.	
3.3	TGF-β	treatment	of	WPMY-1	cells	increases	the	level	of	secreted	Dkk-3	
	
		The	 levels	of	Dkk-3	protein	were	also	examined	during	the	experiments	described	above.	
Interestingly,	while	 TGF-β	 treatment	 of	 cells	 did	 not	 affect	Dkk-3	 levels	 in	 cell	 extracts,	 it	
increased	Dkk-3	 levels	 in	cell	CM	both	 from	control	and	DKK3-silenced	cells	 (Figure	3.6A).	
Densitometry	 analysis	 indicated	 that	 TGF-b	 treatment	 resulted	 in	 an	approximately	2-fold	
increase	 in	 the	 level	 of	 Dkk-3	 in	 cell	 CM	 (Figure	 3.6B).	 These	 results	 suggest	 that	 TGF-β	
treatment	increases	Dkk-3	secretion	or	the	stability	of	secreted	Dkk-3.	It	is	therefore	possible	
that	there	is	negative	feedback	loop,	in	which	TGF-β	signalling	leads	to	increased	secretion	of	
Dkk-3,	which	then	inhibits	TGF-β	signalling.	
3.4	DKK3	silencing	does	not	affect	WPMY-1	cell	proliferation		
	
		In	order	 to	determine	 if	DKK3	 silencing	affected	WPMY-1	cell	proliferation,	Crystal	 violet	
proliferation	assays	were	carried	out	using	parental	WPMY-1	cells,	 two	control	shRNA	cell	
lines	and	the	two	DKK3	shRNA	cell	lines	(Wsh7,	Wsh8).	8000	cells/well	were	plated	in	24-well		
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plates	 in	 triplicate	 and	 stained	 and	 analysed	 at	 days	 1,	 3,	 5	 and	 7	 (Figure	 3.7A).	 The	
proliferation	of	the	cell	lines	was	similar,	without	significant	differences	throughout	the	time	
course.	 Cell	 proliferation	was	 also	 evaluated	 using	MTT	 assays:	 there	were	 no	 significant	
differences	in	the	numbers	of	control	and	DKK3-silenced	cells	72	h	after	plating	at	3	different	
densities	(2000,	4000	and	8000	cells/well)	(Figure	3.7B).	
3.5	DKK3	silencing	increases	WPMY-1	cell	migration	
		Our	laboratory	previously	reported	that	exogenous	Dkk-3	inhibits	PCa	cell	migration	[161].	
Since	myofibroblasts	 have	 the	 capacity	 for	migration	 [280],	 experiments	were	 carried	out	
using	a	modified	Boyden	Chamber	assay	to	determine	if	DKK3	silencing	influences	WPMY-1	
cell	migration.	To	control	for	potential	differences	in	cell	number,	cells	were	also	plated	in	
parallel	in	24-well	plates	and	stained	using	Crystal	violet	at	the	end	of	the	migration	assay.	
This	showed	no	changes,	consistent	with	the	results	in	Section	3.4.	The	migration	assays	were	
carried	out	by	Crystal	violet	staining	and	counting	of	migrated	cells	24	h	after	plating,	using	
ImageJ	software.	The	results	show	that	DKK3	silencing	significantly	 increased	WPMY-1	cell	
migration	(Figure	3.8),	suggesting	that	endogenous	Dkk-3	represses	WPMY-1	cell	migration,	
as	observed	for	exogenous	Dkk-3	in	prostate	cancer	cells.	
3.6	Comparison	of	the	effects	of	DKK3	silencing	on	gene	expression	in	RWPE-1	and	
WPMY-1	cells		
		The	previous	experiments	have	mostly	found	similar	effects	of	DKK3	silencing	on	prostate	
epithelial	(RWPE-1)	and	prostate	stromal	(WPMY-1)	cells,	for	example	the	activation	of	TGF-
b	signalling	described	above.	However,	there	were	also	some	differences	that	might	reflect	
stromal-	or	epithelial	cell-specific	effects.	In	this	section,	I	describe	experiments	using	q-PCR	
to	examine	the	effects	of	DKK3	silencing	on	the	expression	of	genes	predicted,	based	on	the	
literature,	 to	be	 regulated	by	DKK3,	and	compared	 the	effects	of	DKK3-silencing	on	 those	
genes	 in	 RWPE-1	 and	WPMY-1	 cells.	 The	 genes	 that	 were	 examined	were	ACTG2,	 which	
encodes	smooth	muscle	actin	and	is	 important	for	smooth	muscle	cell	differentiation	[44],	
ANGPT1,	 encoding	 angiopoietin	 1,	 which	 is	 upregulated	 upon	 DKK3	 silencing	 in	 primary	
prostate	stromal	cells	[226],	MMP2,	as	DKK3	silencing	increases	its	expression	in	RWPE-1	cells		
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[161]	and	VEGFA,	which	was	reported	to	be	induced	by	Dkk-3	in	endothelial	cells	[236].	 In	
addition,	 given	 that	 Dkk-3	 can	 promote	 embryonic	 stem	 cell	 differentiation	 into	 smooth	
muscle		[281]	and	that	RWPE-1	cell	cultures	contain	a	stem	cell	population	[282],	I	examined	
the	effects	of	DKK3	silencing	on	expression	of	 the	embryonic	 stem	cell	 genes	SOX2,	OCT4	
(POU5F1)	and	NANOG,	as	well	as	s-SHIP,	which	encodes	the	short	form	of	SHIP	(SH2-domain-
containing	5’-inositol	phosphatase)	and	is	expressed	in	RWPE-1	stem/progenitor	cells	[283],	
and	ALDH1A1,	which	is	a	marker	for	malignant	prostate	stem	cells	[284]	and	is	downregulated	
in	prostate	cancer	stroma	[285].		
		First,	q-PCR	was	used	to	compare	the	expression	of	genes	in	control	RWPE-1	and	WPMY-1	
cells.	Several	of	the	genes	were	similarly	expressed	at	low	levels	(Ct	values	>	28:	ALDH1A1,	
NANOG),	moderate	levels	(Ct	values	24–28:	SOX2,	OCT4,	ECM1)	or	high	levels	(Ct	values	<	24:	
VEGFA,	TGFBI).	Among	the	other	genes,	ACTG2,	MMP2,	ANGPT1,	s-SHIP	and	DKK3	were	more	
highly	 expressed	 in	WPMY-1	 cells	 than	 in	 RWPE-1	 cells	 (Figure	 3.9A).	 Next,	 the	 extent	 of	
silencing	of	DKK3	was	determined	in	RWPE-1	control	(NS11)	and	DKK3-silenced	(sh6)	cells.	
This	showed	that	the	expression	of	DKK3	in	sh6	cells	was	12%	of	that	in	NS11	cells	(Figure	
3.9B).	 Analysis	 of	 the	 other	 genes	 revealed	 that	 DKK3	 silencing	 significantly	 increased	
expression	of	s-SHIP	and	MMP2.	 In	addition,	 there	were	 trends	 for	 reduced	expression	of	
SOX2	and	for	increased	expression	of	ANGPT1	and	ACTG2.	There	were	no	clear	effects	of	DKK3	
silencing	on	the	expression	of	the	other	genes	analysed.	A	similar	analysis	was	carried	out	to	
compare	expression	in	control	(PSM3	and	PSM2	combined	data)	with	DKK3-silenced	(Wsh8	
and	Wsh7	combined	data)	WPMY-1	cells	(Figure	3.9C).	Again,	the	extent	of	silencing	of	DKK3	
was	first	determined.	This	showed	that	the	expression	of	DKK3	in	Wsh7/8	cells	was	16%	of	
that	in	PSM2/3	cells.	Examination	of	the	other	genes	revealed	that	DKK3	silencing	reduced	
the	expression	of	ALDH1A1,	SOX2,	NANOG,	ACTG2	and	s-SHIP.	
		In	 summary,	 this	 analysis	 revealed	 some	 similarities	 upon	DKK3	 silencing	 in	RWPE-1	 and	
WPMY-1	cells,	such	as	reduced	SOX2	expression,	and	also	differences.	The	gene	most	affected		
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in	different	ways	in	the	two	cell	lines	was	s-SHIP,	which	was	increased	by	DKK3	silencing	in	
RWPE-1	cells	and	reduced	by	DKK3	silencing	in	WPMY-1	cells.	
3.7	DKK3	silencing	increases	s-SHIP	promoter	activity	in	RWPE-1	cells	
	
		A	vector	in	which	the	expression	of	GFP	is	driven	by	the	mouse	s-SHIP	gene	promoter	has	
been	used	to	enrich	for	the	RWPE-1	stem/progenitor	cell	population	[283].	It	was	therefore	
of	 interest	to	determine	 if	the	differential	effects	of	DKK3	silencing	on	human	s-SHIP	gene	
expression	in	RWPE-1	and	WPMY-1	cells	could	be	observed	using	this	vector.	Toward	this	end,	
control	 and	 DKK3-silenced	 RWPE-1	 and	WPMY-1	 cells	 were	 transfected	with	 GFP	 vectors	
driven	by	the	s-SHIP	promoter	[276].	As	a	control,	a	constitutive	promoter	(CMV)	driving	GFP	
was	 used.	 In	 addition,	 an	 ATF2-responsive	 promoter,	 which	 has	 been	 used	 to	 measure	
noncanonical	Wnt	signalling	in	neural	cells	[277],	was	used.	Transfected	cells	were	analysed	
by	FACS	to	measure	the	fraction	of	GFP-positive	cells	in	each	case.	
		Two	experiments	were	carried	out	and	the	transfection	efficiency	in	the	first	experiment	was	
much	higher	than	in	the	second	experiment.	In	the	first	experiment,	the	percentage	of	s-SHIP-
GFP-positive	cells	was	9.1%	and	10.5%	for	NS11	and	sh6,	respectively,	and	this	was	0.37%	and	
0.43%	 in	 the	second	experiment.	The	percentage	of	ATF2-GFP-positive	cells	was	6.8%	and	
3.1%	 for	NS11	 and	 sh6,	 respectively,	 in	 the	 first	 experiment	 and	 0.28%	 and	 0.12%	 in	 the	
second	experiment.	These	percentages	were	normalised	to	those	from	cells	transfected	with	
CMV-GFP,	which	in	the	first	experiment	was	34%	and	37%	for	NS11	and	sh6,	respectively,	and	
in	 the	 second	 experiment	 was	 1.8%	 and	 1.2%.	 The	 normalised	 results	 indicated	 that	 the	
proportion	 of	 s-SHIP-GFP-positive	 cells	was	 higher	 in	 sh6	 cells	 than	 in	NS11	 cells	 and	 the	
proportion	of	ATF2-GFP-positive	cells	was	slightly	lower	in	sh6	cells	than	in	NS11	cells	(Figure	
3.10).	It	was	not	possible	to	carry	out	a	third	experiment,	so	the	significance	of	these	results	
remains	to	be	determined.	However,	the	results	are	consistent	with	the	q-PCR	results	showing	
increased	expression	of	s-SHIP	 in	DKK3-silenced	RWPE-1	cells.	The	results	 for	the	WPMY-1	
cells	 were	 inconclusive	 because	 the	 two	 experiments	 gave	 opposite	 results	 and	 large	
differences	in	transfection	efficiency	in	the	two	cell	lines.	
		In	summary,	DKK3	silencing	increases	s-SHIP	gene	expression	and	expression	of	GFP	driven	
by	the	s-SHIP	gene	promoter	in	RWPE-1	cells.	Moreover,	DKK3	silencing	has	opposite	effects		
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on	 the	 expression	 of	 s-SHIP	 in	 RWPE-1	 and	WPMY-1	 cells.	 These	 interesting	 observations	
would	 benefit	 from	 further	 studies	 to	 study	 the	 effects	 of	 DKK3	 silencing	 in	 RWPE-1	 and	
WPMY-1	at	the	global	gene	expression	level	using	microarrays	or	RNA-Seq. 
	
Conclusions	
	
		The	results	in	this	chapter	indicate	that	DKK3	silencing	has	similar	but	not	identical	effects	in	
WPMY-1	cells	as	those	observed	in	RWPE-1	prostate	epithelial	cells	[160].	DKK3	silencing	does	
not	affect	proliferation	 in	either	cell	 line,	but	 it	does	 increase	WPMY-1	cell	migration	 (the	
effect	of	DKK3	silencing	on	RWPE-1	cell	migration	has	not	been	tested).	 In	both	cell	types,	
DKK3	 silencing	 increases	 Smad-dependent	 transcriptional	 activity.	 However,	 basal	
transcriptional	activity	is	high	in	WPMY-1	cells,	while	it	 is	low	and,	as	a	result	more	TGF-b-
inducible	in	RWPE-1	cells,	most	likely	because	WPMY-1	cells	secrete	their	own	TGF-b.	Another	
difference	is	that	DKK3	silencing	increased	Smad3	phosphorylation	in	WPMY-1	cells,	whereas	
it	 increases	 Smad2	 phosphorylation	 in	 RWPE-1	 cells.	 Finally,	 DKK3	 silencing	 increases	
expression	of	the	stem/progenitor	cell	gene	s-SHIP	in	RWPE-1	cells	but	reduces	it	in	WPMY-1	
cells.	
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Chapter	four	
	
Results	
	
Analysis	of	the	effects	of	stromal	Dkk-3	on	prostate	
epithelial	and	prostate	cancer	cells	
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Introduction	
	
		Dkk-3	is	abundant	in	the	normal	prostate	epithelium	but	is	found	at	much	lower	levels	in	
prostate	 tumours	 [177].	 Ectopic	 expression	 of	 Dkk-3	 reduces	 prostate	 cancer	 cell	
proliferation,	suggesting	that	the	reduction	in	Dkk-3	in	prostate	tumours	plays	a	role	in	cancer	
progression	 [160,	 177].	 Interestingly,	 Dkk-3	 levels	 have	 been	 reported	 to	 be	 increased	 in	
prostate	cancer	stroma	[226].	However,	it	is	not	clear	if	stromal	Dkk-3	plays	a	protective	or	
tumour-promoting	 role	 in	 prostate	 cancer.	WPMY-1	 cells	 have	 been	 used	 as	 a	model	 for	
reactive	stroma	in	prostate	cancer	[253].	They	may	therefore	provide	a	model	to	test	how	
stromal	Dkk-3	affects	prostate	epithelial	and	prostate	cancer	cell	physiology.	DKK3	silencing	
disrupts	the	ability	of	normal	prostate	epithelial	cells	to	form	acini	in	3D	cultures,	an	effect	
that	can	be	rescued	by	 inhibition	of	TGF-β/Smad	signalling	and	also	by	recombinant	Dkk-3	
[160].	In	Chapter	3,	I	showed	that	WPMY-1	cells	express	Dkk-3	and	that	DKK3	silencing	also	
increases	 TGF-β/Smad	 signalling	 in	 this	 cell	 line.	 In	 this	 chapter,	 I	 describe	 experiments	
determining	the	effects	of	conditioned	media	(CM)	from	control	and	DKK3-silenced	WPMY-1	
cells,	or	of	the	cells	themselves,	on	RWPE-1	cell	proliferation	and	acinar	morphogenesis	and	
on	PC3	cell	 invasion.	 I	have	also	 investigated	the	potential	 role	of	MMPs	 in	mediating	 the	
effects	of	Dkk-3.	
4.1	WPMY-1	cell	CM	promotes	normal	acinar	morphogenesis	of	RWPE-1	cells	in	a	Dkk-
3-dependent	manner.	
	
		The	cell	lines	used	in	these	experiments	were	the	following:	RWPE-1	prostate	epithelial	cells	
expressing	control	shRNA	(NS11	and	NS14)	and	DKK3	shRNA	(sh6	and	sh30),	WPMY-1	prostate	
stromal	 cells	 and	WPMY-1	 cells	 expressing	 control	 shRNA	 (NPSM2	 and	 PSM2)	 and	 DKK3	
shRNA	(Wsh7,	Wsh8).	
		To	 study	 the	 effects	 of	 stromal	 Dkk-3	 on	 RWPE-1	 cells,	 conditioned	 media	 (CM)	 were	
collected	from	WPMY-1	stromal	cells	that	had	been	cultured	in	RWPE-1	cell	culture	medium	
for	 48	 h	 and	 then	 added	 to	 prostate	 epithelial	 cells	 that	 had	 been	 plated	 for	 acinar	
morphogenesis	assays	(Figure	4.1).	As	previously	observed	[160],	DKK3-silenced	sh30	and	sh6	
cells	mostly		
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formed	irregular	acini	(notched	and	deformed)	in	normal	assay	medium	(Figure	4.2).	Addition	
of	WPMY-1	cell	CM	increased	the	number	of	normal	acini	formed	by	sh6	cells,	as	compared	
to	medium	alone	 (Figure	4.2A).	 In	contrast,	CM	from	Wsh8	cells	had	no	significant	effect.	
Moreover,	WPMY-1	cell	CM	reduced	the	number	of	deformed	acini	and	showed	a	trend	for	a	
reduction	in	the	number	of	notched	acini	formed	by	sh6	cells.	
		In	a	second	series	of	experiments,	the	effects	of	CM	from	NPSM2	and	Wsh7	cells	on	sh6	cell	
acinar	 morphogenesis	 were	 compared	 (Figure	 4.2B).	 The	 numbers	 of	 normal	 acini	 were	
generally	 lower	 in	these	experiments.	However,	similar	results	were	obtained:	NPSM2	CM	
increased	the	number	of	normal	acini	and	reduced	the	number	of	notched	acini,	whereas	
Wsh7	CM	had	no	effect.	In	a	third	series	of	experiments,	another	DKK3-silenced	RWPE-1	cell	
line,	 sh30,	 was	 used	 (Figure	 4.2C).	 Treatment	 of	 sh30	 cells	 with	 NPSM2	 CM	 significantly	
increased	the	number	of	normal	acini	and	reduced	the	numbers	of	notched	and	deformed	
acini,	compared	to	medium	alone.	 In	contrast,	Wsh7	cell	CM	did	not	affect	the	number	of	
normal	acini	formed	by	sh30	cells.	However,	in	contrast	to	the	results	in	sh6	cells,	Wsh7	cell	
CM	showed	trends	for	increasing	the	number	of	notched	acini	and	reducing	the	number	of	
deformed	acini	formed	by	sh30	cells,	when	compared	with	medium	alone.	The	differences	
may	reflect	differences	in	the	levels	of	Dkk-3	expressed	by	the	cell	lines:	sh6	cells	express	less	
Dkk-3	than	sh30	cells	[160]	and	Wsh7	cell	CM	contains	more	Dkk-3	than	Wsh8	cell	CM	(Figure	
3.1E).	 In	 summary,	 WPMY-1	 and	 NPSM2	 CM	 are	 able	 to	 rescue	 defective	 acinar	
morphogenesis	in	sh6	and	sh30	cells,	and	this	is	not	the	case	for	Wsh7	and	Wsh8	CM.	
4.2	WPMY-1	cell	CM	has	variable	effects	on	acinar	morphogenesis	in	control	RWPE-1	
cells.	
	
		The	results	above	suggest	that	WPMY-1	cell	CM	improves	acinar	morphogenesis	in	DKK3-
silenced	 cells	 because	 it	 provides	 a	 source	 of	 Dkk-3.	 However,	 the	 rescue	 of	 acinar	
morphogenesis	in	DKK3-silenced	cells	might	also	reflect	a	general	effect	of	stromal	cell	CM	on	
improving	acinar	morphogenesis.	To	determine	if	this	is	the	case,	experiments	were	repeated	
using	control	RWPE-1	cells	that	already	express	endogenous	Dkk-3.	As	previously	observed	
[160],	NS11	and	NS14	cells	mostly	formed	regular	acini	(Figure	4.3).	The	number	of	deformed	
	 89	
acini	 formed	by	NS11	cells	was	 reduced	by	WPMY-1	CM	(Figure	4.3A)	and	by	NPSM2	CM	
(Figure	 4.3B),	 as	 compared	 to	 medium	 alone.	 NPSM2	 CM	 also	 increased	 the	 number	 of	
normal	acini	formed	by	NS11	cells	(Figure	4.3B).	In	contrast,	Wsh8	CM	reduced	the	number	
of	 normal	 acini	 formed	 by	 NS11	 cells	 and	 showed	 a	 trend	 for	 increasing	 the	 number	 of	
notched	 acini	 (Figure	 4.3A).	 However,	 Wsh7	 CM	 did	 not	 significantly	 affect	 acinar	
morphogenesis	of	NS11	cells,	when	compared	to	medium	alone	(Figure	4.3B).	In	experiments	
using	NS14	cells,	NPSM2	CM	slightly	 increased	 the	number	of	normal	acini	and	Wsh7	CM	
reduced	 the	 number	 of	 normal	 acini	 and	 showed	 a	 trend	 for	 increasing	 the	 numbers	 of	
notched	and	deformed	acini,	compared	to	control	medium	(Figure	4.3C).	
		Together,	 these	 results	 indicate	 that	 control	 WPMY-1	 cell	 CM	 is	 able	 improve	 acinar	
morphogenesis	of	prostate	epithelial	cells	that	already	express	endogenous	Dkk-3,	and	that	
this	improvement	is	not	observed	using	CM	from	DKK3-silenced	WPMY-1	cells.	Moreover,	CM	
from	DKK3-silenced	cells	had	a	negative	effect	on	the	number	of	normal	acini	formed	in	two	
sets	of	experiments	(combinations	of	Wsh8/NS11	and	Wsh7/NS14)	but	not	in	one	of	them	
(the	Wsh7/NS11	combination).	The	different	outcome	for	the	Wsh7/NS11	combination	may	
result	from	the	lower	number	of	normal	acini	formed	by	NS11	cells	in	normal	medium	in	that	
particular	series	of	experiments,	which	is	something	that	is	observed	at	higher	cell	passage	
numbers.		
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4.3	WPMY-1	cell	CM	inhibits	proliferation	of	DKK3-silenced	RWPE-1	cells	in	a	Dkk-3-
dependent	manner.	
	
		Although	DKK3	 silencing	 in	RWPE-1	 cells	does	not	affect	 their	proliferation	 in	monolayer	
cultures,	it	increases	their	proliferation	in	3D	cultures,	and	this	is	thought	to	contribute	to	the	
disruption	 of	 acinar	morphogenesis	 observed	 [160].	 Accordingly,	 in	 order	 to	 determine	 if	
stromal	Dkk-3	can	inhibit	the	proliferation	of	DKK3-silenced	RWPE-1	cells,	co-culture	assays	
were	carried	out	combining	sh30	cells	with	NPSM2	or	Wsh8	cells	(Figure	4.4A).	The	co-culture	
of	DKK3-silenced	RWPE-1	cells	with	stromal	cells	that	express	Dkk-3	may	reflect	the	situation	
at	an	early	stage	of	cancer,	where	prostate	epithelial	cells	have	lost	expression	of	Dkk-3	and	
are	 invading	 the	 reactive	 stroma,	 which	 has	 been	 induced	 to	 express	 Dkk-3	 [226].	
Interestingly,	sh30	cell	proliferation	was	significantly	higher	upon	co-culture	with	Wsh8	cells,	
as	 compared	 to	 co-culture	 with	 NPSM2	 cells	 or	 with	medium	 alone	 (Figure	 4.4B).	 These	
results	indicate	that	the	proliferation	of	DKK3-silenced	RWPE-1	cells	is	not	affected	by	the	co-
culture	of	 control	WPMY-1	 cells,	 but	 is	 increased	by	 co-culture	of	DKK3-silenced	WPMY-1	
cells,	 suggesting	 either	 that	 stromal	 Dkk-3	 normally	 inhibits	 the	 activity	 of	 a	 growth-
promoting	stromal	cell	factor	or	that	DKK3	silencing	in	WPMY-1	cells	induces	the	secretion	of	
a	growth-promoting	stromal	cell	factor.	
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4.4	Conditioned	medium	from	DKK3-silenced	WPMY	-1	cells	increases	PC3	cell	
invasion.	
	
		The	ability	of	CM	from	WPMY-1	cells	to	promote	the	formation	of	normal	acini	in	a	Dkk-3-
dependent	manner	is	consistent	with	Dkk-3	preventing	prostate	cancer	progression	at	an	early	
stage	of	prostate	cancer.	Moreover,	the	increased	proliferation	of	DKK3-silenced	RWPE-1	cells	
observed	 in	 the	presence	of	DKK3-silenced	WPMY-1	 cells	 suggests	 that	 stromal	Dkk-3	 can	
inhibit	other	stromal	factors	from	promoting	prostate	epithelial	cell	proliferation.	Studies	in	
our	laboratory	have	shown	that	CM	from	Dkk-3-transfected	cells	inhibits	the	migration	and	
invasion	of	PC3	prostate	cancer	cells	[161].	In	order	to	determine	if	stromal	cell	Dkk-3	also	has	
this	effect,	experiments	were	carried	out	in	which	PC3	cells	were	cultured	in	the	presence	of	
CM	from	control	and	DKK3-silenced	WPMY-1	cells.	The	invasion	of	PC3	cells	was	significantly	
higher	in	the	presence	of	CM	from	DKK3-silenced	Wsh8	cells,	compared	to	in	the	presence	of	
CM	 from	WPMY-1	 cells	 (Figure	 4.5A).	 A	 similar	 result	was	 observed	when	 comparing	 the	
invasion	 of	 PC3	 cells	 in	 the	 presence	 of	 CM	 from	DKK3-silenced	Wsh7	 cells	 and	 CM	 from	
NPSM2	cells	(Figure	4.5B).	Interestingly,	there	were	no	significant	differences	in	the	invasion	
of	PC3	cells	cultured	in	medium	alone	compared	to	culture	in	the	presence	of	CM	from	WPMY-
1	 cells	 or	 NPSM2	 cells.	 Together,	 these	 results	 are	 consistent	 with	 a	 model	 in	 which	 the	
presence	 of	 Dkk-3	 in	 stromal	 CM	 inhibits	 the	 activity	 of	 a	 stromal	 factor(s)	 that	 would	
otherwise	promote	PC3	cell	invasion.	Alternatively,	DKK3	silencing	in	stromal	cells	could	lead	
to	activation	or	increased	expression	of	stromal	factors	that	promote	PC3	cell	invasion.	
		One	possibility	 is	that	stromal	MMPs	are	responsible	for	the	increased	invasion	observed.	
WPMY-1	 cells	 express	 high	 levels	 of	MMP2	 [253],	 and	 Dkk-3	 regulates	 prostate	 epithelial	
acinar	 morphogenesis	 and	 prostate	 cancer	 cell	 invasion	 by	 limiting	 endogenous	 TGF-β-
dependent	MMP	activation	[161].	Although	no	significant	differences	in	MMP2	levels	were		
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Figure	4.5	DKK3-silenced	WPMY-1	cell	CM	increases	PC3	cell	invasion	and	this	effect	is	
inhibited	by	the	MMP2	inhibitor	ARP100.		
(A)	CM	from	DKK3-silenced	(Wsh8)	cells	increases	PC3	cell	invasion,	relative	to	WPMY-1	cell	
CM,	n=3,	* p<0.01	by	Student’s	t	test;	WPMY-1	cell	CM	does	not	affect	PC3	cell	invasion,	
compared	to	serum-free	medium,	n=3.	Left:	representative	photos	of	invaded	PC3	cells	with	
WPMY-1	and	Wsh8	CM	after	staining	with	crystal	violet.	(B)	CM	from	DKK3-silenced	(Wsh7)	
cells	increases	PC3	cell	invasion,	relative	to	control	(NPSM2)	cell	CM,	n=3,	*	p<0.01;	Control	
(NPSM2)	cell	CM	shows	a	trend	for	increasing	PC3	cell	invasion,	compared	to	serum-free	
medium,	n=3.	Left:	representative	photos	of	invaded	cells.	(C)	Invasion	assays	in	the	presence	
of	CM	from	control	(NPSM2)	or	DKK3-silenced	(Wsh8)	in	the	presence	(+)	or	absence	(-)	of	
the	MMP2	inhibitor	ARP100,	all	relative	to	control	(-),	n=3,	*	p<	0.05,	**	p<0.01,	Student’s	t	
test.	Left:	representative	photos	of	invaded	cells;	scale	bars	100	um.	
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observed	in	CM	from	control	and	DKK3-silenced	WPMY-1	cells,	there	was	a	trend	for	higher	
expression	of	MMP2	in	DKK3-silenced	WPMY-1	cell	CM	(Chapter	3,	Figure	3.5B).	To	determine	
if	MMP2	played	a	role	in	the	increased	invasion	observed	in	the	presence	of	CM	from	DKK3-
silenced	WPMY-1	cells,	invasion	assays	were	carried	out	in	the	presence	of	ARP100,	a	selective	
inhibitor	of	MMP2	at	 the	dose	used.	While	ARP100	did	not	affect	PC3	cell	 invasion	 in	 the	
presence	of	control	WPMY-1	CM,	it	reduced	the	invasion	of	PC3	cells	cultured	in	the	presence	
of	CM	from	DKK3-silenced	WPMY-1	cells	 (Figure	4.5C).	These	 results	are	consistent	with	a	
model	in	which	DKK3	silencing	facilitates	MMP2-dependent	prostate	cancer	invasion.	
	
Conclusions	
		WPMY-1	cell	CM	provides	a	source	of	Dkk-3	 that	 rescues	acinar	morphogenesis	 in	DKK3-
silenced	cells.	This	result	consists	with	the	partial	rescue	of	acinar	morphogenesis	in	Dkk-3-
silenced	RWPE-1	cells	by	recombinant	Dkk-3	[160].	Moreover,	WPMY-1	cell	CM	is	also	able	to	
improve	acinar	morphogenesis	of	prostate	epithelial	cells	that	already	express	endogenous	
Dkk-3.	Co-culture	of	DKK3-silenced	WPMY-1	increases	proliferation	of	DKK3-silenced	RWPE-
1	cells	 in	a	Dkk-3	dependent	manner.	Furthermore,	CM	from	DKK3-silenced	WPMY-1	cells	
increases	PC3	cell	invasion,	probably	in	an	MMP2-dependent	manner.	Together,	these	results	
support	 a	 role	 for	 stromal	 Dkk-3	 in	 regulation	 prostate	 epithelial	 cell	 proliferation	 and	
prostate	cancer	cell	invasion,	the	latter	via	effects	on	MMP2.	
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Chapter	five	
	
Results	
	
Identification	and	characterisation	of	secreted	proteins	
affected	by	DKK3	silencing	in	prostate	cells	
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Introduction	
	
		In	the	previous	chapters,	WPMY-1	CM	was	found	to	rescue	acinar	morphogenesis	in	RWPE-
1	 cells	 in	 a	 Dkk-3-dependent	manner.	 In	 addition,	 CM	 from	 DKK3-silenced	WPMY-1	 cells	
increased	PC3	cell	invasion	in	an	MMP2-dependent	manner.	These	results	suggest	that	DKK3	
silencing	 affects	 the	 levels	 and/or	 activity	 of	 secreted	 factors.	 In	 this	 chapter,	 I	 describe	
experiments	carried	out	to	determine	 if	DKK3	silencing	affects	the	 levels	of	other	proteins	
present	 in	WPMY-1	CM.	The	results	obtained	have	been	compared	with	a	parallel	analysis	
carried	out	using	DKK3-silenced	RWPE-1	cells.	An	antibody	array	approach	was	used	for	these	
studies,	 as	 it	 provides	 a	 quick	method	 to	 compare	 the	 levels	 of	 a	 reasonable	 number	 of	
candidate	proteins.	The	levels	of	two	proteins	in	CM,	TGFBI	and	ECM-1,	appeared	to	change	
upon	DKK3	silencing.	Western	blotting	was	carried	out	to	confirm	these	changes	and	q-PCR	
was	used	to	determine	if	these	changes	also	occurred	at	the	mRNA	level.	Finally,	recombinant	
TGFBI	and	ECM1	were	tested	for	their	effects	on	acinar	morphogenesis	of	RWPE-1	cells	and	
invasion	of	PC3	cells.	
5.1	Identification	of	proteins	affected	by	DKK3-silencing	in	CM	from	WPMY-1	and	
RWPE-1	cells	using	antibody	arrays	
	
		The	Proteome	ProfilerTM	Human	Soluble	Receptor	Array,	which	recognises	119	proteins	in	
total,	was	used	for	this	study.	This	kit	is	comprised	of	the	´Non-Haematopoietic	Array´,	which	
contains	62	antibodies,	and	the	´Common	Analytes	Array´,	which	contains	57	antibodies,	in	
both	 cases	 printed	 in	 duplicate.	 Arrays	were	 incubated	with	 CM	 from	 control	 and	 DKK3-
silenced	WPMY-1	 cells	 and	 with	 CM	 from	 control	 and	 DKK3-silenced	 RWPE-1	 cells.	 Each	
experiment	was	carried	out	twice	using	CM	from	independent	cell	cultures.	The	intensities	of	
the	spots,	measured	by	densitometry	of	multiple	exposures,	were	normalised	to	the	averaged	
intensities	of	control	spots	on	the	arrays.	
		The	 results	 of	 Experiment	 (1)	 in	 the	 ‘Non-Haematopoietic	 Array’	 using	 CM	 from	 control	
(PSM2)	and	DKK3-silenced	(Wsh8)	WPMY-1	cells	(Figure	5.1A)	revealed	two	abundant		
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proteins,	TGFBI	and	ECM1.	Considering	the	signals	of	the	control	spots,	the	signal	for	TGFBI	
(circled	in	red)	was	stronger	in	Wsh8	CM	than	in	PSM2	CM,	and	the	signal	for	ECM-1	(circled	
in	green)	was	slightly	weaker	in	Wsh8	CM	than	in	PSM2	CM.	In	Experiment	(2),	more	proteins	
were	detected	and	a	small	increase	in	TGFBI	in	Wsh8	CM	was	observed,	as	was	a	reduction	in	
the	level	of	ECM-1.	Quantitation	and	normalisation	of	the	signals	from	the	two	experiments	
confirmed	the	changes	in	TGFBI	and	ECM-1	(Figure	5.1B).	
		In	experiment	 (1)	using	 the	 ‘Common	Analytes	Array’,	 the	 levels	of	 IL8	 (blue	 circles)	 and	
MMP2	(green	circles)	were	both	lower	in	CM	from	DKK3-silenced	WPMY-1	cells	than	in	CM	
from	control	cells	(Figure	5.1C).	In	Experiment	2,	the	differences	were	less	obvious.	However,	
quantitation	and	normalisation	of	the	densitometry	data	suggested	that	both	proteins	were	
present	at	lower	levels	in	Wsh8	CM,	compared	to	PSM2	CM	(Figure	5.1D).	The	MMP2	result	
was	unexpected,	as	western	blotting	(Figure	3.5A)	showed	a	trend	for	higher	MMP2	in	the	
CM	of	DKK3-silenced	WPMY-1	cells,	compared	to	CM	of	control	cells.	There	is	no	information	
provided	about	the	anti-MMP2	antibodies	used	in	the	array,	so	it	is	not	known	if	the	different	
results	are	because	different	anti-MMP2	antibodies	were	used	in	the	array	and	in	western	
blots.	 
		In	 summary,	 the	 array	data	 indicate	 that	CM	 from	DKK3-silenced	WPMY-1	 cells	 contains	
more	TGFBI	and	slightly	less	ECM-1,	IL-8	and	MMP2	than	CM	from	control	WPMY-1	cells.	
		A	parallel	analysis	was	performed	by	Dr	Diana	Romero	using	CM	from	control	(NS11)	and	
DKK3-silenced	 (sh6)	 RWPE-1	 cells	 (Figure	 5.2).	 The	 results	 using	 the	 ‘Non-Haematopoietic	
Array’	showed	that	DKK3	silencing	did	not	appear	to	affect	the	level	of	TGFBI	(red	circles)	in	
RWPE-1	CM	but	increased	the	level	of	ECM-1	(green	circles)	(Figure	5.2A).	These	results	were	
confirmed	by	densitometry	analysis	of	the	spots	(Figure	5.2B).	The	results	for	the	‘Common	
Analytes	array’	are	not	shown	as	they	did	not	any	produce	consistent	results:	MMP2	was	not	
detected	and	IL-8	was	reduced	in	one	experiment	and	increased	in	the	other.	In	summary,	
DKK3	silencing	increased	ECM-1	in	RWPE-1	cell	CM	and	slightly	reduced	it	in	WPMY-1	cell	CM,	
while	 it	 increased	 TGFBI	 in	 WPMY-1	 cell	 CM	 and	 showed	 no	 effect	 in	 RWPE-1	 cell	 CM.	
However,	these	experiments	were	only	performed	twice,	so	further	experiments	are	required	
to	confirm	the	changes	observed.		
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5.2	DKK3	silencing	increases	TGFBI	levels	in	WPMY-1	and	RWPE-1	cell	CM.	
	
		Experiments	were	carried	out	to	validate	the	proteome	array	hits	and	to	determine	if	the	
changes	observed	at	the	protein	level	reflected	changes	in	gene	expression.	Two	of	the	hits,	
TGFBI	and	ECM-1,	were	chosen	for	further	study	because	they	appeared	to	be	present	at	high	
levels	in	WPMY-1	cell	CM.	In	addition,	TGFBI	is	regulated	by	TGF-b	signalling	and	has	been	
linked	to	prostate	cancer	metastasis	[266]	and	ECM-1	has	been	linked	to	many	types	of	cancer	
[286].Western	blot	analysis	of	TGFBI	in	CM	from	PSM2	and	Wsh8	cells	detected	a	doublet	at	
68-70	kDa	(Figure	5.3A),	the	reported	size	of	TGFBI.	Comparison	of	the	band	intensities	on	
the	blot	with	the	major	proteins	detected	by	Coomassie	Blue	staining	of	a	gel	run	in	parallel	
indicated	 that	 the	 level	 of	 TGFBI	 was	 higher	 in	 Wsh8	 cell	 CM	 than	 in	 PSM2	 cell	 CM.	
Furthermore,	 densitometry	 analysis	 of	 western	 blots	 from	 independent	 batches	 of	 CM,	
indicated	a	small	but	significant	increase	(Figure	5.3B).	However,	q-PCR	analysis	did	not	detect	
any	significant	differences	in	TGFBI	mRNA	levels	in	control	cells	(PSM2	and	PSM3),	compared	
to	in	DKK3-silenced	cells	(Wsh7	and	Wsh8)	(Figure	5.3C).	Interestingly,	western	bot	analysis	
of	TGFBI	in	CM	from	NS11	and	sh6	cells	also	found	higher	levels	of	TGFBI	in	CM	from	DKK3-
silenced	RWPE-1	cells	(Figure	5.3D).	This	contrasted	with	the	results	from	the	array,	where	
there	 was	 no	 apparent	 difference	 (Figure	 5.2A).	 Normalisation	 of	 densitometry	
measurements	from	multiple	western	blots	to	gels	stained	with	Coomassie	Blue	confirmed	
that	the	level	of	TGFBI	was	higher	in	CM	from	sh6	cells	than	in	CM	from	NS11	cells	(Figure	
5.3E).	Moreover,	q-PCR	analysis	showed	that	TGFBI	mRNA	levels	were	significantly	higher	in	
sh6	cells	than	in	NS11	cells.	Taken	together,	the	results	indicate	that	DKK3	silencing	increases	
the	level	of	TGFBI	in	CM	collected	from	WPMY-1	and	from	RWPE-1	cells,	and	increases	TGFBI	
mRNA	levels	in	RWPE-1	cells.		
	
5.3	DKK3	silencing	reduces	ECM-1	levels	in	WPMY-1	cell	CM	and	increases	ECM-1	
levels	in	RWPE-1	cell	CM.	
	
		Similar	experiments	were	performed	 to	measure	 the	effects	of	DKK3	 silencing	on	ECM-1	
protein	and	ECM1	mRNA	levels.	Western	blot	analysis	of	ECM-1	in	CM	from	PSM2	and	Wsh8	
cells	detected	a	protein	of	85	kDa,	the	reported	size	of	ECM-1	(Figure	5.4A).	Comparison	of		
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the	band	intensities	on	the	blot	with	the	major	proteins	detected	by	Coomassie	Blue	staining	
of	a	gel	run	in	parallel	indicated	that	the	level	of	ECM-1	is	lower	in	Wsh8	cell	CM	than	in	PSM2	
cell	 CM.	 This	was	 confirmed	by	densitometry	 analysis	 of	western	blots	 from	 independent	
batches	of	CM	(Figure	5.4B).	However,	q-PCR	analysis	(Figure	5.4C)	did	not	detect	a	difference	
in	the	expression	of	ECM1	mRNA	in	control	cells	(PSM2	and	PSM3),	compared	to	in	DKK3-
silenced	cells	(Wsh7	and	Wsh8).	
		Western	bot	analysis	of	CM	revealed	more	ECM-1	in	CM	from	sh6	cells	than	in	NS11	cells	
(Figure	5.4D),	consistent	with	the	results	from	the	array	(Figure	5.2A).	This	was	confirmed	by	
analysis	of	the	ECM-1	signal	in	western	blots	normalised	to	gels	stained	with	Coomassie	Blue	
(Figure	5.4E).	However,	q-PCR	analysis	did	not	detect	a	difference	in	the	expression	of	ECM1	
mRNA	in	NS11	and	sh6	cells	(Figure	5.4F).	Taken	together,	these	results	partly	confirm	the	
findings	in	the	protein	arrays,	showing	that	DKK3	silencing	reduces	ECM-1	protein	in	CM	from	
WPMY-1	cells	and	increases	ECM-1	protein	in	CM	from	RWPE-1	cells.	In	addition,	the	changes	
in	ECM-1	protein	 levels	 in	CM	do	not	appear	to	result	 from	changes	 in	the	 levels	of	ECM1	
mRNA.	
5.4	Analysis	of	the	effects	of	recombinant	TGFBI	and	ECM-1	on	acinar	morphogenesis	
of	DKK3-silenced	RWPE-1	cells	
	
		In	 order	 to	 determine	 the	 functional	 effects	 of	 increased	 levels	 of	 TGFBI	 and	 ECM-1	 on	
prostate	 cells,	 purified	 recombinant	 human	 TGFBI	 (rhTGFBI)	 and	 ECM-1	 (rhECM-1)	 were	
added	 to	 control	 and	DKK3-silenced	RWPE-1	 cells	 in	 acinar	morphogenesis	 assays.	 To	use	
physiologically	 relevant	 amounts	 of	 recombinant	 proteins	 in	 these	 experiments,	 western	
blots	were	 carried	 out	 to	 compare	 the	 signals	 of	 different	 amounts	 of	 each	 recombinant	
protein	with	ECM-1	and	TGFBI	detected	in	CM	from	RWPE-1	cells.	This	led	to	the	decision	to	
use	1	ug/ml	rhTGFBI	and	100	ng/ml	rhECM-1.	NS11	and	sh6	RWPE-1	cells	were	plated	for	
acinar	morphogenesis	assays	and	treated	with	media	containing	rhTGFBI	or	rhECM-1	every	
two	days,	for	a	total	of	eight	days.	
		The	results	of	experiments	performed	in	DKK3-silenced	(sh6)	cells	indicated	that	treatment	
with	rhTGFBI	had	no	significant	effect	on	acinar	morphogenesis,	compared	with	assay	media	
alone	(Figure	5.5A).	In	contrast,	treatment	with	rhECM-1	resulted	in	a	notable	rescue	of	acinar		
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morphogenesis,	 with	 a	 significant	 increase	 in	 normal	 acini	 and	 a	 significant	 reduction	 in	
deformed	acini.	The	numbers	of	notched	acini	were	similar	in	control	and	treated	cells.	
		The	results	of	experiments	performed	in	control	(NS11)	cells	indicated	that	treatment	with	
rhECM-1	 had	 no	 significant	 effect	 on	 acinar	morphogenesis,	 compared	with	 assay	media	
alone	(Figure	5.5B).	However,	 treatment	with	rhTGFBI	showed	trend	for	reduction	normal	
acini	and	an	increase	in	deformed	acini.	The	numbers	of	notched	acini	were	similar	in	control	
and	treated	cells.	
		In	 summary,	 rhECM-1	 rescued	 acinar	 morphogenesis	 in	 DKK-3-silenced	 cells,	 whereas	
rhTGFBI	 showed	 a	 trend	 for	 disrupting	 acinar	 morphogenesis	 in	 control	 cells,	 suggesting	
tumour-suppressive	and	tumour-promoting	roles	for	ECM-1	and	TGFBI,	respectively,	 in	the	
context	of	the	acinar	morphogenesis	assay.	Inhibition	of	NS11	cell	acinar	morphogenesis	by	
rhTGFBI	would	be	consistent	with	TGFBI	having	a	tumour-promoting	role.	However,	rhTGFBI	
only	showed	a	trend	for	disrupting	acinar	morphogenesis,	suggesting	that	additional	factors	
are	also	required.	The	positive	effect	of	rhECM-1	on	acinar	morphogenesis	was	unexpected,	
since	it	might	be	expected	to	have	a	negative	effect	as	it	is	present	at	higher	levels	in	the	CM	
of	DKK3-silenced	RWPE-1	cells,	compared	to	control	cells	(Figure	5.4B).	One	possibility	is	that	
ECM-1	 levels	 differ	 in	 2D	 and	 3D	 cultures.	 Unfortunately,	 there	 are	 technical	 difficulties	
measuring	the	levels	of	proteins	secreted	by	RWPE-1	cell	acini,	so	this	could	not	be	tested.	
5.5	Analysis	of	the	effects	of	recombinant	TGFBI	and	ECM-1	on	PC3	cell	invasion	
	
		PC3	cell	invasion	is	increased	by	CM	from	DKK3-silenced	WPMY-1	cells	but	not	by	CM	from	
control	WPMY-1	cells.	Moreover,	CM	from	DKK3-silenced	WPMY-1	cells	contains	more	TGFBI	
and	less	ECM-1	than	CM	from	control	WPMY-1	cells.	These	observations	suggest	that	PC3	cell	
invasion	might	be	increased	by	TGFBI	and/or	reduced	by	ECM-1.	To	test	these	possibilities,	
PC3	 cell	 invasion	 assays	 were	 carried	 out	 in	 the	 control	 medium	 or	 medium	 containing	
rhTGFBI,	 rhECM-1	 or	 both	 proteins	 (Figure	 5.6).	 Treatment	 of	 PC3	 cells	 with	 rhTGFBI	
significantly	increased	PC3	cell	invasion,	compared	to	control	medium,	while	treatment	with	
rhECM-1	had	no	effect.	Interestingly,	cell	invasion	was	similar	in	control	cells	and	cells	treated	
with	rhTGFBI	and	rhECM-1	together,	suggesting	that	rhECM-1	inhibits	the	function	of	rhTGFBI.		
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In	 experiments	where	 cells	 were	 plated	 in	 parallel	 and	 treated	 in	 the	 same	way,	 neither	
rhTGFBI	nor	rhECM1	affected	cell	number	during	the	course	of	the	assay.	
		In	summary,	the	results	of	these	experiments	suggest	that	in	the	context	of	prostate	cancer	
cell	invasion,	TGFBI	and	ECM-1	have	tumour-promoting	and	tumour-suppressing	functions,	
respectively.	This	would	be	consistent	with	 the	 levels	of	 these	proteins	 found	 in	CM	from	
WPMY-1	cells,	where	DKK3	silencing	alters	the	balance	of	TGFBI	and	ECM1	in	favour	of	TGFBI,	
which	promotes	PC3	cell	invasion.	
	
Conclusions	
	
		In	this	Chapter,	DKK3	silencing	was	found	to	increase	the	level	of	TGFBI	and	reduce	the	level	
of	ECM-1	in	the	CM	of	WPMY-1	cells.	Based	on	the	intensities	of	the	spots	in	the	antibody	
array,	TGFBI	and	ECM-1	are	among	the	most	abundant	proteins	found	in	WPMY-1	CM.	Their	
potential	relevance	as	downstream	mediators	of	stromal	Dkk-3	is	supported	by	the	results	of	
the	experiments	carried	out	in	PC3	cells	using	recombinant	proteins.	Recombinant	TGFBI	was	
found	to	promote	invasion,	whereas	recombinant	ECM-1	inhibited	the	effects	of	TGFBI.	This	
suggests	that	the	relative	levels	of	TGFBI	and	ECM1	might	be	important.	In	addition,	rhECM-
1	 rescued	 acinar	morphogenesis	 of	 DKK3-silenced	 RWPE-1	 cells.	 This	was	 unexpected,	 as	
ECM-1	levels	increased	in	DKK3-silenced	RWPE-1	cells.	However,	WPMY-1	CM	contains	more	
ECM-1	(and	less	TGFBI)	than	DKK3-silenced	WPMY-1	cell	CM,	so	it	is	consistent	with	the	ability	
of	WPMY-1	CM	to	rescue	acinar	morphogenesis	of	DKK3-silenced	RWPE-1	cells.	
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Chapter	six	
	
Results	
	
Immunohistochemical	analysis	of	Dkk-3,	TGFBI	and	ECM-1	
expression	in	prostate	sections	from	prostate	cancer	
patients	 	
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Introduction	
	
			In	2006,	an	 immunohistochemical	 study	 from	our	group	using	a	commercial	TMA	 found	
heterogeneous	expression	of	Dkk-3	in	prostate	cancer	[177].	Statistical	analysis	of	the	results	
indicated	significantly	 lower	Dkk-3	expression	 in	 tumours	with	a	Gleason	score	of	9	or	10,	
compared	to	Gleason	scores	of	8	and	below,	suggesting	that	loss	of	Dkk-3	corresponds	with	
the	loss	of	glandular	structure.	Similar	results	were	reported	by	other	groups	[207,	208].	It	is	
well-established	 that	 patients	 with	 poorly	 differentiated	 non-metastatic	 tumours	 have	 a	
lower	overall	 survival	 rate,	compared	with	patients	with	well-differentiated	 tumours	 [287,	
288].	 It	was	also	reported	that	Dkk-3	 is	 found	expressed	 in	prostate	tumour	stroma	[208].	
However,	there	are	no	studies	comparing	the	expression	levels	of	Dkk-3	in	benign	and	tumour	
epithelium	and	stroma	and	no	studies	of	proteins	that	are	affected	by	loss	of	Dkk-3	in	the	
prostate.	
		In	 this	 Chapter,	 I	 describe	 results	 from	 immunohistochemical	 examination	 of	 Dkk-3	
expression	in	the	epithelia	and	stroma	of	benign	and	tumour	tissue	sections	from	prostate	
cancer	patients,	and	compare	them	with	the	expression	patterns	of	TGFBI	and	ECM-1.	For	this	
study,	 tissue	 microarrays	 (TMAs)	 from	 the	 Imperial	 Cancer	 Biomarker	 Resource	 Centre	
(ICBRC)	were	subjected	to	immunohistochemistry	with	a	panel	of	antibodies.	In	addition	to	
using	 antibodies	 recognising	 Dkk-3,	 epithelial	 cytokeratin,	 TGFBI	 and	 ECM-1,	 for	 which	 I	
carried	out	 the	 immunohistochemistry,	 the	TMAs	were	stained	by	 the	 ICBRC	 for	SMA	and	
vimentin.		I	also	stained	for	MMP2,	but	the	signal	was	very	weak	and	therefore	not	analysed	
further.		
	
6.1	TMA	description	and	characteristics	
	
	The	TMAs	provided	contained	sections	from	99	PCa	patients	from	the	ICBRC	with	approval	
from	the	Imperial	College	Tissue	Bank	steering	committee	(Project	R15043).	Patient	samples	
were	provided	as	six	multi-core	prostate	samples	with	 four	sections	per	patient,	 two	with	
cancer	and	two	with	adjacent	benign	tissue.	An	example	of	one	of	the	six	arrays	and	a	single	
core	 is	shown	 in	Figures	6.1A	and	B.	TMAs	that	had	previously	been	stained	for	SMA	and	
vimentin	(VIM)	were	also	provided.	Figure	6.1C	shows	an	example	of	a	tumour	with	stroma	
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that	are	positive	 for	both	SMA	and	VIM,	which	has	been	used	to	 indicate	the	presence	of	
myofibroblasts	 (reactive	 stroma)	 [289].	 The	 TMAs	 were	 also	 stained	 using	 anti-pan	
cytokeratin	 (CK)	 antibodies	 to	 detect	 normal	 and	 tumour	 epithelial	 cells,	 and	 with	
Haematoxylin	and	Eosin	(H&E)	to	reveal	tissue	morphology	(Figure	6.1C).	Haematoxylin	is	the	
deep	purple	staining	that	detects	nucleic	acid,	while	eosin	 is	the	pink	staining	that	detects	
proteins	 [290].	 In	 this	 study,	 the	 “quick	 scoring”	method	 [291],	 in	 which	 the	 intensity	 of	
staining	is	scored	visually	and	given	a	number,	was	used	by	two	people	(Zainab	Al	Shareef	and	
Robert	Kypta).	 In	addition,	 the	TMAs	were	 re-analysed	by	a	pathologist	 (James	Carton)	 to	
confirm	the	section	Gleason	scores.		
		Prostate	 samples	 were	 collected	 after	 surgical	 resection	 of	 the	 prostate.	 All	 patients	
underwent	radical	prostatectomy	either	by	Transurethral	resection	of	the	prostate	(TURP),	
except	for	one	patient	who	underwent	abdominoplasty.	Patient	ages	ranged	from	32	to	99	
years,	with	a	median	age	of	63	and	an	average	age	of	62	(Table	6.1).	Patient	PSA	levels	were	
not	provided.	77	patient	tumours	were	classified	as	low	to	moderate	grade	(Gleason	≤	3	+	4)	
and	22	patients	as	high	grade	(Gleason	≥	4	+	3)	PCa.	For	surgically	removed	tumours,	49	were	
Gleason	3+3,	28	were	3+4,	14	were	4+3,	7	were	4+4	and	1	was	4+5.	27	patient	tumours	had	
acute	 inflammation	 (presence	 of	 acute	 inflammatory	 cells	 e.g.	 polymorphonuclear	 cells)	
and/or	chronic	inflammation	(presence	of	cells	with	an	appearance	consistent	with	that	of	
lymphocytes	and	macrophages).	22	of	these	patients	also	had	chronic	stromal	inflammation.	
Furthermore,	42	patient	tumours	showed	evidence	of	perineural	invasion,	two	of	them	also	
showed	vascular	invasion	and	four	of	them	showed	lymphovascular	invasion.	One	of	these	
patients	also	had	lymph	node	metastases.	
		Not	 all	 the	 patient	 tumour	Gleason	 scores	 corresponded	with	 the	Gleason	 scores	 of	 the	
sections	analysed	by	immunohistochemistry.	Among	the	differences	were	8	patient	tumour	
sections	that	contained	only	benign	tissue.	These	were	therefore	excluded	from	the	analysis,	
The	 Gleason	 scores	 of	 the	 sections	 analysed	 by	 immunohistochemistry,	 rather	 than	 the	
patient	Gleason	scores,	were	used	for	the	analysis	of	Dkk-3,	ECM1	and	TGFBI	expression.	
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6.2	Immunohistochemistry	of	smooth	muscle	actin	(SMA)	and	vimentin	(VIM)	
	
		Myofibroblasts	 are	 the	 predominant	 stromal	 cell	 type	 in	 the	 reactive	 stroma	 found	 in	
prostate	cancer	(see	Chapter	I,	Introduction).	To	confirm	the	presence	of	reactive	stroma	in	
the	tumour	sections,	I	looked	for	co-expression	of	SMA	and	VIM.	The	immunohistochemistry	
for	these	markers	was	carried	out	by	Dr	Jenny	Steel	(Imperial	College	London).	Some	tumour	
sections	contained	very	little	stroma	(Figure	6.2A),	while	there	was	more	stroma	in	others	
(Figure	 6.2B).	 Immunohistochemical	 detection	 of	 cytokeratin	 was	 used	 to	 confirm	 the	
presence	of	epithelial	cells.	In	all	except	6	cases,	tumour	stroma	was	positive	for	both	SMA	
and	VIM,	suggesting	that	the	majority	of	patient	tumour	sections	contained	reactive	stroma.		
	
6.3	Dkk-3	expression	is	reduced	in	PCa	and	the	PCa	stroma,	compared	to	in	benign	
epithelium	and	stroma	
	
		As	mentioned	in	the	Introduction,	Dkk-3	expression	in	diseased	prostate	has	been	reported	
to	be	altered	in	both	epithelial	and	stromal	cells.	However,	the	data	for	stromal	cells	from	
patient	stromal	cell	cultures	[226],	and	expression	of	Dkk-3	in	patient	tumour	stroma	has	not	
been	analysed	 in	detail.	Therefore,	 immunohistochemistry	of	the	TMAs	was	carried	out	to	
compare	Dkk-3	expression	in	prostate	tumour	epithelia	and	stroma.	This	was	done	using	a	
validated	antibody	and	conditions	previously	optimised	 in	the	 lab	[177].	The	expression	of	
Dkk-3	was	scored	by	overall	intensity	in	two	sections	each	of	tumour	and	benign	tissue,	using	
the	scoring	categories	0	(negative),	1	(weak),	2	(moderate)	and	3	(strong).	Figure	6.3A	shows	
examples	of	each	category	of	Dkk-3	score	 in	prostate	epithelium,	using	pan-CK	staining	of	
adjacent	 sections	 to	 identify	 the	 epithelial	 cells.	 Dkk-3	 expression	 in	 the	 stroma	 was	
separately	scored	using	the	same	approach.	However,	the	staining	intensity	for	stromal	Dkk-
3	was	lower	than	for	epithelial	Dkk-3,	so	an	adjustment	was	made	to	take	this	into	account	
(Figure	6.3B).	Examples	of	Dkk-3	staining	in	one	patient	are	shown	in	(Figure	6.4).	Analysis	of	
benign	and	tumour	sections	from	this	patient	showed	moderate	Dkk-3	expression	(score	2)	
in	benign	epithelium	and	low	expression	(score	1)	in	tumour	epithelium.	Higher	magnification	
images	 (Figure	6.4B)	 revealed	expression	of	Dkk-3	 in	 luminal	epithelial	 cells	 (score	2)	 (red	
arrow),	some	of	which	had	been	shed	into	the	lumen,	as	well	as	some	staining	(score	1)	in	the	
stroma	(green	arrow).	In	contrast,	Dkk-3	expression	in	this	patient	was	low	(score	1)	in	the		
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tumour	epithelium	 (red	arrow)	and	absent	 (score	0)	 in	 the	 tumour	 stroma	 (green	arrow),	
although	it	was	detected	in	endothelial	cells	(blue	arrow).	
		For	statistical	analysis,	scores	of	0	and	1	were	classified	as	low	Dkk-3	and	scores	of	2	and	3	
were	 classified	as	high	Dkk-3.	 The	 results	 (Table	6.2)	 indicated	 that	Dkk-3	expression	was	
significantly	 lower	 in	 tumour	 epithelium	 than	 in	 benign	 epithelium.	 In	 addition,	 Dkk-3	
expression	was	significantly	lower	in	tumours	of	Gleason	score	>	4+3,	compared	to	tumours	
of	Gleason	score	<	3+4.	Dkk-3	expression	was	also	significantly	lower	in	tumour	stroma	than	
in	benign	stroma.	
		The	reduced	levels	of	Dkk-3	in	tumour	epithelium	are,	in	part,	consistent	with	the	previous	
study	showing	reduced	expression	of	Dkk-3	in	a	prostate	cancer	TMA	of	55	patient	samples	
[177].	In	that	study,	a	statistically	significant	difference	was	observed	only	for	tumours	with	a	
Gleason	score	>	9.	The	difference	might	reflect	the	different	patient	populations	analysed	(UK	
versus	 Korean),	 or	 the	 scoring	 methods	 used,	 since	 the	 previous	 study	 calculated	 the	
percentage	of	Dkk-3-positive	cancer	cells	in	3	random	fields,	with	tumours	below	the	median	
(37.4%)	defined	as	low,	and	those	above	the	median	as	high.	
6.4	TGFBI	expression	is	higher	in	PCa	and	lower	in	PCa	stroma,	compared	to	in	benign	
epithelium	and	the	stroma	respectively.	
	
		Next,	 the	 expression	 of	 TGFBI	 was	 investigated.	 TMAs	 were	 subjected	 to	 TGFBI	
immunostaining	and	the	same	scoring	system	was	applied,	analysing	overall	intensity	in	two	
sections	each	of	tumour	and	benign	tissue,	using	the	scoring	categories	0	(negative),	1	(weak),	
2	(moderate)	and	3	(strong).	Figure	6.5A	shows	examples	of	each	category	of	TGFBI	score	in	
prostate	epithelium,	using	pan-CK	staining	of	adjacent	sections	to	identify	the	epithelial	cells.	
TGFBI	expression	in	the	stroma	was	scored	in	a	similar	manner,	separately	(Figure	6.5B).	
		Examples	of	TGFBI	staining	 in	one	patient	are	shown	in	(Figure	6.6).	This	patient	has	 low	
(score	1)	TGFBI	expression	in	benign	epithelium	(red	arrow)	and	moderate	(score	2)	TGFBI	
expression	 in	 benign	 stroma	 (green	 arrow).	 The	 tumour	 section	 from	 this	 patient	 shows	
strong	(score	3)	TGFBI	expression	in	tumour	cells	and	weak	(score	1)	TGFBI	expression	in		
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tumour	 stroma.	 Higher	 magnification	 images	 (Figure	 6.6B)	 show	 expression	 of	 TGFBI	 in	
benign	prostate	basal	and	luminal	epithelial	cells,	as	well	as	in	some	stromal	cells.	
		For	statistical	analysis,	scores	of	0	and	1	were	classified	as	low	TGFBI	and	scores	of	2	and	3	
were	 classified	as	high	TGFBI.	 The	 results	 (Table	6.3)	 indicated	 that	TGFBI	expression	was	
significantly	higher	in	tumour	epithelium	than	in	benign	epithelium.	There	were	no	significant	
differences	in	TGFBI	expression	in	high	and	low	Gleason	grade	tumours.	In	addition,	TGFBI	
expression	was	significantly	lower	in	tumour	stroma	than	in	benign	stroma.	
		Together,	 the	 results	 above	 and	 in	 Section	 6.3	 suggest	 that	 there	 may	 be	 an	 inverse	
correlation	between	the	expression	of	Dkk-3	and	TGFBI	in	prostate	cancer	but	not	in	prostate	
cancer	stroma.		
6.5	Analysis	of	ECM-1	expression	in	prostate	TMAs	
	
		Next,	the	expression	of	ECM-1	was	investigated	using	the	same	scoring	system.	Figure	6.7A	
shows	 examples	 of	 each	 category	 of	 ECM-1	 score	 in	 prostate	 epithelium,	 using	 pan-CK	
staining	of	adjacent	sections	to	identify	the	epithelial	cells.	ECM-1	expression	in	the	stroma	
was	 scored	 in	 a	 similar	manner,	 separately	 (Figure	 6.7B).	 There	 was	 a	 problem	with	 the	
immunohistochemical	 reaction	 for	 some	of	 the	 TMAs,	 so	 only	 67	 of	 the	 prostate	 tumour	
samples	could	be	analysed.	ECM-1	expression	in	the	stroma	was	generally	weak	(score	1)	or	
undetectable	(score	0),	with	a	score	of	2	observed	 in	only	5	benign	stroma	sections	and	2	
cancer	 stroma	 sections.	 In	 contrast,	 ECM-1	 expression	 was	 generally	 highly	 expressed	 in	
epithelium.	In	cancer	epithelium,	scores	of	0	or	1	were	only	observed	in	6	patients.	ECM-1	
was	also	strong	in	benign	epithelium.	Interestingly,	22	of	the	cancer	sections	and	none	of	the	
benign	sections	had	a	score	of	3,	suggesting	that	ECM-1	is	more	highly	expressed	in	cancer	
epithelium	 than	 in	 benign	 epithelium.	 However,	 the	 majority	 of	 the	 benign	 and	 cancer	
sections	expressed	moderate	levels	of	epithelial	ECM-1	(score	2).	
		Examples	of	ECM-1	staining	in	patients	are	shown	in	(Figure	6.8).	Patient	1	in	Figure	6.8A	
has	 a	 low	 (score	 1)	 ECM-1	 expression	 in	 benign	 epithelium	 and	 high	 (score	 2)	 ECM-1	
expression	in	cancer	(red	arrows).	Patient	2	in	Figure	6.8B	has	low	ECM-1	expression	in	benign	
epithelium	(score	2)	and	strong	(score	3)	ECM-1	expression	in	cancer.	
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For	statistical	analysis,	scores	of	0	and	1	were	classified	as	low	ECM-1	and	scores	of	2	and	3	
were	classified	as	high	ECM1.	The	results	(Table	6.4),	indicated	that	ECM-1	expression	was	
significantly	higher	in	tumour	epithelium	than	in	benign	epithelium.	However,	there	were	no	
significant	differences	in	ECM1	expression	in	benign	and	tumour	stroma	or	in	high	and	low	
Gleason	grade	tumours.	
6.6	Inverse	correlation	of	Dkk-3	and	TGFBI	expression	in	low-Gleason-grade	PCa	
	
		In	Chapter	5,	DKK3	silencing	was	found	to	increase	expression	of	TGBI	and	ECM-1	in	RWPE-
1	 cells.	 Since	Dkk-3	expression	 in	 the	TMA	was	 significantly	 lower	 in	PCa,	 compared	 to	 in	
benign	epithelium,	and	expression	of	both	TGFBI	and	ECM-1	was	significantly	higher	in	PCa	
than	in	benign	epithelium,	it	was	of	interest	to	determine	if	there	was	an	inverse	correlation	
between	the	expression	of	Dkk-3	and	TGFBI	or	ECM-1.	
		Examination	of	patient	sections	suggested	that	this	might	be	the	case	for	Dkk-3	and	TGFBI.	
For	example,	Figure	6.9A	shows	a	tumour	section	from	a	patient	with	low	expression	of	TGFBI	
and	 high	 expression	 of	 Dkk-3	 in	 the	 cancer	 epithelium,	 and	 Figure	 6.9B	 shows	 a	 tumour	
section	from	a	patient	with	high	expression	of	TGFBI	and	low	expression	of	Dkk-3	in	the	cancer	
epithelium.	In	addition,	TGFBI	was	expressed	in	the	cancer	stroma.	
		Statistical	 analysis	 of	 the	 data	 (Table	 6.5)	 indicated	 that	 that	 there	 is	 indeed	 an	 inverse	
correlation	between	the	expression	of	Dkk-3	and	TGFBI	in	cancer.		Stratification	for	Gleason	
score	indicated	that	this	correlation	was	in	the	low	Gleason	score	tumours,	but	not	in	the	high	
Gleason	score	tumours.	In	contrast,	there	was	no	correlation	of	Dkk-3	and	TGFBI	expression	
in	benign	epithelium,	benign	stroma	or	cancer	stroma,	although	there	was	a	trend	for	positive	
correlation	of	Dkk-3	and	TGFBI	in	cancer	stroma	(p	=	0.057).	
6.7	Positive	correlation	of	Dkk-3	and	ECM1	expression	in	low-Gleason-grade	PCa	
stroma	
	
		Although	Dkk-3	levels	were	found	to	be	reduced	and	ECM-1	levels	were	increased	in	PCa,	
there	was	no	correlation	between	Dkk-3	and	ECM-1	in	patient	tumour	sections	(Table	6.5).	
There	was,	however,	a	positive	correlation	between	Dkk-3	and	ECM-1	in	cancer	stroma.	An	
example	of	this	is	shown	in	Figure	6.10,	in	which	there	is	expression	of	stromal	Dkk-3	and		
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stromal	ECM-1	(both	score	1).	Stratification	for	Gleason	score	indicated	that	this	correlation	
was	in	the	low	Gleason	score	tumours	but	not	in	the	high	Gleason	score	tumours	(Table	6.5).	
However,	the	expression	of	ECM-1	in	the	stroma	was	generally	weak,	so	the	significance	of	
this	correlation	remains	unclear.	
6.8	Positive	correlation	of	ECM-1	and	TGFBI	in	cancer	stroma	of	low-Gleason-grade	
PCa	
	
		Finally,	given	that	both	TGFBI	and	ECM-1	were	found	to	be	more	highly	expressed	in	cancer,	
the	possibility	of	 a	 correlation	between	ECM-1	and	TGFBI	was	 also	examined.	 The	 results	
indicated	that	there	was	a	trend	for	positive	correlation	of	ECM-1	and	TGFBI	in	cancer	(Table	
6.5).	in	addition,	there	was	a	positive	correlation	of	ECM-1	and	TGFBI	in	tumour	stroma	of	low	
Gleason	score	sections.	An	example	is	shown	in	Figure	6.11,	where	there	is	moderate	(score	
2)	expression	of	both	TGFBI	and	ECM-1	in	tumour	stroma.	Again,	given	the	weak	expression	
of	ECM-1	in	the	stroma,	the	significance	of	this	correlation	remains	unclear.	
		Together,	the	results	above	reveal	some	correlations	of	expression	among	Dkk-3,	TGFBI	and	
ECM-1,	the	most	interesting	of	which	is	the	inverse	correlation	of	Dkk-3	and	TGFBI	in	cancer.	
	
6.9	Analysis	of	correlations	between	DKK3,	TGFBI	and	ECM1	gene	expression	and	PCa	
patient	survival	
	
		The	patient	data	available	 for	 the	 Imperial	College	TMAs	did	not	 include	any	 information	
about	 patient	 survival.	 Therefore,	 to	 determine	 if	 there	 might	 be	 a	 link	 between	 the	
expression	of	Dkk-3,	TGFBI	or	ECM-1	and	patient	survival,	their	gene	expression	patterns	were	
analysed	 using	 PROGgene,	which	 provides	 patient	 survival	 data	 for	many	 types	 of	 cancer		
(http://watson.compbio.iupui.edu/chirayu/proggene/database/index.php).	The	PCa	dataset	
GSE70768	[292]	was	used	because	it	contains	a	sufficient	number	of	relapses	for	statistical	
analysis.	 Correlation	 of	 gene	 expression	 with	 respect	 to	 relapse-free	 survival	 of	 prostate	
cancer	patients	(n	=	110)	was	analysed	by	taking	the	median	gene	expression	value	for	each	
gene	and	then	dividing	patients	 into	high	(above	the	median)	and	low	(below	the	median)	
expressors.	 Relapse-free	 survival	 was	 significantly	 higher	 in	 patients	 with	 high	 DKK3	
expression	(6/55	relapsed)	than	in	patients	with	low	DKK3	expression	(12/55	relapsed)	(Figure	
6.12A).	In	contrast,	there	was	no	significant	difference	for	TGFBI	expression,	with	10/55	high		
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TGFBI	expressors	and	8/55	low	expressors	relapsing	(p	=	0.32)	(Figure	6.12B).	Expression	of	
ECM1	showed	a	trend	for	association	with	relapse-free	survival,	with	7/55	high	expressors	
and	11/45	 low	expressors	 relapsing	 (p	=	0.17,	not	shown),	and	a	second	dataset	 from	the	
same	 study	 (GSE70769;	n	=	91),	 showed	higher	 relapse-free	 survival	 in	patients	with	high	
ECM1	expression	(p	=	0.03),	with	20/46	high	expressors	and	25/45	low	expressors	relapsing	
(Figure	 6.12C).	 A	 another	 dataset	 [293]	 (MSKCC)	 was	 analysed	 for	 patient	 survival	 using	
camcAPP	 (http://bioinformatics.cruk.cam.ac.uk/apps/camcAPP/)	 [294].	 This	 also	 showed	 a	
correlation	between	low	DKK3	expression	and	reduced	patient	survival	(p=0.021,	not	shown)	
but	there	was	no	correlation	for	ECM1	or	TGFBI.	
		The	DKK3	 gene	 expression	 results	 are	 consistent	with	 the	 TMA	 results,	which	 showed	 a	
reduction	in	Dkk-3	expression	in	high	Gleason	grade	prostate	tumours.	The	TGFBI	and	ECM1	
gene	expression	results	seem	to	contrast	with	the	results	from	the	TMAs,	where	both	proteins	
were	more	 highly	 expressed	 in	 cancer.	However,	 TGFBI	 and	 ECM-1	 protein	 levels	 did	 not	
correlate	with	high	Gleason	grade	cancer,	 so	 their	expression	may	not	have	an	 impact	on	
patient	survival.	Another	possibility	is	that	the	regulation	of	TGFBI	and	ECM-1	at	the	mRNA	
and	protein	levels	differs,	and	so	the	gene	expression	data	do	not	reflect	what	is	observed	at	
the	protein	level.	
		There	are	two	caveats	that	should	be	taken	into	account	with	respect	to	the	interpretation	
of	 the	 immunohistochemistry	data.	 The	 first	 caveat	 is	 regarding	negative	 control	 staining,	
where	no	primary	antibody	is	used.	In	order	to	reduce	the	possibility	that	some	of	the	signal	
observed	for	Dkk-3	and	the	other	antigens	is	background	staining,	the	TMAs	should	have	been	
stained	in	parallel	and	developed	for	the	same	amount	of	time	as	was	used	for	each	antibody	
tested.	Although	this	was	not	done,	negative	control	staining	was	carried	out	in	the	lab	on	
test	 sections	 when	 the	 different	 antibodies	 were	 being	 assessed	 for	 use	 in	
immunohistochemistry.	In	addition,	it	 is	likely	that	Jenny	Steel	carried	out	negative	control	
staining	 of	 the	 TMAs	 when	 staining	 for	 SMA	 and	 Vimentin,	 but	 as	 she	 has	 taken	 early	
retirement,	this	cannot	be	confirmed.	The	second	caveat	is	regarding	the	fact	that	there	are	
some	 differences	 in	 the	 Gleason	 scores	 of	 the	 sections	 in	 the	 TMA,	 as	 compared	 to	 the	
Gleason	scores	of	the	original	patient	tumours.	This	 is	because	the	TMA	only	contains	two	
small	parts	of	each	tumour,	and	these	were	selected	to	include	areas	with	stroma.	There	is	
therefore	less	cancer	present	in	the	TMA	sections	and	in	some	cases	these	areas	may	not	be	
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representative	of	the	sections	that	were	examined	by	the	pathologist	after	surgery.	In	fact,	
there	were	 nine	 patient	 samples	 in	 the	 TMA	 that	 did	 not	 contain	 tumour	 cells	 and	were	
excluded	from	the	analysis.	This	should	not	affect	the	correlation	of	expression	of	Dkk-3,	ECM-
1	 and	 TGFBI	 but	 it	 could	 have	 complicated	 attempts	 to	 correlate	 expression	with	 patient	
survival	data,	if	they	had	been	available.	
	
Summary	
	
		Analysis	of	the	TMAs	found	a	significant	reduction	of	Dkk-3	expression	in	cancer	tissue	and	
in	cancer	stroma	in	high	Gleason	score	tumours	(≥	43),	whereas	TGFBI	expression	was	found	
to	be	higher	in	cancer	and	lower	in	cancer	stroma,	compared	to	benign	tissue.	ECM-1	was	
higher	 in	cancer	than	 in	benign	epithelium.	Moreover,	 there	was	an	 inverse	correlation	of	
Dkk-3	and	TGFBI	expression	in	low	Gleason	score	(≤43)	PCa.	However,	in	low	Gleason	score	
PCa	 stroma,	 ECM-1	 showed	 positive	 correlations	 with	 Dkk-3	 and	 TGFBI.	 The	 DKK3	 gene	
expression	 results	 are	 consistent	 with	 the	 TMA	 results,	 showing	 a	 reduction	 in	 DKK3	
expression	 in	 high	 Gleason	 grade	 prostate	 tumours	 and	 a	 correlation	 of	 high	 DKK3	 with	
relapse-free	 survival.	 However,	 the	 gene	 expression	 data	 for	 TGFBI	 and	 ECM1	 were	 less	
consistent	 with	 the	 TMA	 data,	 suggesting	 that	 TGFBI	 and	 ECM-1	 levels	 might	 be	 better	
analysed	at	the	protein	level.	 	
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		The	 development	 of	 an	 in	 vitro	 prostate	 epithelial-stromal	 cell	 co-culture	 model	 is	 an	
important	step	for	testing	the	function	of	Dkk-3	in	epithelial-stromal	cell	communication,	and	
will	help	towards	the	identification	of	Dkk-3	targets	that	can	be	further	investigated	in	the	
future	using	primary	prostate	tumour	material	from	patients	and	in	mouse	models.	This	could	
then	lead	to	more	accurate	and	reproducible	data	to	aid	in	the	investigation	of	Dkk-3	and	its	
targets,	as	possible	new	ways	to	develop	therapies	to	be	tested	in	patients	in	clinical	trials.	
		As	a	model	system,	I	used	WPMY-1	prostate	stromal	cells	and	RWPE-1	prostate	epithelial	
cells.	The	fact	that	both	cell	lines	were	derived	from	the	peripheral	zone	of	the	prostate	of	
the	same	patient	[224,	253]	adds	strength	to	their	use	together	as	a	model	for	communication	
between	prostate	epithelial	and	stromal	cells,	as	the	two	cell	lines	are	likely	to	have	a	more	
similar	 genetic	 background	 than	 prostate	 stromal	 and	 epithelial	 cell	 lines	 from	 different	
sources.	RWPE-1	 cells	were	already	known	 to	 secrete	and	 respond	 to	Dkk-3	 [177].	 In	 this	
thesis,	WPMY-1	cells	were	also	found	to	express	and	secrete	high	levels	of	Dkk-3,	similar	to	
primary	prostate	stromal	cells		[226].	
		It	will	be	important	to	confirm	the	results	obtained	using	the	WPMY-1/RWPE-1	model	using	
additional	 prostate	 stromal	 and	 epithelial	 cell	 lines.	 I	 recently	 cultured	 a	 PShTert,	 a	
telomerase-immortalised	human	prostate	 stromal	 cell	 line	 (PShTert)	 [295]	 and	 found	 that	
these	cells	also	secrete	high	levels	of	Dkk-3,	so	they	could	be	used	to	confirm	the	results,	as	
could	primary	prostate	stromal	cells	(PrSC),	which	have	been	used	previously	to	study	Dkk-3	
[226].	Although	there	is	not	a	good	alternative	cell	line	to	RWPE-1,	primary	prostate	epithelial	
cells	(PrEC)	can	form	spheres	that	resemble	RWPE-1	acini	[296].	However,	PrEC	only	undergo	
15	population	doublings,	so	it	would	be	necessary	to	optimise	a	method	for	rapid	and	efficient	
DKK3	silencing,	for	example,	using	lentiviral	vectors.	
		DKK3	silencing	 in	WPMY-1	cells	did	not	affect	 their	proliferation.	However,	 in	contrast	 to	
PrSC,	where	TGF-β	increases	myofibroblast	differentiation,	as	measured	by	increased	levels	
of	SMA	[44,	226],	neither	TGF-β	nor	DKK3	significantly	affected	SMA	protein	levels	in	WPMY-
1	cells	(Figure	3.5).	The	lack	of	effect	of	TGF-b	could	be	because	TGF-b	signalling	is	already	
active	in	WPMY-1	cells.	DKK3	silencing	did	however	reduce	the	expression	of	the	SMA	gene	
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ACTG2	(Figure	3.9).	However,	there	are	two	SMA	genes,	ACTA2	(aortic	smooth	muscle	actin)	
and	ACTG2	(enteric	smooth	muscle	actin).	These	genes	encode	99%	identical	proteins	that	
are	both	recognised	by	the	SMA	antibody.	If	ACTA2	is	more	highly	expressed	than	ACTG2	but	
not	affected	by	DKK3	silencing,	this	would	mask	effects	on	ACTG2	in	western	blots.	Analysis	
of	ACTA2	mRNA	expression	may	resolve	this	issue.	If	this	is	not	the	case,	the	different	results	
in	 PrSC	 and	 WPMY-1	 cells	 could	 be	 because	 WPMY-1	 cells	 are	 immortalised,	 and	 their	
differentiation	is	not	terminal,	unlike	primary	cells,	so	their	basal	level	of	SMA	may	not	be	as	
high	as	in	PrSC	and	so	it	would	be	less	easy	to	detect	a	reduction	by	western	blotting.	Indeed,	
SMA	protein	was	difficult	to	detect	by	western	blotting	in	WPMY-1	cells.	
		DKK3	silencing	in	WPMY-1	cells	also	reduced	the	expression	of	ALDH1A1,	SOX2,	NANOG	and	
s-SHIP	 (Figure	 3.9),	 which	 are	 known	 to	 be	 expressed	 in	 stem/progenitor	 populations	 in	
epithelial	 cells.	 It	 is	 not	 known	 if	 these	 genes,	 and	 possibly	 ACTG2,	 are	 expressed	 by	 a	
stem/progenitor	 cell	 population	 in	WPMY-1	 cells.	 To	 test	 this,	 it	 would	 be	 interesting	 to	
isolate	putative	stem/progenitor	cells	from	WPMY-1	cells.	One	could	then	determine	if	DKK3	
silencing	affects	the	putative	stem/progenitor	cell	population	and	if	the	expression	of	these	
genes	above	is	enriched	in	that	population.	The	preliminary	experiments	carry	out	to	test	this	
possibility	using	s-SHIP-GFP	as	a	potential	way	to	enrich	for	stem/progenitor	cells	did	not	yield	
any	consistent	results	in	WPMY-1	cells.	Future	studies	could	use	other	methods	to	enrich	for	
potential	 stem/progenitor	 cells	 in	 WPMY-1	 cells,	 for	 example	 sorting	 for	 cells	 with	 high	
aldehyde	dehydrogenase	(ALDH)	activity	using	the	ALDEFLUORTM	assay.		
		An	interesting	result	that	came	from	the	q-PCR	analysis	is	that	DKK3	silencing	had	opposite	
effects	on	s-SHIP	expression	in	WPMY-1	and	RWPE-1	cells.	The	reason	for	this	is	not	known,	
but	it	suggests	that	Dkk-3	has	different	functions	in	prostate	stromal	and	prostate	epithelial	
cells	and	that	the	difference	may	relate	to	stem/progenitor	cell	differentiation,	since	s-SHIP	
has	been	proposed	to	play	a	role	in	prostate	stem/progenitor	cells	[283].	The	idea	that	Dkk-3	
silencing	affects	stem/progenitor	cell	differentiation	is	consistent	with	studies	showing	that	
Dkk-3	promotes	mouse	embryonic	stem	cell	differentiation	into	smooth	muscle	cells	[281],	
and	that	ectopic	DKK3	expression	in	mesenchymal	basal	breast	cancer	cells	partially	restores	
epithelial	cell	morphology	[201].	In	previous	studies	in	the	lab,	Dkk-3	silencing	did	not	appear	
to	affect	expression	of	differentiation	markers	in	RWPE-1	cells	[160].	However,	the	expression	
and	function	of	Dkk-3	in	RWPE-1-derived	prostate	stem/progenitor	cells	has	not	been	studied	
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in	any	detail.	In	addition,	PC3	cell	cultures	contain	a	small	population	of	stem/progenitor	cells	
[297]	that	can	be	enriched	by	suspension	culture.	
		Different	functions	for	Dkk-3	in	WPMY-1	and	RWPE-1	cells	could	result	from	differences	in	
the	activity	of	Dkk-3	secreted	by	different	cell	types,	for	example,	there	could	be	differential	
glycosylation	or	proteolytic	processing	of	Dkk-3	in	stromal	and	epithelial	cells	that	could	have	
an	impact	on	its	function	[173,	298]	Alternatively,	the	response	of	stromal	and	epithelial	cells	
to	Dkk-3	 could	be	different	because	 they	express	different	Dkk-3	 receptors.	 This	question	
could	be	resolved	by	identifying	the	putative	Dkk-3	receptors	and	determining	their	relative	
expression	in	stromal	and	epithelial	cells	and/or	by	comparing	the	effects	of	Dkk-3	secreted	
by	WPMY-1	and	RWPE-1	cells	in	the	assays	used	in	this	thesis.	
		A	large	part	of	this	thesis	used	DKK3-silenced	WPMY-1	cell	CM	to	study	the	effects	of	stromal	
Dkk-3	on	prostate	epithelial	cells.	A	key	result	was	that	Dkk-3	from	WPMY-1	CM	increased	the	
numbers	of	normal	acini	formed	by	RWPE-1	cells.	This	may	result	from	the	Dkk-3-dependent	
effects	that	have	been	observed	on	epithelial	cell	proliferation	and	would	be	consistent	with	
studies	from	the	lab	showing	that	purified	recombinant	Dkk-3	protein	partially	rescues	acinar	
morphogenesis	 [160].	 There	 is	 considerable	 evidence	 for	 epithelial	 Dkk-3	 increases	
TGFβ/Smad	signalling	in	RWPE-1	prostate	epithelial	cells	[160,	299].	This	was	also	observed	
in	 WPMY-1	 cells,	 where	 DKK3	 silencing	 increased	 basal	 Smad3	 levels	 and	 Smad3	
phosphorylation	and	CAGA-luciferase	gene	reporter	activity.	However,	the	results	of	the	gene	
reporter	assays	indicated	that	basal	TGFβ/Smad	signalling	is	higher	in	WPMY-1	cells	than	in	
RWPE-1	cells.	In	addition,	in	RWPE-1	cells	the	change	observed	upon	DKK3	silencing	was	in	
Smad2,	 not	 Smad3	 [160].	 This	 difference	might	 account	 for	 the	different	 effects	 of	Dkk-3	
silencing	on	the	proliferation	of	the	two	cell	types,	since	Smad2	and	Smad3	can	have	different	
effects	in	some	cell	systems	[111-113].		
		Dkk-3	 from	 WPMY-1	 CM	 also	 inhibited	 PC3	 cell	 invasion.	 The	 MMP2	 inhibitor	 ARP100	
inhibited	the	pro-invasive	effects	of	CM	from	DKK3-silenced	WPMY-1	cells,	suggesting	a	role	
for	MMP2,	 the	main	MMP	 family	member	 inhibited	 by	 ARP100	 at	 the	 dose	 used,	 in	 this	
response	to	Dkk-3.	This	finding	is	consistent	with	those	from	previously	published	work	from	
the	 lab	 showing	 that	 DKK3	 silencing	 increases	 MMP	 expression	 and	 activity	 in	 primary	
prostate	epithelial	cells	and	RWPE-1	cells	[161].	Therefore,	it	is	possible	that	Dkk-3	secreted	
by	prostate	 stroma	 regulates	 the	 activity	 of	MMP2	 to	 exert	 paracrine	 effects	 on	prostate	
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epithelial	and	prostate	cancer	cells.	However,	there	was	only	a	trend	for	an	increase	in	MMP2	
protein	and	MMP2	mRNA	levels	in	DKK3-silenced	WPMY-1	cells.	This	suggests	that	silencing	
of	 Dkk-3	might	 affect	 the	 activity,	 rather	 than	 the	 level,	 of	MMP2,	 or	 that	 it	 affects	 the	
expression	of	other	factors	that	regulate	MMP2	activity.		
		A	TGF-β-induced	increase	the	level	of	Dkk-3	protein	in	WPMY-1	cell	CM	was	also	observed.	
Together	with	the	other	results	obtained,	this	suggests	a	negative	feedback	model	in	which	
the	loss	of	epithelial	Dkk-3	leads	to	activation	of	TGF-β	signalling,	which	then	increases	Dkk-3	
secretion	by	stromal	cells,	 leading	to	inhibition	of	TGF-β	signalling	and	MMP2	(Figure	7.1).	
Consistent	with	this	model,	loss	of	Dkk-3	has	been	associated	with	metastasis	of	various	types	
of	cancer,	including	osteosarcoma	[300],	melanoma	[301]	and	urothelial	carcinoma	[302],	and	
a	link	to	MMP2	has	been	observed	in	some	cases	[301,	302].	In	addition,	Dkk-3	is	a	proteolytic	
target	of	MMP2	and	MMP9	in	fibroblasts	[303],	suggesting	further	possibilities	for	crosstalk.	
Moreover,	our	 lab	has	shown	that	MMP	 inhibition	 in	Dkk-3-silenced	RWPE-1	cells	 rescues	
acinar	morphogenesis	and	inhibits	PC3	cell	invasion	[161],	consistent	with	the	anti-metastatic	
role	of	Dkk-3	involving	regulation	of	TGF-β-dependent	MMP	signals.	
		Despite	 the	 considerable	 evidence	 linking	 Dkk-3	 and	 TGF-β/Smad	 signalling,	 we	 do	 not	
understand	this	at	the	mechanistic	level.	Some	studies	have	led	to	the	proposal	that	Dkk-3	
acts	 intracellular	 [2].	A	very	 recent	 report	described	an	alternative	start	 site	 in	 the	mouse	
Dkk3	promoter	 that	produces	a	new	 intracellular	gene	product,	Dkk3b,	which	 inhibits	 cell	
proliferation	by	binding	to	b-catenin	in	a	complex	with	b-TrCP	[178].	However,	it	is	not	known	
if	this	intracellular	form	of	Dkk-3	also	exists	in	human	cells.	On	the	other	hand,	the	effect	of	
CM	containing	Dkk-3	on	PC3	cell	invasion	is	more	consistent	with	Dkk-3	having	an	extracellular	
function,	 for	 example	 mediated	 by	 cell-surface	 Dkk-3	 receptors.	 Consistent	 with	 this,	
zebrafish	Dkk3	(Dkk3a)	has	been	shown	to	bind	to	zebrafish	α6	integrin	(Itga6b)	to	stimulate	
Myf5	 promoter	 activity	 during	 myogenesis	 [215,	 304].	 As	 Dkk3a	 is	 only	 42%	 identical	 to	
human	 Dkk-3,	 it	 is	 not	 clear	 if	 human	 Dkk-3	 binds	 to	 integrins.	 However,	 a	 potential	
interaction	of	human	Dkk-3	with	integrins	may	be	worth	exploring,	as	there	is	a	link	between	
integrin	avb6	and	TGF-β1/Smad3/MMP2	in	PCa	[305],	and	the	latter	proteins	are	affected	by	
DKK3	silencing.	Another	recent	study	that	may	be	relevant	is	the	discovery	of	a	new	receptor	
for	Dkk-1	called	cytoskeleton-associated	protein	4	(CKAP4),	which	binds	to	the	p85α	subunit		
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of	PI3K	[198].	The	binding	of	Dkk-1	to	CKAP4	involves	the	Cys1	domain	of	Dkk-1,	not	Cys2,	
which	binds	to	LRP5/6	receptors.	Dkk-3	Cys2	does	not	bind	to	LRP5/6	but	it	remains	to	be	
determined	if	Dkk-3	Cys1	can	bind	to	CKAP4.	There	is	also	a	recent	report	that	addition	of	
recombinant	Dkk-3	to	HUVEC	cells	activates	the	ALK1	receptor	[236],	but	binding	of	Dkk-3	to	
ALK1	was	not	demonstrated.		
		Regarding	TGF-b	expression	in	prostate	tumour	stroma,	heterogeneous	expression	of	TGF-b	
levels	and	activity	have	been	reported,	correlating	to	the	number	of	stromal	cells,	particularly	
fibroblasts,	to	cancer	aggressiveness,	and	to	loss	of	stromal	TΒRII,	which	has	been	observed	
in	 the	more	 than	60%	of	 prostate	 cancer	 patients	 [306].	Alterations	 in	 the	 level	 of	 TGF-b	
secreted	by	 fibroblasts	may	be	a	 critical	 step	 in	 switching	 fibroblasts	 to	 cancer-associated	
fibroblasts	 (CAFs)	 [306].	 This	 switch,	 which	 is	 thought	 to	 be	 linked	 to	 the	 loss	 of	 TΒRII	
expression,	which	alters	the	response	to	TGF-b,	could	be	affected	by	the	expression	level	of	
Dkk-3.	In	addition,	high-grade	tumours	(Gleason	8-10)	have	high	levels	of	MMP2	and	MMP9	
[307].	MMPs	secreted	by	stromal	cells,	 rather	 than	by	PCa	cells,	play	an	 important	 role	 in	
contributing	to	stromal	cell	promotion	of	cancer	cell	invasion	[308,	309].	The	amount	of	Dkk-
3	in	the	stroma	could	therefore	be	important	for	controlling	the	paracrine	effects	of	MMP2.		
		The	 results	 of	 the	 antibody	 array	 indicate	 that	 Dkk-3	 affects	 the	 levels	 of	 several	 other	
proteins	secreted	by	WPMY-1	cells.	One	of	these,	TGFBI,	is	known	to	be	a	direct	gene	target	
of	TGF-b/Smad	signalling,	consistent	with	DKK3	silencing	increasing	TGF-b/Smad	signalling.	
The	other	major	protein	affected,	ECM-1,	has	been	reported	to	be	involved	in	cell	invasion	in	
other	types	of	cancer.	Both	these	secreted	proteins	may	be	relevant	to	the	function	of	Dkk-3	
in	the	prostate	gland,	particularly	as	reactive	stroma	affect	tumour	angiogenesis	[226,	310]	
and	activate	mediators	of	 TGF-β1	action	 [310],	which	are	both	properties	 that	have	been	
reported	to	be	affected	by	the	expression	of	Dkk-3.	A	recent	report	found	that	recombinant	
Dkk-3	promotes	angiogenesis	in	endothelial	(HUVEC)	cells	by	stimulating	activation	of	VEGF	
expression	via	Smad	1/5/8	phosphorylation	and	recruitment	of	Smad4	to	the	VEGF	promoter	
[236].	It	remains	to	be	determined	if	this	also	occurs	in	prostate	stromal	cells.	
		TGFBI	 is	an	extracellular	adaptor	protein	that	mediates	cellular	adhesion	to	ECM	proteins	
such	as	collagen,	fibronectin	and	laminins,	and	its	effects	are	thought	to	depend	on	which	
members	of	the	integrin	family	are	available	for	it	to	bind	to	on	cells,	since	TGFBI	can	associate	
with	 several	 integrin	 family	members	 via	 its	 RGD	 sequence	 [311].	 The	precise	 function	of	
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TGFBI	in	cancer,	and	particularly	in	PCa,	is	still	unclear,	however.	Moreover,	detailed	studies	
on	the	role	TGFBI	in	PCa	have	not	been	published.	However,	one	study	proposed	that	TGFBI	
promotes	 PCa	 cell	migration,	 based	on	 the	observation	 that	 over-expression	of	 long	non-
coding	RNA	H19	and	H19-derived	miR-675	inhibited	PCa	cell	migration,	and	this	correlated	
with	repression	of	TGFBI	mRNA	translation	[266].	Although	this	report	did	not	demonstrate	
that	TGFBI	directly	promotes	PCa	migration,	it	suggested	a	tumour-promoting	role	for	TGFBI	
in	PCa.	This	would	be	consistent	with	my	findings	that	recombinant	TGFBI	increases	PC3	cell	
invasion	(Figure	5.6).		In	addition,	the	results	of	experiments	using	recombinant	TGFBI	in	PCa	
are	 consistent	 with	 TGFBI	 playing	 a	 pro-tumorigenic	 role	 in	 PCa:	 it	 showed	 a	 trend	 for	
disrupting	acinar	morphogenesis	in	RWPE-1	cells	(Figure	5.5)	and	it	increased	PC3	cell	invasion	
(Figure	5.6).	
		The	immunohistochemistry	results	indicated	that	TGFBI	expression	is	significantly	higher	in	
PCa	than	in	benign	prostate	(Table	6.3).	In	addition,	there	was	an	inverse	correlation	of	TGFBI	
and	Dkk-3	expression	in	PCa	tissue	(Table	6.5),	which	is	consistent	with	the	increased	levels	
of	 TGFBI	 observed	 upon	 DKK3	 silencing	 in	 RWPE-1	 cells	 (Figure	 5.3).	 In	 contrast,	 TGFBI	
expression	was	lower	in	tumour	stroma,	compared	to	in	benign	stroma	(Table	6.3)	and	did	
not	show	an	inverse	correlation	with	Dkk-3,	in	fact	there	was	a	trend	for	a	positive	correlation	
(Table	6.5).	This	suggests	that	the	link	between	Dkk-3	and	TGFBI	is	not	the	same	in	cancer	
stroma	as	in	cancer.		
		The	 inverse	 correlation	 between	 TGFBI	 and	 Dkk-3	 in	 cancer	 was	 only	 observed	 in	 low	
Gleason	 score	 (<	 3,	 4)	 tumours,	 suggesting	 that	 the	 link	 between	Dkk-3	 and	 TGFBI	 is	 less	
important	as	tumours	become	more	advanced.	Indeed,	the	patient	survival	data	(Figure	6.12)	
suggest	 that	 high	 DKK3	 but	 not	 low	 TGFBI	 mRNA	 expression	 correlate	 with	 relapse-free	
survival	of	PCa	patients.	It	will	be	important	to	compare	TGFBI	and	Dkk-3	protein	levels	in	a	
larger	 cohort	 of	 patients	 with	 more	 clinical	 data	 in	 order	 to	 determine	 if	 there	 is	 any	
correlation	with	PCa	progression.	
		Dkk-3	silencing	has	been	observed	to	activate	TGF-β/Smad-dependent	transcription	both	in	
prostate	epithelial	cells	[299]	and	in	prostate	stromal	cells	(Figure	3.4).	However,	the	exact	
mechanism	of	action	of	Dkk-3	in	the	regulation	of	TGF-β	and	its	gene	target,	TGFBI,	requires	
further	investigation.	In	RWPE-1	cells,	a	significant	elevation	of	TGFBI	mRNA	was	observed	in	
DKK3-silenced	RWPE-1	cells,	suggesting	that	Dkk-3	regulates	TGFBI	gene	expression	(Figure	
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5.3).	In	contrast,	DKK3	silencing	did	not	affect	TGFBI	mRNA	levels	in	WPMY-1	cells,	although	
there	was	 an	 increase	 in	 the	 level	 of	 TGFBI	 protein	 in	WPMY-1	 cells	 by	western	 blotting,	
suggesting	 that	Dkk-3	 affects	 TGFBI	 at	 the	 protein	 level.	Moreover,	 the	 increase	 in	 TGFBI	
mRNA	in	DKK3-silenced	RWPE-1	cells	(2-fold)	was	less	than	the	increase	in	TGFBI	protein	(5-
fold).	Assuming	that	the	level	of	protein	reflects	the	level	of	mRNA	-	which	is	not	always	the	
case	-	it	is	possible	that	DKK3	silencing	increases	TGFBI	both	at	the	mRNA	level	(in	RWPE-1	
cells	only)	and	at	the	protein	level	(both	RWPE-1	and	WPMY-1	cells).		
		In	the	original	proteome	arrays,	there	was	no	clear	difference	in	the	level	of	TGFBI	in	DKK3-
silenced	and	control	CM	from	RWPE-1	cells	(Figure	5.2).	The	reasons	for	this	are	not	clear.	
One	possibility	is	that	it	reflects	differences	in	the	collection	and/or	storage	of	the	CM	before	
use	 in	 the	array	and	 the	western	blots,	as	 the	RWPE-1	proteome	array	experiments	were	
carried	out	by	Dr	Romero	and	the	western	blots	were	carried	out	 later	 in	the	year	by	me.	
Another	possibility	is	that	the	different	results	reflect	differences	in	the	antibodies	used	to	
detect	TGFBI	in	the	array	and	in	western	blots,	for	example,	we	do	not	know	the	epitopes	of	
the	array	antibodies	and	they	might	not	detect	all	isoforms	of	TGFBI.	
		ECM-1	is	the	other	major	protein	in	CM	that	was	found	to	be	affected	by	Dkk-3	silencing.	In	
this	case,	the	protein	array	results	showed	cell	type-specific	effects	of	Dkk-3	silencing:	a	small	
reduction	in	WPMY-1	cells	(Figure	5.1)	and	an	increase	in	RWPE-1	cells	(Figure	5.2),	and	these	
effects	 were	 clearer	 when	 CM	 were	 probed	 for	 ECM-1	 by	 western	 blotting	 (Figure	 5.4).	
However,	in	both	cell	types,	Dkk-3	silencing	had	no	effect	on	ECM1	mRNA	levels,	suggesting	
that	Dkk-3	silencing	affects	ECM-1	protein	stability	or	secretion.	Western	blotting	of	control	
and	 DKK3-silenced	 RWPE-1	 and	 WPMY-1	 cell	 extracts	 gave	 variable	 results	 in	 different	
experiments	and	were	therefore	not	presented	in	this	thesis.	In	WPMY-1	cell	extracts,	ECM-
1	was	detected	and	showed	no	difference	or	 showed	a	 reduction	upon	DKK3	silencing.	 In	
RWPE-1	cells,	ECM-1	was	difficult	 to	detect	 in	extracts.	These	results	suggest	that	most	of	
ECM-1	is	secreted	and	that	the	increase	of	ECM-1	in	CM	from	DKK3-silenced	RWPE-1	cells	is	
a	result	of	increased	secretion	or	increased	stability	of	secreted	ECM-1.	
		Although	ECM-1	has	been	 reported	 to	promote	 cancer	 cell	migration	 in	 several	 types	of	
cancer,	 its	mechanism	of	action	 in	cancer	 is	not	clear.	A	 recent	study	 in	metastatic	breast	
cancer	 cell	 lines	 showed	 that	 ECM1	 gene	 silencing	 reduces	 expression	 of	 TGFBR2	 [312],	
suggesting	a	possible	mechanism	linked	to	TGF-b	signalling.	However,	other	studies	in	breast	
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cancer	point	to	alternative	mechanisms,	such	as	through	interaction	with	the	EGF	receptor	
and	activation	of	ERK	[313].	The	ECM-1	immunohistochemistry	results	also	suggest	a	potential	
pro-tumorigenic	 role	 for	ECM-1,	 since	 it	was	more	highly	expressed	 in	PCa	 than	 in	benign	
prostate	epithelium	(Table	6.4).	However,	there	was	also	a	positive	correlation	of	Dkk-3	and	
ECM-1	in	cancer	stroma	(Table	6.5),	and	high	ECM1	gene	expression	was	found	to	correlate	
with	relapse-free	survival	of	PCa	patients	(Figure	6.12).	Moreover,	the	results	of	the	studies	
using	recombinant	ECM-1	were	more	consistent	with	ECM-1	playing	a	tumour	inhibitory	role	
in	 PCa,	 as	 ECM-1	 increased	 normal	 acinar	 morphogenesis	 in	 DKK3-silenced	 RWPE-1	 cells	
(Figure	5.5)	and	inhibited	the	pro-invasive	activity	of	TGFBI	in	PC3	cell	invasion	assays	(Figure	
5.6).	There	was	not	time	to	follow-up	the	invasion	assay	results,	so	one	can	only	speculate	on	
how	ECM-1	inhibited	the	invasion	response	to	TGFBI.	One	possibility	is	that	ECM-1	inhibits	
MMP9	activity,	 as	has	been	observed	 in	 vitro	 [271].	Another	 interesting	possibility	 is	 that	
ECM-1	competes	with	TGFBI	for	binding	to	integrins	on	PC3	cells.	As	mentioned	above,	TGFBI	
contains	an	integrin-binding	RGD	sequence.	A	recent	study	in	dendritic	cells	found	that	ECM-
1	competes	with	RGD	peptides	to	directly	bind	to	αv	integrins,	and	thereby	blocks	αv	integrin-
mediated	activation	of	latent	TGF-β,	resulting	in	inhibition	of	Th17	cell	differentiation	[314].	
Integrin	avb6	is	known	to	be	expressed	by	PC3	cells	and	to	promote	their	migration	[305],	so	
it	is	possible	that	ECM-1	inhibits	TGFBI-induced	invasion	by	blocking	its	ability	to	activate	this	
integrin.	
		DKK3	silencing	reduced	ECM-1	levels	in	WPMY-1	cells	(Figure	5.4),	and,	consistent	with	this,	
there	was	a	positive	 correlation	of	ECM-1	with	Dkk-3	 in	 low	Gleason	score	cancer	 stroma	
(Table	6.5).	The	correlation	of	Dkk-3	and	ECM-1	in	stroma	could	be	interpreted	as	reflecting	
a	situation	where	the	loss	of	Dkk-3	in	cancer	cells	leads	to	increased	expression	of	stromal	
Dkk-3	and	stromal	ECM-1	as	a	homeostatic	response	to	prevent	tumour	progression.	
		In	conclusion,	the	results	obtained	during	the	course	of	this	thesis	can	be	used	to	propose	a	
negative	 feedback	 model	 that	 implicates	 Dkk-3	 and	 TGF-β	 signalling	 in	 the	 regulation	 of	
epithelial-stromal	interactions	that	take	place	during	PCa	initiation	and	progression	(Figure	
7.1).	The	loss	of	Dkk-3	in	the	benign	prostate	epithelium	leads	to	activation	of	TGF-β	signalling.	
This	leads	to	increased	expression	of	pro-invasive	molecules	by	prostate	cancer	cells,	such	as	
TGFBI	and	MMP2	that	have	the	potential	to	promote	progression	to	PCa.	However,	at	the	
same	time,	the	activation	of	TGF-β	signalling	also	leads	to	increased	secretion	of	stromal	Dkk-
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3,	which	provides	a	first	line	of	defence.	The	results	of	the	WPMY-1	cell	experiments	suggest	
that	stromal	Dkk-3	can	attenuate	prostate	epithelial	cell	proliferation	and	restore	prostate	
epithelial	architecture	(as	reflected	by	the	results	of	the	acinar	morphogenesis	assays)	and	
also	has	the	ability	to	inhibit	PCa	invasion.	The	loss	of	stromal	Dkk-3	is	therefore	predicted	to	
lead	 to	 further	 disruption	 of	 the	 prostate,	 increased	 proliferation	 and	 PCa	 cell	 invasion.	
Regarding	 the	 role	 of	 ECM-1	 in	 this	 model,	 it	 could	 also	 form	 part	 of	 the	 Dkk-3	 stromal	
defence,	as	its	expression	correlates	with	that	of	Dkk-3	in	WPMY-1	cells,	it	inhibits	the	effects	
of	TGFBI	on	PC3	cell	 invasion	and,	 like	DKK3,	 its	gene	expression	correlates	with	increased	
relapse-free	 survival.	 To	 test	 this	model,	 it	will	 be	 important	 to	 confirm	 the	 results	 using	
additional	prostate	epithelial	 and	prostate	 stromal	 cell	 line	models,	 and,	 if	 possible,	using	
cultures	of	primary	prostate	stromal	and	epithelial	cells.	Ultimately,	 in	vivo	studies	in	mice	
will	be	 required.	First,	however,	 it	will	be	necessary	 to	examine	 the	expression	of	 the	key	
molecules	in	Dkk3	mutant	mouse	prostate,	to	determine	if	the	they	are	altered	in	Dkk3	null	
prostate	epithelium	and	stroma	in	a	similar	pattern	as	observed	in	the	human	cell	line	model	
system	used	here.	
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Supplementary	Tables	
	
Solution	 10%	gel	 8%	gel	 Stacking	gel	
dH2O	 5.9	ml	 6.9	ml	 	2.1	ml	
30%	acrylamide	mix	 5	ml	 4	ml	 	0.5	ml	
1.5	m	Tris	pH	8.8	 3.8	ml	 3.8	ml	 	0.38	ml	
10%	SDS	 150	 µl	 150	 µl	 	30	µl	
10%	APS	 150	 µl	 150	 µl	 	30	µl	
TEMED	 6	µl	 9	µL	 3	µl	
	
Supplementary	Table	1	Solutions	for	polyacrylamide	gel	electrophoresis	(PAGE)	
Buffers	 Recipe	
10X	running	buffer	 30.3	g	Tris	base	
142.5	g	glycine	
dH₂O	to	1	Iitre	
1X	running	buffer	 100	ml	10X		
10	ml	10%	SDS	
890	ml	dH₂O	
5X	transfer	buffer	 29.1	g	Tris	base	
14.56	g	glycine	
18.75	ml	10%	SDS	
dH₂O	to	1	Iitre	
1X	transfer	buffer	 200	ml	10X	
200	ml	MeOH	
600	ml	dH₂O	
10X	APS	 1	g	APS	
9	ml	dH₂O	
Skimmed	milk	blocking	buffer	 5	g	Skimmed	milk	
powder	
95	ml	1X	TBST	
BSA	blocking	buffer	 5	g	BSA	(Sigma	
A7906)		
95	ml	1X	TBST	
10X	TBST	
1X	TBST	
100	ml	TBST,	900	ml	
dH₂O	
	
Supplementary	Table	2	Buffers	
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Protein	 Reference	 Species	 Dilution	
Dkk-3	 R&D	AF1118	 goat	 1:200	(i)	1:500	(w)	
ECM-1	
Proteintech	11521-1-AP	
	
Santa	Cruz	sc-365946	
rabbit	
	
mouse	
1:500	(w)	
1:200	(i)	
1:500	(w)	
TGFBI	(b-IgH3)	 Santa	Cruz	sc-28660	 rabbit	
1:50	(i)	
1:50	(w)	
Pan	cytokeratin	 Thermo	Scientific	MA5-13156	(AE1/AE3)	 mouse	 1:200	(i)	
Smooth	muscle	
Actin	antibody	
(SMA)	
Abcam	[4A4]	ab119952	 mouse	 1:50	(i)	1:1000	(w)	
MMP2	 Invitrogen	 mouse	 1:400	(i)	1:1000	(w)	
Smad2	 Cell	Signaling	sampler	kit	#9963	 rabbit	 1:1000	(w)	
Smad3	 Abcam	ab40854	 Rabbit	 1:2000	(w)	
Smad4	 Cell	Signaling	sampler	kit	#9963	 rabbit	 1:1000	(w)	
phospho-Smad3	 R&D	AB3226	 mouse	 1:1000	(w)	
GAPDH	 Santa	Cruz	sc-59541	 mouse	 1:5000	(w)	
	
Supplementary	Table	3	Primary	antibodies	used	for	western	blotting	(w)	and	
immunohistochemistry	(i)	
	
Antibody	 Reference	 Dilution	
Peroxidase	Donkey	
Anti-Goat	IgG	(H+L)	 Stratech	705-035-147-JIR	 1:10,000	(w)	
Peroxidase	Donkey	
Anti-Mouse	IgG	(H+L)	 Stratech	715-035-150-JIR	 1:10,000	(w)	
Peroxidase	Donkey	
Anti-Rabbit	IgG	(H+L)	 Stratech	711-035-152-JIR	 1:10,000	(w)	
Biotinylated	Anti-
Mouse	IgG	(H+L)	 Vector	BA-2000	 1:200	(i)	
Biotinylated	Anti-Goat	
IgG	(H+L)	 Vector	BA-9500	 1:200	(i)	
Biotinylated	Anti-
Rabbit	IgG	(H+L)	 Vector	BA-1000	 1:200	(i)	
	
Supplementary	Table	4	Secondary	antibodies	used	for	western	blotting	(w)	and	
immunohistochemistry	(i)	
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Western	stripping	 Recipe	 Protocol	
Method	1	(stringent)	 20	ml	10%	SDS,	6.25	
ml	 1M	 Tris	 pH	 6.8,	
67.5	ml	dH2O	to	100	
ml;	 before	 use	 add	
150	 ul	 β-
mercaptoethanol	 to	
20	ml.	
Incubate	membrane	at	
50oC	 30	 min,	 shaking	
every	 10	 min,	 wash	
extensively	 with	 1X	
TBST	and	block.	
	
Method	2	(gentle)		 0.2	M	NaOH	
	
Rinse	in	dH2O,	wash	in	
0.2	 M	 NaOH	 5	 min,	
wash	 in	 dH2O	 and	
block.	
	
Supplementary	Table	5	Western	blotting	stripping	methods	
	
	
Reagent	 Source	 Working	conc.	
Recombinant	human	TGF-β1		 R&D	240-B-002	 10	ng/ml	
SB431542	 Sigma	S4317	 1	uM		
ARP100	 Santa	Cruz	 100	nM	
Puromycin	 Sigma	AC154	 0.75	 ug/ml	 RWPE-1,	
1.5	ug/ml	WPMY-1	
Recombinant	human	ECM1	 R&D	3937-EC	50	µg	 100	ng/ml	
Penicillin-streptomycin	
solution	(100X)		
Invitrogen	 15140-
122	
1X	
Recombinant	human	TGFBI	 R&D	3409-BG	50	µg	 1	ug/ml	
	
Supplementary	Table	6	Drugs	and	proteins	used	for	experiments	
	
	 154	
	
Proteome	Profiler	reagents	 Recipe	
1X	Array	Buffer	8/1	 1	ml	Array	Buffer	8	+	9	ml	Array	Buffer	1	
1X	Washing	buffer	 40	ml	wash	buffer	+	960	ml	dH₂O	
Detection	antibody	Cocktail	N	or	C	 Reconstitute	detection	antibody	Cocktail	N	
or	C	in	100	µl	dH₂O	
Chemi	Reagent	Mix	 Mix	 equal	 volumes	 of	 Chemi	 Reagents	 1	
and	2	within	15	minutes	of	use	
	
Supplementary	Table	7	Proteome	Profiler	reagents	
	
	
Histochemistry	reagents	 Recipe	
TBS	50	mM	 25	ml	1	M	Tris	pH	7.6,	15	ml	5	M	NaCl	
dH2O	to	500	ml	
Sodium	citrate	pH	6.0	 2.9	g	Na	Citrate	in	1	l	dH₂O	
ImmPACT	DAB	 1	 ml	 of	 ImmPACT	 DAB	 diluent,	 1	 drop	 of	
ImmPACT	DAB	Chromogen	(Vector,	SK-4105)	
Vector	stain		 5	ml	of	50	mM	TBS	mixed	with	2	drops	Reagent	
A	and	2	drops	reagent	B	(Vector	ABC	kit	PK-600)	
3%	H₂O₂	 100	µl	30%	H₂O₂	(Sigma	H1009)	in	900	µl	PBS	
	
Supplementary	Table	8	Histochemistry	reagents	
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